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Abstract 
 
     Polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs) are 
persistent environmental contaminants that share physical and neurotoxic properties. 
Developmental PCB exposure has been associated with impulsive behavior in 
laboratory species and human cohorts, while little is known about whether PBDEs have 
similar effects. Both PCBs and PBDEs have been shown to perturb dopaminergic 
neurotransmission. The behavioral and neurochemical effects of PCBs parallel changes 
seen in children with attention deficit hyperactivity disorder (ADHD). The aims of this 
research were to further investigate the effects of PCBs and PBDEs on inhibitory control 
and dopaminergic signaling using a rodent model. The findings were anticipated to 
provide insight into the role that these environmental contaminants have on 
mechanisms and manifestations of impulsive behavior and provide insights as to 
whether exposure to PCBs and/or PBDEs may be a contributing factor in ADHD.       
     Female Long Evans rats received daily oral doses of either 3 or 6 mg/kg of an 
environmentally-relevant PCB mixture, 11.4 or 22.8 mg/kg of the commercial PBDE 
solution DE-71, or corn oil vehicle (i.e., 5 treatment groups) from 4 weeks prior to 
breeding through weaning at postnatal day (PND) 21. Starting on PND 90, male-female 
pairs of offspring from each litter were tested on either a task that assesses impulsive 
action, differential reinforcement of low rates of responding (DRL) task, or a task that 
assesses impulsive choice, delay discounting (DD). After subjects were trained on 
either task, they received drug challenges with the D1/D2 receptor antagonist 
flupenthixol (FLU), amphetamine (AMPH), and then FLU/AMPH together. It was 
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hypothesized that PCB or PBDE exposure would result in impulsive performance on 
both tasks, while during the drug trials there would be shifts in the dose-response 
curves so that performance on both tasks would be improved by AMPH and impaired by 
FLU to a greater extent than in controls. Tissue punches from 4 brain regions important 
for DRL and DD performance were collected at PND 90 from littermates of those being 
behaviorally tested. Western blots were performed on the punches to examine for 
differences in expression of dopamine transporter (DAT) between treatment groups. It 
was hypothesized that DAT expression would be reduced with PCB or PBDE exposure. 
     PCB/PBDE-related effects on performance were not found on either the DRL or DD 
task, nor did the drug trials differentially alter the primary performance measures of 
impulsive behavior in treated groups relative to controls. The lack of effects of PCBs on 
DRL performance is in contrast to previous studies. However, some reasons why 
positive findings may have been obscured included potential insensitivity of the versions 
of the tasks used, particularly DD, in eliciting differences in impulsive behavior, and 
experimental manipulations in diet, contaminant dose, strain of rat or other 
unrecognized factors. In addition to the behavioral findings, DAT expression did not 
differ between treated and control subjects. This differs from the findings in previous in 
vivo and in vitro studies. However, DAT expression was examined 70 days after 
contaminant exposure ceased in the current study versus immediately after exposure 
ceased in prior studies. Thus, any possible changes in DAT expression could have 
resolved by the time brains were examined at PND 90 in the current study. While the 
current study did not allow insight into the role that PCBs and PBDEs have in impulsive 
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behavior and dopaminergic signaling, a better understanding of experimental factors 
that can influence the outcome of in vivo and in vitro studies was gained.   
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Chapter 1: Background 
 
1. Introduction 
     The neurodevelopment of an individual, which progresses in a predictable manner 
from conception to adulthood, occurs across 4 main domains: motor, cognitive, speech 
and language, and social-emotional development (Patel et al. 2010). Abnormalities in 
normal maturation processes of any of these domains result in neurodevelopmental 
disabilities. Approximately 1 in 6 children in the United States have been reported as 
having a neurodevelopmental disability, with the prevalence increasing from 12.84% to 
15.04% over the period of 1997-2008 (Boyle et al. 2011). Because the consequences of 
these disorders often extend throughout the lifespan, neurodevelopmental disabilities 
carry a high cost to society.  
     The example of attention deficit hyperactivity disorder (ADHD), which is a common 
developmental disorder characterized by impulsive behavior, hyperactivity, and 
inattention (Aguiar et al. 2010), is illustrative of the social cost, not to mention the 
incalculable personal cost, of developmental disorders. Using data from a large, 
nationally representative sample of 34,000 adults, it was determined that the subgroup 
of ADHD individuals in the study had increased prevalence of comorbid psychiatric 
disorders and significantly higher tendencies to engage in behaviors that reflected poor 
planning and impulsivity, to suffer more lifetime traumas, and to perceive poorer health 
and social support and more stress when compared to non-ADHD adults (Bernardi et al. 
2012). Furthermore, Pelham et al. (2007) estimated an annual societal cost in the 
United States of $42.5 billion for ADHD in childhood and adolescence (in 2005 dollars). 
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This was estimated using a cost of illness approach which included factors such as 
costs of physical and psychosocial health care, special education, and crime and 
delinquency. 
     While it has been long understood that the developing nervous system is especially 
sensitive to insult from toxicants (Rice & Barone 2000), more recently it has become 
better understood that developmental chemical exposures not only impact the early life 
stages (Mendola et al. 2002; Williams & Ross 2007), but also the later life stages 
(Landrigan et al. 2005). This has led to considerable interest in recent years in 
examining the intersection of genes and environment early in the life course as a basis 
for the development of adult health disorders (the Developmental Origins of Health and 
Disease concept), which has invigorated interest in understanding the role of early 
environmental exposures in ADHD (Swanson et al. 2009; Barouki et al. 2012).  
     It has been shown that environmental and genetic factors both have roles in the 
development of ADHD (Hudziak et al. 2005), with epigenetic processes potentially 
mediating individual risk for the development of the disorder (Thapar et al. 2007; Mill & 
Petronis 2008). There are numerous environmental risk factors, including chemical 
exposures, that have been associated with a diagnosis of ADHD, to varying extents 
(Banerjee et al. 2007; Pineda et al. 2007; Millchap 2008). However, establishing 
causality is extremely difficult.  
     Perhaps a more fruitful approach is to examine the influence of environmental 
exposures on domains of behavior such as response inhibition or attention that are 
impaired in ADHD, similar to the approach proposed in Research Domain Criteria 
project spearheaded by the National Institute of Mental Health (Morris & Cuthbert 2012). 
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Focusing more on behavioral domains allows for a focus on mechanisms that 
encompass characteristics found across several disorders. This approach also helps 
avoid some of the uncertainties associated with investigating clinically diagnosed, 
heterogeneous disorders such as ADHD (Stefanatos & Baron 2007). This is not to imply 
that disorders such as ADHD should not be studied, but instead it implies that also 
studying the individual abnormal behaviors that together comprise a disorder can 
provide new information about the causes of the disorder.  
     The study of neurodevelopmental effects of environmental contaminant exposures 
lends itself to this behavioral domain-oriented approach. For example, a recent 
publication examined the parallels between the cognitive domains that are affected by 
lead and polychlorinated biphenyl (PCB) exposures and those affected by ADHD (Eubig 
et al. 2010). Both similarities and differences between the behavioral domains affected 
by developmental exposure to these two contaminants and those affected in ADHD 
were noted (e.g., both affect response inhibition but lead affects attention to a greater 
extent than PCBs). This allowed a better understanding of the role these contaminants 
may play as risk factors for ADHD, but it also raised questions about the roles these 
contaminants may play in other disorders that include impulsive or inattentive behavior 
in their clinical presentations (e.g., substance abuse).  
     With this in mind, the current project examined how developmental contaminant 
exposures may affect different aspects of impulsive behavior. Specifically, two 
contaminants were examined: PCBs, for which a much greater body of knowledge 
exists regarding their neurodevelopmental effects, and polybrominated diphenyl ethers 
(PBDEs), which are similar to PCBs in many ways but for which much less is known 
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about their neurodevelopmental effects. It is hoped that the findings from this project will 
provide new insights into how PCBs and PBDEs affect not only impulsive behavior, but 
also how closely the effects of these compounds on impulsive behavior parallel those 
seen in ADHD children. 
 
2. Neurotoxicity of PCBs and PBDEs 
     PCBs are considered a legacy contaminant in that even though production ceased in 
the United States by 1977, environmental contamination remains ubiquitous and 
concentrations in air, water, soil, and biota have been declining very slowly because of 
the chemical stability of PCBs (ATSDR 2000; Beyer & Biziuk 2009). Due to their 
lipophilic nature and their environmental persistence, PCBs bioaccumulate and then 
biomagnify up the food chain (Beyer & Biziuk 2009). One of the main sources of PCB 
exposure in humans is the consumption of fish (Domingo & Bocio 2007). PCB 
concentrations in individuals who consume fish are significantly higher than levels in 
non-fish eaters (Humphrey et al. 2000). Transplacental and lactational passage of PCBs 
from mothers to their offspring occurs (Dekoning & Karmaus 2000), with fish 
consumption by mothers prior to or during pregnancy significantly increasing PCB 
concentrations in cord blood and breast milk (Stewart et al. 1999).  
     PBDEs have seen extensive use as additive flame retardants to plastics and in 
coatings for textiles (Darnerud et al. 2001). Due to their lipophilic nature and relative 
environmental persistence, PBDEs are also found in air, water, and sediments, but 
especially seem to bioaccumulate in aquatic biota (Darnerud et al. 2001; Hale et al. 
2003). Until the 2005 phase out of the production of most PBDEs in North America 
 5 
 
(Crimmins et al. 2012), concentrations of PBDEs were exponentially increasing both in 
Great Lakes fish, with a doubling time of 3-4 years (Zhu & Hites 2004), and in humans, 
with a doubling time of approximately 5 years (Hites 2004), so that human PBDE serum 
levels surpassed those of PCBs (Sjodin et al. 2004; Schecter et al. 2005). In adults, 
ingestion of PBDEs through food may be a significant source of exposure, with fish 
having higher PBDE concentrations than meat or dairy products (Schecter et al. 2004). 
Transplacental exposure occurs (Schecter et al. 2007), with maternal and cord blood 
PBDE concentrations being highly correlated and statistically indistinguishable (Mazdai 
et al. 2003). PBDEs also partition into breast milk (Schecter et al. 2010), with PBDE 
concentrations in breast milk beginning to surpass those of PCBs (She et al. 2007). This 
has resulted in nursing infants experiencing the highest daily PBDE exposure of all life 
stages (Johnson-Restrepo & Kannan 2009). However, PBDEs differ from PCBs in that, 
after infancy, ingestion of house dust is suspected to the primary exposure route of 
PBDEs, particularly for toddlers (Jones-Otazo et al. 2005; Johnson-Restrepo & Kannan 
2009; Toms et al. 2009). 
     PCBs and PBDEs share some structural and functional similarities. PCBs consist of 
2 phenyl rings with up to 10 chlorine substitutions for a total of 209 possible congeners 
(ATSDR 2000). Depending on the substitution pattern of the chlorines, the biphenyl 
rings of individual PCB congeners can either assume a coplanar or a non-coplanar 
conformation (Safe 1994). Coplanar PCBs are of concern because they can bind aryl 
hydrocarbon receptor to produce effects such as hepatic enzyme induction and 
carcinogenicity (Safe 1994). However, coplanar PCBs have limited neurobehavioral 
effects – it is the non-coplanar congeners that are primarily responsible for behavioral 
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impairments following developmental exposure (Fischer et al. 1998; Sable & Schantz 
2006). PBDEs are comprised of an ether binding 2 phenyl ring constituents that have up 
to 10 bromine substitutions for a total of 209 possible congeners (Darnerud et al.2001). 
The ether linkage, in addition to the larger bromine atoms, forces PBDEs into non-
coplanar configurations (Hardy 2002). Accordingly, PBDEs are not active at aryl 
hydrocarbon receptor (Peters et al. 2006). 
     Non-coplanar PCBs and PBDEs also affect neurons in similar manners. PCBs and 
PBDEs have been shown to disturb intracellular calcium homeostasis by inhibiting 
mitochondrial and endoplasmic reticular calcium sequestration (Kodavanti et al. 1996; 
Kodavanti & Ward 2005; Dingemans et al. 2010) through their interactions with 
ryanodine receptors (Wong et al. 1997; Pessah et al. 2006; Kim et al. 2011). PCBs and 
PBDEs can also stimulate protein kinase C translocation to the cell membrane 
(Kodavanti et al. 1994; Kodavanti & Ward 2005). Together, these mechanisms can 
impair normal neuronal growth during development (Kodavanti 2004) as well as 
contribute to oxidative stress (Fonnum & Mariussen 2009). Non-coplanar PCBs and 
PBDEs also decrease expression and impair the function of dopamine transporter 
(DAT) and vesicular monoamine transporter 2 (VMAT2) (Mariussen & Fonnum 2001; 
Mariussen & Fonnum 2003; Richardson & Miller 2004; Caudle et al. 2006; Bradner et al. 
2013), potentially in an additive manner (Dreiem et al. 2010). These changes increase 
free dopamine in the cytosol, which is readily oxidized and thus contributes to oxidative 
stress and dopaminergic neuronal damage seen with PCB exposure (Caudle et al. 
2006; Lee et al. 2012).  
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     Additionally, both PCBs and PBDEs interfere with normal thyroid hormone 
functioning through several different mechanisms (Zoeller 2007; Fonnum & Mariussen 
2009; Dingemans et al. 2011). Thyroid hormone plays vital roles in many aspects of 
brain development (Patel et al. 2011), so any chemical that perturbs thyroid hormone 
signaling may have deleterious effects on neurodevelopment and behavioral functioning 
(Zoeller et al. 2002). It should be noted that the PCB and PBDE mixtures to be used in 
the current study have both been shown to decrease circulating thyroid hormone 
concentrations in neonatal rats (Poon et al. 2011). 
     Given the similarities in exposure routes, chemical profiles, and neurotoxic effects of 
PCBs and PBDEs, it should not be a surprise that developmental exposure to either 
type of contaminant has been associated with detrimental neurobehavioral effects (see 
Eubig et al. 2010 and Costa & Giordano 2007 for reviews). In examining the laboratory 
and human epidemiologic studies on the effects of PCBs (Eubig et al. 2010), it is 
evident that response inhibition is one of the behavioral domains adversely affected by 
PCBs. 
 
3. Response Inhibition and Impulsivity 
     The construct of response inhibition describes the inhibition or stopping of actions 
that occur in response to cues or triggers in the subject’s environment. As situational 
circumstances or goals change, response inhibition is an important component in 
stopping a current course of action and reorienting behavior towards an original or new 
goal (Logan 1994). Response inhibition can occur before an action begins, or it can stop 
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an action that has already begun. The converse of response inhibition is the inability to 
inhibit actions, which is commonly termed impulsive behavior or impulsivity.   
     An oft quoted definition is that “impulsivity encompasses a range of actions which 
are poorly conceived, prematurely expressed, unduly risky or inappropriate to the 
situation and that often result in undesirable consequences” (Daruna & Barnes 1993). 
This broad definition reflects that there are a variety of impulsive behaviors which are 
interrelated, but which also have their own patterns of behavioral manifestations and 
underlying neuroanatomical and neurochemical substrates. Several authors have 
attempted to define and categorize different varieties of impulsivity seen in human and 
animal subjects (Evenden 1999; Nigg 2000; Dick et al. 2010; Fineberg et al. 2010). Yet 
the risk of subdividing behavior into too many subcategories is that the ability to see 
connections between the various types of behavior may be compromised. For this 
reason, dividing impulsivity into impulsive choice and impulsive action (Winstanley et al. 
2010; Broos et al. 2012) is a good point from which to start an investigation. More 
detailed subcategorizations could then be used to address subsequent experimental 
questions. 
     Impulsive behavior is a common problem. A recent survey using data from the 
National Epidemiologic Survey on Alcohol and Related Conditions concluded that the 
prevalence of self-reported impulsivity in the adult general population is 16.9% 
(n=34,653) (Chamorro et al. 2012). Smaller surveys report that impulsivity peaks in 
childhood and then declines during adolescence and into adulthood (see Steinberg et 
al. 2008 for a brief review), a trend which was confirmed in the Chamorro et al. (2012) 
study. The main concern is that impulsive individuals are vulnerable to developing 
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psychopathologic disorders (Beauchaine et al. 2008). Impulsivity is an important 
component of attention deficit hyperactivity disorder (ADHD) (Moeller et al. 2001; 
Adams et al. 2008; Groman et al. 2009), substance and alcohol use disorders (Groman 
et al. 2009; Dick et al. 2010; Robbins et al. 2012), mood (bipolar) and personality 
(borderline) disorders (Moeller et al. 2001), and what are termed impulse-control 
disorders such as pathological gambling, kleptomania, and trichotillomania (obsessive 
hair pulling) (American Psychiatric Association 2000a).  
 
4. Overview of ADHD 
     ADHD is a common developmental disorder, with a worldwide prevalence estimated 
at 5.29% (Polanczyk et al. 2007). However prevalence estimates vary based on criteria 
for diagnosis, among other factors. For example, the Centers for Disease Control and 
Prevention (2010) reported a 9.5% prevalence of ADHD among children aged 4-17 
years in the United States in 2007 using the relatively loose criteria of parental report of 
diagnosis.  
     The current, most commonly used diagnostic criteria for ADHD involve 18 behavioral 
items divided between an inattentive dimension and a hyperactive/impulsive dimension 
(American Psychiatric Association, 2000b) (see Figure 1.1, reprinted from Aguiar et al. 
(2010)). The two dimensions allow distinction between 3 different subtypes of ADHD. A 
predominately inattentive subtype (ADHD-PI) is diagnosed if at least 6 items from the 
inattentive dimension are present; a predominately hyperactive/impulsive subtype 
(ADHD-PH) is diagnosed if at least 6 items from the hyperactive/impulsive dimension 
are present; and a combined subtype (ADHD-C) is diagnosed if at least 6 items from 
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each of the two dimensions are present. Additional criteria include that some of the 
abnormal behaviors must have been present before age 7 and that the behaviors cause 
significant functional impairments in 2 or more social, academic, or occupational 
settings.  
     Classifying patients into different subtypes allows for more individualized treatment, 
especially in regards to non-pharmacologic therapies. Overall, ADHD is diagnosed 
approximately 2.5 times more frequently in boys than girls (Polanczyk et al. 2007). 
ADHD-C is the most frequently reported subtype in both sexes, but ADHD-C is more 
common in boys and ADHD-PI is more common in girls who are referred for psychiatric 
evaluation (Biederman et al. 2002).  
     Up to two-thirds of individuals with ADHD either concurrently exhibit or later develop 
additional psychiatric disorders, with comorbidity rates ranging up to 50% for 
internalizing disorders, such as depression, and 90% for externalizing or disruptive 
disorders (Young 2008; Taurines et al. 2010). Oppositional defiant disorder and conduct 
disorder are the most commonly diagnosed comorbid disorders (Taurines et al. 2010), 
with externalizing disorders such as these being more commonly found in ADHD males 
(Rucklidge 2010). But numerous other conditions including depression, anxiety 
disorders, substance abuse disorders, and bipolar disorder are also commonly 
diagnosed (Young 2008; Taurines et al. 2010), with internalizing disorders such as 
depression and anxiety disorders being more common in ADHD females (Rucklidge 
2010). 
     A particular challenge is that ADHD symptoms are heterogeneous across affected 
individuals, even within each subtype (Stefanatos & Baron 2007). Although classifying 
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children by ADHD subtype may be valid for individuals at the time of initial diagnosis, 
the problem is that individuals do not necessarily remain true to their subtypes over time 
(Willcutt et al. 2012). This variability between individuals and over time may reflect the 
influence of different causative pathways in addition to the influence of comorbidities 
and external factors (Stefanatos & Baron 2007; Swanson et al. 2007; Willcutt et al. 
2012). For these reasons, relying upon clinical symptomatology to define ADHD can be 
important in recognizing the problem and initiating treatment, but it does not provide 
strong insight into the causative factors that result in the clinical manifestations of 
ADHD. 
 
5. Impulsive Behavior and ADHD 
     Several important cognitive functions are impaired in ADHD children, particularly 
executive functioning, attention, temporal information processing, and response to 
reinforcement (Nigg & Nikolas 2008). A review by Aguiar et al. (2010) examined the 
strength of evidence for executive function and attention domains being affected in 
ADHD based on findings from meta-analyses of behavioral tasks. It was concluded that 
the strongest evidence was for response inhibition, both verbal and nonverbal working 
memory, and sustained attention being abnormal in ADHD, although cognitive flexibility, 
planning and alertness are also abnormal to a lesser extent. This section will focus on 
the evidence for impaired response inhibition (i.e., impulsive behavior) in ADHD. 
     Given that behaviors are mediated by distinct neural pathways, using behavioral 
assessment measures to examine specific neuropsychological functions is an initial 
step towards gaining further insight into the biological foundations of both normal and 
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abnormal behavior (Winstanley et al. 2006). Additionally, incorporating behavioral 
assessment measures allows a more quantitative approach, as opposed to the 
qualitative information provided by clinical diagnostic scales such as the one in Figure 
1.1. Four different behavioral tasks used to evaluate impulsive behavior in ADHD are 
the stop signal response time (SSRT) task, the continuous performance test (CPT), 
differential reinforcement of low rates of responding (DRL), and delay discounting.  
 
SSRT and ADHD 
     The SSRT task requires subjects to make a rapid response to “go” signals (e.g., 
pressing a button on the left if “<” appears on the video screen and pressing a button on 
the right if “>” appears). “Stop” signals, which are either an auditory signal (a tone) or a 
visual signal (a letter on the screen), occur during a limited number of trials (typically 20-
25%) in the testing session. The SSRT task allows the assessment of the time required 
for the subject to inhibit the already initiated response to press a button (i.e., the SSRT) 
once the stop signal is presented, so one specific aspect of impulsive behavior is being 
evaluated (Chamberlain & Sahakian 2007). Meta-analyses of the SSRT task show that 
ADHD is associated with slower inhibition of the ongoing response (increased SSRT), 
with a moderate effect size for the difference (Cohen’s d = 0.54-0.63) (Aguiar et al. 
2010). One challenge to these findings arises from recent studies suggesting that longer 
SSRTs in ADHD children may be due to a more variable and inaccurate response style 
rather than an inhibitory deficit per se (Alderson et al. 2008; de Zeeuw et al. 2008). 
 
CPT and ADHD 
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     The CPT requires that a subject respond as quickly as possible to a target on the 
screen while suppressing responses to non-targets. Responding to non-targets 
(commission errors) is a measure of impulsive action. Meta-analyses of commission 
errors on the CPT show that a higher rate of errors is associated with ADHD, with a 
moderate effect size for the difference (Cohen’s d = 0.51-0.56) (Aguiar et al. 2010). 
However, although increased commission errors have been associated with impulsive 
behavior in ADHD children (as opposed to only being associated with a diagnosis of 
ADHD) (Egeland & Kovalik-Gran 2010), this has not been demonstrated in all studies 
(e.g., Epstein et al. 2003). One reason for this variability between studies may be that 
the error rate can vary depending on the frequency with which the target is presented 
(Conners et al. 2003), with different studies using different versions of the CPT.  
 
DRL and ADHD 
     DRL assesses impulsive action and the ability to withhold a response over time. 
Throughout the test session a button or lever is available for the subject to press. During 
each trial, a press after a pre-determined time interval has elapsed (e.g., 15 sec; DRL 
15 sec) results in the delivery of a reinforcer, while a press before the interval has 
elapsed results in the interval timer resetting. In order to perform well on the task, the 
subject must realize that it is necessary to withhold pressing for a length of time at the 
beginning of each trial.  
     Four studies using DRL to assess ADHD children have been published. Two studies 
using a DRL 6 sec task, one with a 15 min session length for 6-8 year olds and the 
other with an 8 min session length for 6-11 year olds, found that hyperactive subjects 
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had significantly greater number of responses and lower efficiency ratios of reinforced 
versus total presses (Gordon 1979; McClure & Gordon 1984), which suggests impulse 
control problems in the hyperactive children. However a similar study (DRL 6 sec for 8 
min in 8-13 year olds) did not replicate these findings (Daugherty & Quay 1991). The 
sample size of each treatment group was smaller in this third study (n = 15 normal, 9 
ADHD, 10 conduct disorder/ADHD), as opposed to the 2 studies by Gordon and 
colleagues (n = 20 normal, 20 ADHD for both), which may have affected the ability to 
detect significant differences. A more recent study obtained parent and teacher ratings 
for the presence of characteristic ADHD and oppositional/defiant disorder (ODD) 
behaviors in 165 6-12 year olds (Avila et al. 2004). The children were tested with a DRL 
10 sec task (8 min session length), along with tasks that assessed other aspects of 
impulsivity. A principal components analysis of the results determined that the DRL 
efficiency ratio was not significantly correlated with the ADHD behavioral ratings, 
although it was correlated with ODD ratings. The authors suggest that DRL assesses a 
different aspect of inhibitory control that is more reflective of delay aversion. This 
possibility can not be eliminated since impaired response inhibition and delay aversion 
are both characteristics of ADHD that may vary between individuals (Sonuga-Barke 
2005).  
     Besides its potential useful role in assessing ADHD children, DRL also has been 
used in children developmentally exposed to environmental contaminants including 
PCBs (Stewart et al. 2006) and perfluorinated chemicals (Gump et al. 2011), and was 
sensitive enough to detect an association of exposure with impulsive behavior. 
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Delay Discounting and ADHD 
     The delay discounting or delay of gratification paradigm involves making a choice 
between a smaller reward that is delivered immediately and a larger reward that is 
delivered after a delay. Typically, subjects choose the larger-delayed reward when the 
delay is short, but then begin to choose the smaller-immediate reward as the delay 
length increases (Tesch & Sanfey 2008). Hence they discount the value of the larger 
reward in order to avoid longer delays. In this context, the decision to choose the 
smaller-immediate reward is interpreted as impulsive choice, with the paradigm more 
closely assessing decision-making processes rather than impulsive motor activity 
(Winstanley et al. 2006). 
     ADHD children generally choose the smaller-immediate reward more than non-
ADHD children (Winstanley et al. 2006; Scheres et al. 2010), with moderate effect sizes 
reported for individual studies (Cohen’s d = 0.57-0.71) (Sonuga-Barke et al. 2008). 
While the underlying reason that ADHD children favor the smaller-immediate reward 
may remain a matter of active debate (Sagvolden et al. 2005; Sonuga-Barke et al. 
2005), delay discounting has been shown to be able to distinguish a different aspect of 
impulsivity than is assessed by other tasks, such as the SSRT, in both ADHD and non-
ADHD populations (Solanto et al. 2001; Reynolds et al. 2008). 
 
6. PCBs, PBDEs, and Impulsivity 
     If the role of environmental contaminants in developmental disorders such as ADHD 
is to be understood, then an important initial step is to examine whether contaminants 
such as PCBs and PBDEs impact behavioral domains that are affected in ADHD. In this 
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section, the evidence that PCBs and PBDEs affect response inhibition will be 
considered. 
     Studies in rodents, monkeys, and human populations have examined the effects of 
developmental PCB exposure on response inhibition. Three studies in rats and 1 in 
monkeys used the DRL task to assess impulsive behavior. While these studies are 
discussed in detail in Chapter 3, a brief summary follows. Holene et al. (1999) studied 
the effects of lactational exposure to the non-coplanar congener PCB 153 in female 
rats. It was found that the PCB-exposed subjects had shorter times between responses 
and earned fewer rewards than controls. Sable et al. (2009) evaluated the effects of 
perinatal exposure to an environmentally-relevant PCB mixture (Fox River Mix; 
Kostyniak et al. 2005) in rats. PCB exposure resulted in smaller efficiency ratios 
(reinforced:non-reinforced responses), which is in contrast to an earlier study from the 
same laboratory in which the same perinatal exposure period and DRL testing paradigm 
were used but PCB-related effects were not found (Sable et al. 2006). The DRL study in 
monkeys involved exposure to a PCB mixture from birth to 20 weeks of age (Rice 
1998). DRL testing at age 4.5 years revealed increased responding, fewer rewards 
earned, and shorter times between responses in PCB-exposed monkeys. Several other 
studies of developmental PCB exposure in rats and monkeys have used a related task, 
the fixed interval task to assess for impaired response inhibition, as reviewed by Eubig 
et al. (2010). The fixed interval task is similar to DRL, but subjects are not penalized for 
early responding in the former task. The most common findings in many, but not all, of 
the fixed interval studies were increased responding and shorter times between 
responses in PCB-exposed subjects. 
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     The effects of developmental PCB exposure on response inhibition in humans have 
been examined in 3 prospective cohorts: the Oswego, New York cohort, the Michigan 
cohort, and the New Bedford, Massachusetts cohort. In the Oswego cohort, participants 
were tested on a CPT task at ages 4.5, 8, and 9.5 years (Stewart et al. 2003; Stewart et 
al. 2005). At each age, a higher incidence of commission errors was associated with 
PCB exposure. The 9.5 year-old participants were also tested on DRL and PCB 
exposure was associated with increased responding, shorter times between responses, 
and fewer rewards earned (Stewart et al. 2006). In the Michigan cohort, participants 
were tested on a CPT at ages 4 and 11 years (Jacobson et al. 1992; Jacobson & 
Jacobson 2003). A higher incidence of commission errors was associated with PCB 
exposure at age 11, but not age 4. This association was only seen in children that had 
been formula fed, indicating that breast feeding had a protective effect despite being a 
source of PCB exposure postnatally. Participants in the New Bedford cohort were tested 
on a CPT at age 8, but no association between commission errors and PCB exposure 
was found (Sagiv et al. 2012). However, the CPT used in this study had a low target 
presentation rate. This results in a greater likelihood of omission errors and a lesser 
likelihood of commission errors and, thus, is better at detecting inattention than 
impulsivity. The same children were assessed for ADHD-like behaviors using the 
Conners’ Rating Scale for Teachers (Sagiv et al. 2010). Positive associations were 
found between cord blood levels of PCBs and several subscales of the test, including 
the DSM-IV Hyperactive-Impulsive subscale.  
     A limited number of animal studies have examined impulsive behavior subsequent to 
developmental PBDE exposure in rodents. Driscoll et al. (2009) perinatally exposed rats 
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to the commercial PBDE solution, DE-71. Exposure then continued post-weaning via 
the chow through the time the subjects were tested on a version of the 5-choice serial 
reaction time task. PBDE exposure resulted in increased premature responding, which 
is considered indicative of impulsive behavior. These results were not replicated when 
the exposure period was limited to postnatal days (PND) 6 to 12 (Driscoll et al. 2012). In 
a study by Rice et al. (2009), mice were dosed with congener BDE 209 from PND 2 to 
15. Subjects were then either tested on a fixed interval task beginning in young 
adulthood (PND 90) or at 16 months of age. Only in the older cohort were significant 
increases in responding seen.          
     The cognitive effects of developmental PBDE exposure have been examined in 
prospective human cohorts, although specific tests of impulsive behavior have not been 
used except for a CPT in one study (Eskenazi et al. 2013). In that study of the 
CHAMACOS cohort in California, maternal prenatal PBDE levels were not associated 
with changes in commission errors on the CPT at age 5. The same children were 
assessed at age 7 for ADHD-like behavior using the Conners’ Rating Scale for 
Teachers. Higher serum PBDE concentrations in the children at the time of testing were 
positively associated with higher scores on several subscales, including the 
Hyperactive-Impulsive subscale, but no association was found with maternal prenatal 
PBDE levels. Children in the COMPARE cohort in the Netherlands were evaluated at a 
similar age, 5 to 6 years, using the NEPSY-II neuropsychological battery, and the 
parents filled out an 18 item ADHD questionnaire (Roze et al. 2009). Levels of individual 
PBDE congeners from prenatal maternal serum were not associated with poorer scores 
on the Inattention subscale of the NEPSY-II. Interestingly, there was not an association 
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for PCB 153 either, but there were positive associations for hydroxylated PCB 
congeners with the Inattention subscale score. None of the contaminants were 
associated with the results of the ADHD questionnaire. Children were assessed at a 
very young age, 2.5 years-old, using the Infant-Toddler Social and Emotional 
Assessment in a cohort from North Carolina (Hoffman et al. 2012). PBDE 
concentrations in the mothers’ breast milk were associated with a higher score on the 
Activity/Impulsivity subscale.  
     Thus, animal studies suggest that PCB exposure has a role in impulsive behavior, 
and neurobehavioral assessments from human PCB-exposed cohorts corroborate the 
findings from the animal studies. Animal behavioral studies of PBDE exposure suggest 
that PBDEs also may have a role in impulsive behavior. However, because only a 
limited number of PBDE studies address this question, it is difficult to draw conclusions. 
Although studies of human cohorts suggest that PBDEs may have a role in impulsive 
behavior, this is based on scores from behavioral rating scales. There is a need for 
studies in which quantifiable behavioral tasks are used to assess the effects of 
developmental PBDE exposure on response inhibition. 
 
7. Similarities in Neurochemical Alterations Seen in ADHD and with PCB and 
PBDE Exposure 
     Given the similarities in impulsive behavior seen in ADHD and with PCB and, 
possibly, PBDE exposure, it is important to consider the neurochemical mechanisms 
that underlie the behavioral effects. Gaining a better understanding of the 
neurochemical changes involved in PCB and PBDE exposure, and how these changes 
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relate to ADHD, will be beneficial in elucidating the roles that developmental 
contaminant exposure could have in the clinical manifestations of ADHD. 
 
ADHD and the Dopamine Hypothesis 
     As already discussed, ADHD is a complex disorder with varying clinical phenotypes. 
The etiology of ADHD involves a genetic component to a large extent, but it is a 
disorder involving many genes of small effect, with no gene identified thus far that 
accounts for more than 3 to 4% of the total variance in ADHD (Smith et al. 2009). 
Likewise, environmental factors are also acknowledged as having a role in the 
development of ADHD, with epigenetic processes potentially serving as the interface 
between genes and environment in mediating risk for the development of ADHD in the 
individual (Thapar et al. 2007; Mill & Petronis 2008). A current hypothesis about the 
etiology of ADHD that combines what is known about environmental and genetic factors 
is the dopamine hypothesis (Swanson et al. 2007; Genro et al. 2010). It is postulated 
that hypofunctional dopamine signaling is responsible for many of the behavioral deficits 
seen in ADHD. This is supported by several lines of evidence including animal studies 
demonstrating the behavioral profile seen with hypodopaminergic functioning, studies of 
polymorphisms in dopamine-related genes and ADHD risk, imaging studies of 
dopaminergic functioning in ADHD individuals, and pharmacologic studies of the impact 
of dopaminergic drugs on ADHD-like behaviors in animal models and ADHD patients. 
     Mesocortical and mesolimbic dopaminergic modulation of cortical-striatal circuits has 
been shown to be important for executive functioning, particularly inhibitory control 
(Sonuga-Barke et al. 2005; Brennan & Arnsten 2008; Dalley et al. 2008). It has been 
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proposed that hypofunctional mesocortical dopaminergic input to the appropriate 
cortical-striatal circuits plays an important role in the deficits in response inhibition and 
attention seen in ADHD (Sagvolden et al. 2005). Studies using animal models have 
demonstrated the importance of dopaminergic signaling in impulsive behavior (reviewed 
by Winstanley et al. 2006). For example, it has been shown that depleting the medial 
prefrontal cortex of dopamine increased responding and decreased the time between 
responses on a DRL task in rats (Sokolowski & Salamone 1994). Also, although it is 
indirect evidence for the dopamine hypothesis, it is interesting that in ADHD patients 
similar brain regions which receive dopaminergic innervation are affected. 
Neuroimaging studies have found size reductions in areas including the prefrontal 
cortex and caudate nucleus of the striatum (Valera et al. 2007; Nigg & Nikolas 2008; 
Makris et al. 2009). Functional imaging studies have also demonstrated hypoactivity in 
these regions in ADHD patients (Dickstein et al. 2006; Makris et al. 2009).  
     Candidate gene studies have suggested the involvement of genes involved in 
dopaminergic neurotransmission in ADHD, with the most consistent findings being for 
polymorphisms in the DAT gene (DAT1 or SLC6A3) and the D4 receptor gene (DRD4) 
(Gizer et al. 2009; Smith et al. 2009). While the most commonly studied D4 receptor 
variant in ADHD has been shown to have a blunted response to dopamine binding 
(Biederman & Faraone 2005), the functional significance of DAT variants in ADHD is 
less clear and likely context dependent (Madras et al. 2005). Molecular imaging studies 
by Volkow et al. have demonstrated decreased striatal D2/3 receptor and DAT binding 
in ADHD patients (e.g., Volkow et al. 2009), which suggests that a hypodopaminergic 
state exists in ADHD. However, many of the earlier studies showed increased striatal 
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DAT binding in ADHD patients (Nikolaus et al. 2007; del Campo et al. 2011), which 
could suggest that ADHD instead involves a hyperdopaminergic state. However, if 
increased DAT binding is due to primary changes in gene expression of DAT1, i.e., 
overexpression of DAT during neurodevelopment or due to abnormalities of a DAT1 
variant (Krause 2008), then increased DAT expression would result in a 
hypodopaminergic state because dopamine would be cleared from the synapse more 
efficiently than usual.  
     The efficacy of the stimulant medications amphetamine and methylphenidate in 
treating ADHD is another argument that supports the dopamine hypothesis for ADHD. 
Stimulants have larger effect sizes than non-stimulants for improvement of ADHD 
symptoms (Biederman & Faraone 2005). Both medications prevent DAT from clearing 
dopamine from the synapse, while amphetamine also promotes dopamine release into 
the synapse, thus increasing synaptic dopamine concentrations (Madras et al. 2005). 
Lending some support to the argument that a hypodopaminergic state exists in ADHD, 
Volkow et al. (2007) found that medication-naïve, adult ADHD patients released less 
dopamine in the caudate when administered methylphenidate than did non-ADHD 
controls. But concordance of findings in the human studies is elusive. It was 
demonstrated in medication-naïve, adolescent ADHD patients who were administered 
methylphenidate that the more impulsive patients experienced a greater release of 
striatal dopamine than the less impulsive patients (Rosa-Neto et al. 2005). However, 
given that either too little or too much dopamine release in the prefrontal cortex can 
impair cognitive functioning (Brennan & Arnsten 2008), the argument follows that if 
stimulants increase synaptic dopamine levels, then patients in a hypodopaminergic 
 23 
 
state are the ones who are more likely to experience improvements in cognitive 
functioning when administered stimulant medications.  
 
PCBs, PBDEs, and Dopamine 
     PCBs and PBDEs are hypothesized to create a hypodopaminergic state, which could 
play a role in the cognitive changes seen subsequent to developmental exposure. Both 
in vitro and in vivo evidence supports the argument that PCBs reduce dopamine 
concentrations in the brain and, specifically, in the synapse. Some evidence also exists 
that PBDEs exert similar effects. 
     Perinatal exposure to non-coplanar congener PCB 47 has been shown to decrease 
dopamine concentrations in the frontal cortex and striatum at PND 90 (Seegal et al. 
1997). Two studies of prenatal exposure to non-coplanar PCB 153 reported similar 
findings: either decreased striatal dopamine at PND 21 (Castoldi et al. 2006) or an initial 
increase in brain dopamine and its metabolites through 6 weeks of age followed by a 
persistent decrease from 9 weeks to 1 year of age (Honma et al. 2009). However, 
perinatal exposure to the congener mixtures Aroclor 1016 or Aroclor 1254 (Morse et al. 
1996; Zahalka et al. 2001) did not result in significant changes in brain dopamine 
concentrations. These investigations were carried further by in vitro work demonstrating 
that a 1:1 mixture of Aroclor 1254 and 1260 caused a dose-dependent decrease in 
dopamine in striatal slices and an increase of dopamine in the surrounding media 
(Chishti et al. 1996), and that an environmentally relevant PCB mixture (Fox River Mix; 
Kostyniak et al. 2005) decreased tissue dopamine and increased media dopamine in an 
organotypic co-culture derived from embryonic rat striatum and ventral mesencephalon 
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(Lyng et al. 2007). Finally, a study in which in vivo microdialysis of the striatum was 
used to quantify free (i.e., synaptic) dopamine after Aroclor 1254 exposure revealed that 
dopamine concentrations were elevated after the first 3 days of exposure, but thereafter  
dopamine concentrations were decreased as exposure continued beyond 1 week 
(Seegal et al. 2002). This study also showed that even though changes were occurring 
in synaptic dopamine levels, striatal tissue levels of dopamine did not differ from 
controls. Thus, PCB exposure has been shown to induce functionally significant 
alterations in synaptic dopamine concentrations, regardless of whether tissue 
concentrations were altered.  
     Investigations into the mechanisms for dopaminergic changes have shown that 
tyrosine hydroxylase and L-aromatic amino acid decarboxylase, the 2 enzymes in the 
synthetic pathway of dopamine from its precursor tyrosine, are affected by PCBs. 
Choksi et al. (1997) exposed striatal preparations to non-coplanar PCB congeners and 
found that tyrosine hydroxylase activity was inhibited in the preparations from Sprague-
Dawley and, to a lesser extent, Long Evans rats, which suggests that there may be 
some strain differences in sensitivity to PCBs. In the previously mentioned organotypic 
co-culture study, it was shown that PCB exposure resulted in decreases in tyrosine 
hydroxylase and DAT expression (Lyng et al. 2007). In a separate, in vitro study, non-
coplanar PCB congeners were shown to increase DOPA and decrease dopamine 
concentrations in catecholaminergic PC12 cells (Angus et al. 1997). This specifically 
points to an inhibition of L-aromatic amino acid decarboxylase.  
     PBDEs have not received as much scrutiny as to their effects on neuronal dopamine 
content and synthesis. One study involved exposing adult mice to DE-71 for 1 month 
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(Bradner et al. 2013). Striatal dopamine and metabolites were decreased in PBDE-
exposed subjects, but striatal tyrosine hydroxylase expression was unaffected. A 
separate study exposed mice to 3 different dosages of congener BDE 47 on PND 10 
(Gee et al. 2011). Only mice receiving the middle dose (10 mg/kg) demonstrated an 
increase of dopamine levels in the frontal cortex, but not the striatum, at PND 15, at 
PND 20, and at 4.5-5 months of age. The differences between these 2 studies suggest 
that differences in age, dose, and length of PBDE exposure all might differentially 
mediate changes in dopaminergic signaling. 
      An area that has generated much interest is the effects of PCBs and PBDEs on the 
functioning of the dopamine transporters DAT and VMAT2, which clear dopamine from 
the synapse and cytosol, respectively. This is extensively discussed in Chapter 5, but a 
brief review follows. Both transporters should function in concert to terminate synaptic 
signaling and to minimize cytosolic dopamine accumulation. Alterations of synaptic 
dopamine can impact many different cognitive functions in which dopamine signaling 
plays important roles (Seamans & Yang 2004). Alterations in cytosolic dopamine can 
affect neurotransmission but can also, if dopamine is elevated, result in oxidative 
damage (Guillot & Miller 2009). Several studies have demonstrated that both PCB 
mixtures and individual non-coplanar congeners reduce the expression and impair the 
functioning of DAT and VMAT2 (Mariussen & Fonnum 2001; Mariussen et al. 2001; 
Richardson & Miller 2004; Caudle et al. 2006; Tian et al. 2011). It has been shown that 
the commercial PBDE mixture, DE-71, also reduces expression and impairs functioning 
of DAT and VMAT2 (Mariussen & Fonnum 2003; Bradner et al. 2013). Furthermore, it 
has been demonstrated that the Fox River PCB Mix is 2 to 3 times more potent than 
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DE-71 at inhibiting DAT uptake of dopamine in a synaptosome model, and that PCBs 
and PBDEs have an additive effect in this regard (Dreiem et al. 2010). 
     It is clear that dopaminergic signaling is affected in ADHD and also by PCB and 
PBDE exposure. There is evidence that a hypodopaminergic state exists in the brain in 
ADHD, but there are also studies that suggest the opposite. What is emerging from the 
literature is that DAT expression and other aspects of dopaminergic neurotransmission 
may vary between ADHD individuals and may also change in response to 
environmental influences, including pharmacotherapy (del Campo et al. 2011; Swanson 
et al. 2011). Studies in laboratory species suggest that developmental exposure to 
PCBs and PBDEs induce a hypodopaminergic state. So it is conceivable that PCBs and 
PBDEs could contribute to the clinical manifestations of ADHD in individuals through 
interactions with dopaminergic neurotransmission. However, this direct link would be 
very challenging to investigate in human populations.   
 
8. Gaps in Knowledge 
     Neurodevelopmental disorders such as ADHD have their roots in both genetic and 
environmental factors. Interactions between genes and environment are believed to 
result in the clinical manifestation of developmental disorders in individual patients. 
Assessing the contributions of environmental contaminant exposures during 
neurodevelopment is important for gaining a better understanding of these interactions. 
In the case of ADHD, affected individuals often have problems with inhibitory control 
and thus are prone to both performing impulsive actions and making impulsive choices. 
Furthermore, problems with response inhibition are common across several 
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developmental disorders, so it may be more fruitful to first investigate the effects of 
environmental exposures on response inhibition in general, and then to use the findings 
to inform research on inhibitory control problems seen in individual disorders.  
     Developmental exposure to PCBs has been shown to cause impulsive action, 
whereas there has been little inquiry into whether PBDEs, which share several key 
neurotoxic properties with PCBs, also have similar effects. Whether either type of 
contaminant affects impulsive choice has not been investigated. It is established that 
dopamine is an important neuromodulator of response inhibition, with perturbations in 
synaptic dopamine concentrations resulting in impulsive behavior. There is strong 
evidence that PCBs affect dopaminergic neurotransmission. A smaller number of 
studies have addressed whether PBDEs share this effect, but the results so far suggest 
that they do. Most studies have focused on the effects of PCBs and PBDEs on 
dopamine in the striatum, which is a brain region that is heavily innervated by 
dopaminergic neurons. Less attention has been given to whether PCBs and PBDEs 
affect dopaminergic signaling in other regions such as the prefrontal cortex and nucleus 
accumbens. These regions, in addition to the striatum, play important roles in the 
performance of behavioral tasks that are used to assess impulsive behavior.  
     Investigation of whether PCBs and PBDEs affect impulsive choice is an important 
step that should be taken in order to better understand the role that developmental 
exposure to these contaminants plays in disorders such as ADHD in which impulsive 
choice is an important clinical component. Also, examining the effects of PCBs and 
PBDEs on dopaminergic signaling in response to pharmacotherapies used to treat 
disorders such as ADHD, and in regions of the brain that are important for response 
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inhibition, will lead to a better understanding of how PCBs and PBDEs influence 
disorders, such as ADHD.  
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9. Figure 
Figure 1.1. Diagnostic Criteria for ADHD1
 
1Reprinted with permission from Aguiar et al. (2010).  
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Chapter 2: Specific Aims 
 
     This research investigated the effects of polychlorinated biphenyls (PCBs) and 
polybrominated diphenyl ethers (PBDEs) on inhibitory control using a rodent model. The 
primary goals were (1) to assess the effects of developmental PCB and PBDE 
exposure on two distinct aspects of response inhibition, impulsive action and 
impulsive choice, and (2) to use additional approaches including systemic drug 
challenges and western blot analyses of dopamine transporter protein expression 
in specific brain regions to gain a better understanding of the neurochemical 
mechanisms through which PCBs and PBDEs impair distinct aspect of response 
inhibition. PCB-exposed animals and children show deficits on several different types 
of learning tasks that require inhibitory control for their successful execution, but the 
underlying changes in cognitive processing responsible for these deficits are not well 
understood. A closer evaluation of specific aspects of inhibitory control impaired by 
developmental PCB exposure should lead to a better overall understanding of the 
cognitive deficits associated with this exposure. Additionally, because similar behavioral 
problems are seen in children with attention deficit hyperactivity disorder (ADHD), these 
studies may lead to a better understanding of this common childhood disorder. The 
experiments were performed using a PCB mixture (the Fox River Mix) that models the 
PCB congener profile in fish consumed by a human population. These studies also 
evaluated the effects of PBDEs on response inhibition. Worldwide use of PBDEs as 
flame retardants has resulted in increasing levels in the environment and human tissue. 
This is of concern given that PBDEs and non-coplanar PCBs have similar molecular 
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structures and similar intracellular effects, including changes in catecholamine signaling, 
and, thus, may have similar effects on behavioral function. 
The specific aims of this research were to: 
1. Use a rodent model (Long Evans rat) to assess the effects of developmental 
exposure to PCBs and PBDEs on two distinct aspects of response inhibition. 
Previous studies have reported impaired inhibitory control following developmental PCB 
exposure, but closer examination of the specific aspects of response inhibition affected 
by PCBs is lacking. Additionally, recent studies suggest that developmental exposure to 
PBDEs may also affect inhibitory control. Two behavioral tasks, differential 
reinforcement of low rates of responding (DRL) and delay discounting (DD), were used 
to evaluate the effects of PCBs and PBDEs on two aspects of response inhibition, the 
ability to stop an action before it begins (DRL) and the ability to choose a delayed but 
larger reward over an immediate but smaller reward (DD). These tasks were also 
selected to allow better evaluation of the extent to which the deficits seen with PCBs 
and PBDEs parallel those seen in ADHD. It was hypothesized that PCB- and PBDE-
exposed rats would exhibit more pronounced deficits on DRL and DD tasks as 
compared to controls. 
2. Use drug challenges to assess the role of perturbations in dopaminergic 
neurotransmission in mediating the effects of developmental exposure to PCBs 
and PBDEs on response inhibition. Reduced dopaminergic neurotransmission has 
been documented following both PCB and PBDE exposure and is also present in 
ADHD. Systemically-administered agents that alter dopaminergic synaptic activity were 
used to further investigate the role of the dopaminergic system in PCB- and PBDE-
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induced deficits in response inhibition. It was hypothesized that there would be shifts 
in the dose-response curves such that performance of PCB- and PBDE-exposed 
animals on DRL and DD tasks would be more improved by drugs that enhance 
dopaminergic neurotransmission and would be more disrupted by drugs that 
reduce dopaminergic neurotransmission as compared to controls. 
3. Use western blot analysis to quantify expression of the dopamine transporter 
in specific regions of the prefrontal cortex and striatum following developmental 
exposure to PCBs and PBDEs. PCBs and PBDEs have been shown to inhibit synaptic 
uptake of dopamine via the dopamine transporter. This research expanded the current 
body of knowledge by quantifying expression of dopamine transporter in 4 specific brain 
regions: medial prefrontal cortex and orbitofrontal cortex (prefrontal regions) and 
nucleus accumbens and dorsal striatum (striatal regions). These brain regions are 
important in the regulation of the DRL and DD tasks. It was hypothesized that 
expression of dopamine transporter would be reduced in the prefrontal cortex 
and striatum of rats developmentally exposed to PCBs and PBDEs. 
     Together these results were anticipated to provide evidence that would help us to 
understand the role of changes in dopamine signaling in specific regions of the 
prefrontal cortex and striatum in mediating deficits in specific components of inhibitory 
control following PCB and PBDE exposure. These studies were also anticipated to 
provide further insight both into the neurochemical alterations that occur in ADHD and 
the influence of environmental factors on the clinical manifestations of ADHD.  
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Chapter 3: Effects of PCBs and PBDEs on the Differential Reinforcement of Low 
Rates of Responding Task 
 
1. Introduction 
     The focus of the current project is to examine the effects of developmental exposure 
to polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs) on 
response inhibition. Impulsive behavior can be divided into two types: impulsive action 
and impulsive choice (Winstanley et al. 2010; Broos et al. 2012). This chapter will 
examine the effects of PCBs and PBDEs on impulsive action. 
     Differential reinforcement of low rates of responding (DRL) is an operant task that 
assesses impulsive action.  In typical DRL tasks, a subject presses a lever to initiate 
each trial, and then must withhold responding on the lever until a predetermined interval 
of time (required inter-response time or IRT) passes in order to receive reinforcement 
for the 2nd lever press. If the lever is pressed before the required IRT elapses, the trial 
clock is reset, and the subject must wait for another full required IRT to pass before a 
lever press results in reinforcement. Thus, DRL tasks assess the ability to withhold a 
response over time.  
     One advantage of DRL is that it assesses what Evenden (1999a) terms the 
“execution” stage of carrying out an action without involving overtly aversive punishment 
(e.g., an electric shock) for an incorrect action, thus avoiding the confounder of anxiety 
seen in some tests with an aversive component. It is generally accepted that DRL 
performance allows for assessment of response inhibition, with increases in lever 
pressing and decreases in reinforcers earned reflecting impulsivity (Evenden 1999b; 
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Monterosso & Ainslie 1999). Many species have been assessed using the DRL task 
(see Kramer & Rilling 1970 for an early review), and because homologous brain regions 
are known to be involved in mediating performance on this task in rodents and humans 
(Robbins et al. 2012), DRL tasks are well-suited for cross-species comparisons. 
     The main drawback of DRL is that task performance relies on other various aspects 
of cognition, including the ability to estimate time, and can be affected by alterations in 
motivation and attention (Bizot 1998). However this drawback can be said to be true for 
any behavioral task, so what is most important is to consider these other influences on 
performance when interpreting study results. 
      
Neurobiology of DRL Performance 
     Anatomic regions important for DRL performance have been investigated, mostly by 
lesion studies. The roles of the frontal cortex, the dorsal striatum, and the nucleus 
accumbens have all been investigated in this manner. 
     Findings from studies where the medial prefrontal cortex (mPFC) was lesioned 
suggest involvement of this area in DRL performance. However the findings from 
different studies were not always consistent. Generally, when the more ventral region of 
the mPFC (prelimbic and infralimbic cortices) was damaged, DRL performance was 
impaired as indicated by increased frequency of lever pressing and decreased 
frequency of earning reinforcers in rats (Nonneman et al. 1974; Numan et al. 1975; 
Rosenklide & Divac 1975; Izaki et al. 2007) and mice (Cho & Jeantet 2010). Yet this did 
not hold true for all studies (Kolb et al. 1974). When only the dorsal aspect of the mPFC 
(cingulate cortex) was lesioned, DRL performance was not affected (Neill 1976; Finger 
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et al. 1987). Findings from studies where the ventrolaterally-located orbitofrontal cortex 
(OFC) was lesioned are less consistent, with both impairments (Kolb et al. 1974; Neill 
1976) and improvements (Nonneman et al. 1974) in DRL performance reported. Given 
that the authors that did not find effects with mPFC lesions did find effects with OFC 
lesions, and vice versa, it is possible that differences in DRL methodology between 
studies may have influenced the findings. 
      The striatum also appears to have a role in DRL performance, although fewer 
studies have focused on this region. Lesioning the dorsal striatum in mice (Cho & 
Jeantet 2010) and the central caudate in rats (Schmaltz & Isaacson 1968) did not have 
an effect on DRL performance. However the nucleus accumbens (ventral striatum) does 
appear to have a role in DRL performance, with damage to this region, specifically the 
core of the nucleus accumbens rather than the shell, impairing successful DRL 
performance (Reading & Dunnett 1995; Pothuizen et al. 2005).  
     Thus, both the mPFC and the nucleus accumbens appear to have important roles in 
DRL performance, while the importance of the OFC and the dorsal striatum is less 
certain. These regions correspond with the ventromedial PFC and the nucleus 
accumbens in humans, which are considered important for response inhibition tasks 
that involve a “waiting” component (Robbins et al. 2012). 
     It is well established that dopaminergic signaling has an important role in response 
inhibition and, by extension, in impulsive behavior (Winstanley et al. 2006; Pattij & 
Vanderschuren 2008; Dalley & Roiser 2012). Evidence for the role of dopaminergic 
signaling is derived from a variety of studies including systemic injections of dopamine 
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agonists and antagonists, brain region-specific injections of dopaminergic drugs, and 
dopamine-specific lesioning studies. 
     In general, systemic administration of amphetamine (AMPH) increases lever 
pressing and decreases reinforcers earned in the DRL task in rodents (Robbins & 
Iversen 1973; Sanger et al. 1974; van Haaren et al. 1986; Wiley et al. 2000; Cheng & 
Liao 2007; Ferguson et al. 2007). However the effects are biphasic, with higher dosages 
(≥3.0 mg/kg) typically causing dramatic decreases in lever pressing, likely due to the 
stereotypies seen with higher AMPH doses (Sanger et al. 1974; van Haaren et al. 1986; 
Wiley et al. 2000). In accordance with this, treatment with the D1 receptor antagonist 
SCH 23390 decreased lever pressing, while combining SCH 23390 with AMPH resulted 
in a cancelling of each individual drug's effect on lever pressing (Cheng & Liao 2007). 
The D2 autoreceptor antagonists raclopride (Cheng & Liao 2007) and haloperidol (van 
Hest 1988) similarly decreased lever pressing, while combining raclopride with AMPH 
attenuated the effects of either drug alone (Cheng & Liao 2007). Thus, D1 and D2 
receptors both have roles in lever pressing on the DRL task, with lever pressing 
increasing when dopamine binds both receptors, and lever pressing decreasing when 
binding of dopamine to either receptor alone is antagonized.  
     The findings from studies focusing on the role of dopamine in specific brain regions 
in mediating DRL performance are in agreement with the systemic drug studies 
reviewed above. Infusion of dopamine and AMPH into the ventral anterior striatum in 
rats increased lever pressing (Neill 1976; Neill & Herndon 1978). In these studies, the 
infusions were dorsal to the nucleus accumbens. Sokolowski and Salamone (1994) 
investigated the role of dopamine in the mPFC by injecting 6-hydroxydopamine, which 
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is selectively neurotoxic for dopaminergic neurons, into the mPFC. They found that DRL 
lever pressing increased. Although these results seem paradoxical because they mirror 
those seen with AMPH, the authors speculate that it is possible that the prefrontal 
cortex inhibits subcortical motor activity. When dopaminergic input to the mPFC is 
removed, then inhibitory input to behavioral functions such as lever pressing, which is 
influenced by the striatum, may also be removed, resulting in increased lever pressing. 
     It is important to recognize that dopamine is not the sole neurotransmitter that 
modulates response inhibition. Serotonin (5-HT) also plays an important role, with the 
relative importance of dopamine and serotonin differing with the type of response 
inhibition and impulsivity (e.g. impulsive action vs. impulsive choice) (Pattij & 
Vanderschuren 2008; Eagle & Baunez 2010). Administration of a 5-HT1A receptor 
agonist resulted in decreased DRL lever pressing (Evenden et al. 1995), while 5-HT 
depletion in the nucleus accumbens, but not the frontal cortex, resulted in increased 
lever pressing (Fletcher et al. 2009). However results of a study of serotonergic 
manipulations in combination with AMPH suggest that while 5-HT has a role in DRL 
performance, the role of dopamine is more prominent (Mele & Caplan 1980). 
 
Previous Studies Examining the Effects of PCBs and PBDEs on DRL Performance 
     Studies of DRL performance subsequent to developmental PCB exposure have 
demonstrated that PCBs exposure causes less efficient performance in rodents (Holene 
et al. 1999; Sable et al. 2006; Sable et al. 2009), monkeys (Rice 1998), and humans 
(Stewart et al. 2006). Studies utilizing the DRL task to examine the effects of PBDE 
exposure on response inhibition have not been performed. However, Rice et al. (2009) 
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determined that developmental PBDE exposure in mice resulted in increased lever 
pressing in the fixed interval (FI) task. In the FI task, there is a predetermined interval of 
time which must elapse before a lever press results in reinforcement. However, unlike 
with DRL, premature lever pressing is not penalized.   
     The effects of lactational exposure to the non-coplanar congener PCB 153 in female 
rats were examined by Holene et al. (1999). PCB 153 was chosen because it typically 
comprises a large portion of the sum of PCBs quantified in human biological samples 
(Longnecker 2003). This study was a follow-up to one in which male rats were exposed 
to PCB 153 via nursing (Holene et al. 1998). In the earlier study with males, PCB 153 
resulted in increased lever pressing on the FI task. The study with females did not find 
any effects on FI performance, but then the subjects were placed on a conjunctive 
variable interval 120 sec.-DRL 14 sec. schedule which means that, on average, the 
DRL component of the schedule was in effect every 120 sec. The PCB-exposed 
females had shorter IRTs between lever presses and earned significantly less 
reinforcers than controls.  
     The effects of perinatal exposure to an environmentally relevant PCB mixture, the 
Fox River Mix (Kostyniak et al. 2005), on rats of both sexes was examined by Sable et 
al. (2006). In this study, dams were exposed to 0, 1, 3, or 6 mg/kg/day of the Fox River 
Mix. Offspring were tested on other behavioral tasks starting at post-natal day (PND) 
90, so DRL 15 sec. testing did not begin until approximately PND 240 and then 
continued for 30 days. Differences between PCB-exposed groups and the control group 
were not seen. However, the DRL component was followed with an extinction 
component during which lever pressing was never reinforced. Subjects exposed to 6 
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mg/kg PCBs lever pressed more frequently than other groups during the extinction 
component.  
     In a subsequent study, which also examined developmental methylmercury 
exposure, PCB-only treatment groups included dams that were exposed to 0, 1, or 3 
mg/kg/day of the Fox River Mix (Sable et al. 2009). DRL testing of the offspring began 
at approximately PND 180. Both the 1 and 3 mg/kg PCB groups had significantly 
smaller ratios of reinforced:non-reinforced responses. However there was not a 
significant difference in the number of lever presses or reinforcers delivered between 
these groups and the control group. The effect of 0.5 and 1 mg/kg AMPH on DRL 
performance was also evaluated. In controls of both sexes, 0.5 and 1 mg/kg AMPH 
significantly reduced the ratio of reinforced:non-reinforced lever presses in a dose-
dependent manner. In PCB-exposed males (both treatment groups), 1 mg/kg AMPH did 
not decrease the ratio to the extent that it did in controls, while there was not a 
difference in the effect of AMPH in females exposed to PCBs versus controls. Thus the 
higher dose of AMPH was less disruptive to DRL performance in males developmentally 
exposed to PCBs than it was in control males, but the same was not true for females.  
     While no studies have examined the effects of PBDEs on DRL performance, in one 
study Rice et al. (2009) evaluated the effects of daily oral exposure of PBDE congener 
209 (BDE 209) from PND 2 to 15 in mice on a FI schedule. No effects on FI 
performance were seen in subjects that began testing at approximately PND 90. 
However a separate cohort began testing at 16 months of age. In the older cohort, 
significant increases in lever pressing were seen in the 20 mg/kg exposure group as 
compared to controls and the 6 mg/kg exposure group. 
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     In monkeys, performance on DRL was assessed in a cohort of males dosed with a 
PCB mixture from birth to 20 weeks of age (Rice 1998). The PCB mixture was 
synthesized to contain 15 PCB congeners typically found in human breast milk in 
Canada. At 4.5 years of age, the cohort was tested on a DRL 30 sec. schedule (Rice 
1998). PCB-exposed subjects had increased responding, earned fewer reinforcements, 
and had shorter IRTs. 
     DRL has also been used to assess the consequences of prenatal PCB exposure in 
children. Stewart et al. (2006) evaluated the performance of 167 9.5-year old children 
on a DRL 20 sec. schedule during a 1 hour testing session. Both a decreased number 
of reinforcers earned and shorter IRTs were associated with higher concentrations of 
PCBs in the umbilical cord blood                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
     Based on what is known about the effects of PCBs and, to a much lesser extent, 
PBDEs on response inhibition, it was hypothesized that developmental PCB or PBDE 
exposure would result in poorer performance on DRL as compared to controls. 
Experimental measures of performance that could be affected included total lever 
presses, reinforcers earned, the ratio of reinforced:non-reinforced presses, and post-
reinforcement pause.  
     Based on what is known about the effects of PCBs and PBDEs on dopaminergic 
signaling, it was further hypothesized that developmental PCB or PBDE exposure 
would result in a shift in the dose response curve to dopaminergic agents. More 
specifically, based on in vivo evidence that PCBs result in lower synaptic concentrations 
of dopamine (Seegal et al. 2002), AMPH administration to PCB- or PBDE-exposed rats 
was predicted to improve DRL performance at lower doses and impair performance at 
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higher doses, although to less of an extent than in controls. Also, the D1/D2 receptor 
antagonist flupenthixol (FLU) was predicted to impair DRL performance to a greater 
extent in PCB- or PBDE-exposed subjects than in controls. 
 
2. Methods 
2.1. Animals and Exposure 
     Eighty-nine female and 89 male Long Evans rats were purchased from Harlan 
Laboratories (Indianapolis, IN) in four cohorts spaced 11 weeks apart, on average. 
Efforts were made to balance the number of subjects in each contaminant treatment 
group within and across cohorts. The females were approximately 8-10 weeks and the 
males 10-12 weeks of age upon arrival. The rats were singly housed in polycarbonate 
shoebox cages with pine bedding in a temperature- and humidity-controlled room (22 
°C, 40–55% humidity) on a 12-hour light–dark cycle (lights on at 0830 h). Food pellets 
(2020X Teklad Global Extruded Rodent Diet, Harlan Laboratories) and tap water were 
available ad libitum. All subjects were housed in facilities fully accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC). The Institutional Animal Care and Use Committee (IACUC) at the University 
of Illinois at Urbana-Champaign approved all procedures, which were in accordance 
with the guidelines of the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals (National Research Council, 2011). 
     Females were allowed to adapt to the vivarium for 6 days. They were then assigned 
to 1 of 5 exposure groups, balanced for body weight, and daily oral exposure to either 
PCBs or PBDEs exposure was initiated (see Table 3.1 for exposure groups). Exposure 
 56 
 
continued for 28 days prior to breeding to establish a maternal burden of PCBs or 
PBDEs. Exposure then continued during breeding and through pregnancy and lactation 
until PND 21.  
     The PCB mixture, termed the Fox River Mix, was formulated to parallel the PCB 
congener profile found in walleye, a popular fish consumed by sport anglers, in the 
contaminated Fox River in Wisconsin (Kostyniak et al. 2005). The mixture consisted of a 
combination of 4 different Aroclor mixtures: 35% Aroclor 1242 (Lot KB 05-415, 
Monsanto), 35% Aroclor 1248 (Lot F-110, AccuStandards), 15% Aroclor 1254 (Lot KB 
05-612, Monsanto), and Aroclor 1260 (Lot 021-020, AccuStandards). A new batch of 
the Fox River Mix was prepared for these studies using the same protocol described by 
Kostyniak et al. (2005). The Fox River Mix dosages of 3 and 6 mg/kg/day were chosen 
based on prior findings in this laboratory of effects on response inhibition as assessed 
by a DRL task (Sable et al. 2009) and extinction of DRL responding (Sable et al. 2006). 
     The commercial PBDE mixture, DE-71 (lot 7550OK20A, Great Lakes Chemical 
Corp.; gift of Kevin Crofton, USEPA), was chosen because its congener profile is similar 
to that found in fish in the Great Lakes (Manchester-Neesvig et al. 2001). Dreiem et al. 
(2010) suggested that the Fox River Mix is 2-3 times as potent as DE-71 in affecting 
dopaminergic signaling in vitro in rats. Given that 11.4 mg/kg DE-71 is isomolar to 6 
mg/kg of the Fox River Mix, DE-71 dosages of 11.4 and 22.8 mg/kg were chosen in an 
effort to have PCB and PBDE dosages that were approximately equipotent to 3 and 6 
mg/kg of the Fox River Mix.  
     For dosing, contaminants were diluted in corn oil (Mazola Corn Oil; ACH Food 
Companies, Inc.; Cordova, TN) and solutions were pipetted onto ½ of a vanilla wafer 
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cookie (Nabisco Nilla Wafers; Mondelez International; Deerfield, IL) at an appropriate 
volume (approximately 0.4 mL/kg body weight) to obtain the target dosages. For each 
subject, dosing volumes were adjusted daily according to body weight. The control 
subjects received cookies treated with corn oil alone. The cookies were fed to the 
females daily at approximately 1100 h. During breeding, the females were separated 
from the males each day for approximately 2 hours while the cookie was consumed.  
     The dosing solutions had target concentrations of 7.5 and 15 mg PCB/g, and 28.5 
and 57 mg PBDE/g, respectively. After the solutions were prepared, contaminant 
concentrations in the corn oil solutions were confirmed in the analytical toxicology 
laboratory of Paul Kostyniak, State University of New York at Buffalo. The results were 
then used to adjust the volumes of dosing solution given to subjects, if necessary, to 
attain the target dosages.  
 
2.2. Breeding, Pregnancy, and Weaning 
     Four weeks after contaminant exposure was initiated, each female was paired with a 
male in a hanging wire cage for 24 hrs daily, with the exception of the time females 
were removed for daily contaminant dosing. Food and tap water were available ad 
libitum. The wire cage allowed for daily assessment of sperm plugs that fell to the paper 
beneath, with the presence of sperm plugs being evidence that copulation occurred. 
Females that had evidence of sperm plugs by the 6th morning after pairing began were 
returned to their home cages for the duration of the experiment. Females that did not 
have evidence of sperm plugs were re-paired with different males that had produced 
sperm plugs with other females. Regardless of whether sperm plugs were seen upon 
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the 2nd pairing, all remaining females were returned to their home cages on the 9th 
morning.  
     Dosing was continued throughout pregnancy. Typically dams birthed, cleaned, and 
nursed their litters overnight, so if a clean litter with milk in their stomachs was present 
by 1100 h then that day was considered PND 0. If pups were present but had not been 
cleaned or nursed, a quick count of the number of pups was done and the dam and litter 
was not disturbed again until the afternoon when the number of pups was recounted. 
The presence of more pups indicated that parturition had continued and, thus, the next 
morning was considered PND 0. If no new pups were present, then the current day was 
considered PND 0. The pups were sexed and examined for gross abnormalities on PND 
0. All males and then all females were weighed as 2 separate groups so that average 
male and female weights could be calculated. Females that did not give birth were 
retained for a minimum of 23 days past the 9th morning of breeding, and then they were 
sacrificed and their uteri were examined for implantation sites. 
     Each litter had to have a minimum of 6 pups birthed by the dam to be included in the 
study. For litters with more than 8 pups, pups were culled to reduce the litter size to 8 
pups on PND 2. If a litter had 6 pups and there was a litter with >8 PND 2 pups 
available, 1 or 2 pups from the larger litter were cross-fostered to the smaller litter, but 
only if the donor litter was either in the control treatment group or in a group that was 
exposed to an equal or lesser dose of the same contaminant. This was done to attempt 
to equalize the relative amount of contaminant exposure via nursing per pup across 
litters. A total of 9 pups were cross-fostered from 5 donor litters to 7 recipient litters. One 
ear of cross-fostered pups was clipped to permit identification so that developmental 
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data from these pups were excluded from the study. All cross-fostered pups were 
euthanized on PND 21. On PND 7, PND 14, and PND 21, individual pup weights were 
recorded for each litter. Beginning on PND 10, pups within each litter were examined for 
eye opening. The numbers of male and female pups with open eyes were recorded 
each day until all pups had open eyes. 
     On PND 21, pups in each litter were ideally allocated as thus: 2 male-female pairs 
for behavioral testing (one pair for the DRL task; one pair for the delay discounting task, 
see Chapter 4), 1 pair for western blot analysis of brains on PND 21, and 1 pair for 
western blot analysis of brains on PND 90. Since litters did not always have equal 
numbers of each sex, preference was given to forming pairs for behavioral testing. This 
sometimes resulted in only one sex from a litter being available for PND 21 or PND 90 
western blot analysis. All dams and pups allocated for PND 21 analysis were 
euthanized by overexposure to CO2 followed by decapitation. The pups’ brains were 
quickly removed, weighed, and then snap frozen in liquid nitrogen. The brains were 
stored at -80° C until western blot analysis was performed. The dams’ livers and the 
pups’ livers and thymi were removed and weighed. The remaining pups were placed in 
a room with the same ambient and housing conditions described for the dams, except 
that the 12-hour light–dark cycle was reversed (lights off at 0830 h) for the remainder of 
the study. 
 
2.3. Behavioral Testing Procedures 
     Beginning at approximately PND 30, remaining pups of the same sex and same 
contaminant exposure group were double- or triple-housed. Their ears were punched at 
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that time to facilitate individual identification. Starting at PND 70, food restriction 
commenced for pups that were to begin behavioral testing. This was necessary so that 
food pellets could be used as reinforcement for the behavioral task. Target weights 
were either 85% of the weight at PND 70 or 350 g for males over 360 g and 250 g for 
females over 260 g. Food was gradually restricted so that weight loss occurred over 2 
weeks. Then enough food was provided to maintain body weight and allow for a 
maximum of 5 g weight gain each week until maximum weights of 350±25 g for males 
and 250±15 g for females were attained. Subjects allocated for western blot analysis of 
PND 90 brains were not food restricted. On PND 90 these subjects were euthanized by 
overexposure to CO2 followed by decapitation. Brains were collected, frozen, and stored 
the same as for the PND 21 brains. 
     Behavioral testing was conducted in 12 automated operant chambers (Med 
Associates; St. Albans, VT) housed in sound attenuated cubicles, with each ventilated 
by a fan. Each operant chamber contained 2 retractable response levers located 6 cm 
above the floor on either side of the centrally located pellet trough. A stimulus cue light 
was positioned above each response lever. An external pellet dispenser delivered 45 
mg AIN-76A purified rodent food pellets (TestDiet; Richmond, IN). An 80 decibel white-
noise generator masked extraneous sounds, while a house light positioned at the rear 
of the chamber provided general illumination. The experimental contingencies were 
programmed using Medstate Notation programming language (Med Associates; St. 
Albans, VT). 
 
Autoshaping (Training Phase 1) 
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     Daily sessions of operant testing were conducted 6 days per week excluding 
Sundays. Beginning at PND 90, an autoshaping program (training phase 1) was used to 
train the subjects to press the response levers. Both levers were extended for the entire 
session. The right cue light was programmed to illuminate for 15 sec every 3 minutes. If 
either lever was pressed while the cue light was illuminated, the cue light was 
extinguished and the response was reinforced. Otherwise, the cue light was 
extinguished and reinforcement was delivered at the end of the 15 sec period even 
though a response did not occur. Reinforcement consisted of one food pellet being 
dispensed and a 90 decibel tone sounding for 40 msec. If either lever was pressed 
before the 15 sec period began, reinforcement was delivered and the cue light above 
that lever illuminated for 40 msec. After 10 lever presses were attained by pressing any 
combination of response levers, delivery of reinforcers became contingent on lever 
presses so that every lever press was reinforced (i.e., a fixed ratio 1 (FR1) 
contingency). The house light and white noise remained on for the entire session. 
Autoshaping sessions terminated after either 60 minutes had elapsed or 100 reinforcers 
were delivered. Criterion for advancement to the next phase of training was 99 or 100 
lever presses for 2 consecutive sessions. Autoshaping was completed in 2.8 sessions 
on average (range 2 to 4). 
 
Fixed Ratio Training (Training Phases 2 and 3) 
     The next two training phases elicited lever pressing in response to cue light 
illumination. At the onset of each session for training phase 2, one of the levers was 
extended at random and the cue light above it was illuminated. Every response was 
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reinforced, thus continuing the FR1 contingency. After 5 lever presses, the lever 
retracted and the cue light extinguished while the opposite lever was extended and the 
opposite cue light illuminated. Active levers and lights alternated after every 5th lever 
press so the subject would not learn to associate reinforcement with a particular lever 
(i.e., develop a side bias). White noise was present but the house light was not 
illuminated throughout this and all subsequent phases.  Animals were required to earn 
100 reinforcers across three consecutive sessions of phase 2 in order to move to the 
next training phase. This phase was completed in 3 sessions on average (all subjects 
completed in 3 days except for one that was mistakenly tested for only 2 days). Training 
phase 3 followed the same contingencies as phase 2 except that only the right 
response lever was used, which remained true for all remaining phases of the 
experiment. Subjects trained on phase 3 for 2 sessions with no criterion for 
advancement, except 3 subjects were mistakenly trained for 3 days. 
 
DRL Training (Training Phases 4-6) 
     The next 3 phases of training introduced delays during which the subject had to 
withhold lever pressing in order to receive reinforcement. All trials were initiated by a 
lever press, and sessions terminated after 90 min elapsed or 200 reinforcers were 
delivered. During training phase 4, a 5 sec minimum required IRT was required in order 
to receive reinforcement (DRL 5). If the subject initiated a trial and then pressed the 
lever before 5 sec elapsed, the clock was reset so that the subject had to wait a 
minimum of 5 sec before pressing again in order to receive reinforcement. DRL 5 
training lasted 2 sessions, except for 3 subjects mistakenly trained for 3 days. Phase 5 
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required a 10 sec interval to elapse in order for presses to be reinforced (DRL 10). DRL 
10 training lasted 2 sessions for all subjects. The required IRT in phase 6 was 15 sec 
(DRL 15). Subjects remained on this phase for a minimum of 30 daily sessions (range 
30 to 34, average 31.8) except for one subject that was mistakenly tested for 29 days. 
The drug trials commenced for all subjects on the same day. 
 
Drug Trials (Phase 7) 
     The experimental parameters for phase 7 were identical to those in phase 6: DRL 
15. AMPH dosages were selected based on those used in similar DRL studies (Sanger 
et al. 1974; van Haaren et al. 1986; Ferguson et al. 2007). Because studies examining 
the effects of acute FLU administration on DRL performance could not be located, FLU 
dosages were selected based on those used in studies of a different task of response 
inhibition, delay discounting (Cardinal et al. 2000; Floresco et al. 2008). Drugs were 
prepared each day of administration and then protected from light to prevent 
photodecomposition. Each drug was administered at 4 different doses, including a 
saline-only vehicle control which ensured that each subject served as its own control. 
cis-Flupenthixol (FLU) (Sigma-Aldrich; St. Louis, MO) was prepared on injection days by 
dissolving the drug in 0.9% sterile saline to concentrations of 0 (vehicle), 0.05, 0.125, 
and 0.25 mg/mL for respective doses of 0, 0.05, 0.125, and 0.25 mg/kg. d-
Amphetamine sulfate (AMPH) (Sigma-Aldrich; St. Louis, MO) was prepared on injection 
days by dissolving the drug in 0.9% sterile saline to concentrations of 0 (vehicle), 0.25, 
0.5, and 1.0 mg/mL for respective doses of 0, 0.25, 0.5, and 1.0 mg/kg. Intraperitoneal 
injections of FLU and AMPH were administered 30 and 10 minutes, respectively, before 
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testing, based on their pharmacokinetic properties (Jorgensen et al. 1969; Kunh and 
Schanberg 1978).  
     Injections were administered in 3 successive blocks: FLU, then AMPH, then 
FLU/AMPH combined (COMBO) (see Figure 3.1). Each dose within a block was 
administered once to each subject, with the dosing order individually randomized using 
a balanced Latin Square design. Drugs were administered on Tuesdays and Fridays, 
with 7 calendar days between each block of injections. Additional saline injections were 
given both two and one day before the FLU block, one day before the AMPH block, one 
day before the COMBO block, and one day after the COMBO block. The first additional 
saline injection was performed to acclimate the subjects to the injection procedure. 
Results from the subsequent additional saline days were examined to assess whether 
baseline performance remained stable across the drug trials.  
 
2.4. Data Analysis 
     All statistical analyses were conducted using SPSS for Windows (version 20.0, 
SPSS Inc.; Chicago, IL) with statistical significance set at p<0.05. For some repeated-
measures factors, a sphericity violation was noted. In these instances a Greenhouse-
Geisser correction was used to reduce the risk of a Type I error if ε was <0.75 and a 
Huynh-Feldt correction was used if ε was ≥0.75 (Rogan et al. 1979). Analyses requiring 
these corrections are reported using the adjusted degrees of freedom rounded to the 
nearest integer. When significant main effects or interactions were obtained, post hoc 
one-way ANOVA followed by Tukey’s least significant difference (LSD) analyses were 
performed. Data are reported as mean ± SEM. 
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Reproductive and Developmental Endpoints 
     Reproductive endpoints (see Table 3.1) included the live birth rate, which is the 
percent of dams delivering ≥1 live pup. If a dam delivered any live pups then endpoints 
from her litter were included in analyses of litter size, percent live pups delivered, 
percent male pups delivered, and percent gestational weight gain. Litter size was the 
number of live pups delivered on PND 0. Percent live pups delivered was litter size / the 
number of uterine implantation sites. Percent gestational weight gain was (gestation day 
21 weight – gestation day 0 weight) / gestation day 0 weight. In addition, percent 
lactational weight gain and ratio of liver weight:body weight on PND 21 were measured 
for the dams with litters with ≥6 pups. Percent lactational weight gain was (highest 
lactational weight – weight after parturition) / weight after parturition. Dependent 
measures were analyzed using between-subjects ANOVAs with treatment group as the 
independent variable. 
     Developmental endpoints (see Table 3.2) included weights on PND 0 (birth weight), 
PND 7, PND 14, and PND 21 (weaning weight). Ratios of brain, liver, and thymus to 
body weight, and day of eye opening (of at least 1 eye), were also examined. 
Dependent measures were analyzed using between-subjects ANOVAs with treatment 
group and sex as independent variables.  
     A total of 66 dams and their litters had data included. Of the 89 dams that began the 
study, 23 had data excluded for the following reasons: failure to eat daily cookie (1), not 
pregnant (10), placentation sites present but no live pups delivered (2), <5 pups in litter 
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(6), poor maternal care and/or cannibalization of pups (4). Seven control dams were 
among the 23 excluded. 
 
DRL Dependent Measures 
     Sixty male-female pairs completed behavioral testing and were included in the 
analyses of drug trials. Their allocation to treatment groups is as follows: 12 pairs of 
control, 13 pairs of 3 mg/kg PCB, 11 pairs of 6 mg/kg PCB, 11 pairs of 11.4 mg/kg 
PBDE, and 13 pairs of 22.8 mg/kg PBDE. Three pairs of subjects from the 6 mg/kg PCB 
group were removed from the study: 1 pair because the female died of unknown causes 
before PND 90, and 2 pairs because 1 member of each pair was injured. The data from 
one of the latter pairs was included in the analyses of training data but not of drug trials. 
Three additional litters were not included in the study: 1 litter had all female pups, and 2 
litters had only 1 male-female pair which were assigned to a concurrent behavioral 
study rather than to the DRL study. 
     Five dependent measures were evaluated. Total lever presses were presses that 
occurred during the IRT phase of DRL, so presses that initiated each trial were 
excluded. Reinforcers earned reflects the number of lever presses that resulted in 
delivery of reinforcement (i.e., presses that occurred after the required IRT elapsed). 
The ratio of reinforced:non-reinforced presses is the number of presses that were 
reinforced divided by the number of presses that were premature and thus did not result 
in reinforcement. Post-reinforcement pause spans the time from when the subject made 
a reinforced lever press to the time when it made the next lever press to begin a new 
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trial. The latency to collect reinforcement is the length of time the subject took to collect 
the food pellet after it made a reinforceable press.  
 
Training 
     The dependent measures total lever presses and reinforced:non-reinforced lever 
presses from the first day of DRL 5, DRL 10, and DRL 15 were analyzed separately 
using 2 (sex) x 5 (treatment) mixed ANOVAs with sex (nested within litter) as the 
repeated measures factor (Hughes 1979). Also, total lever presses and reinforced:non-
reinforced lever presses from the first 30 days of DRL 15 were averaged across six day 
blocks to yield 5 blocks of testing. These measures were then separately analyzed 
using 5 (block) x 2 (sex) x 5 (treatment) mixed ANOVAs with block and sex (nested 
within litter) as the repeated measures factors.  
     Performance on all 5 dependent measures (total lever presses, ratio of 
reinforced:non-reinforced presses, reinforcers earned, post-reinforcement pause, and 
latency to collect reinforcement) was separately examined for testing block 5 using sex 
(2) x treatment (5) repeated-measures ANOVAs with sex (nested within litter) as the 
repeated measures factor. This was done in order to examine baseline performance 
before drug trials began. 
 
Drug Trials 
     All 5 dependent measures (total lever presses, ratio of reinforced:non-reinforced 
presses, reinforcers earned, post-reinforcement pause, and latency to collect 
reinforcement) were analyzed separately for FLU, AMPH, and COMBO trials using 4 
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(dose) x 2 (sex) x 5 (treatment group) mixed ANOVAs with dose and sex (nested within 
litter) as the repeated measures factors. For post-reinforcement pause, 1outlier was 
noted at 0.05 mg/kg FLU which increased the mean pause time for the same sex and 
treatment group by 72%. For latency to collect reinforcement, 1 outlier was detected at 
0.25 mg/kg FLU and 3 were detected for 0 mg/kg AMPH which increased the mean 
latencies for the same sex and treatment groups by 44% to 91%. Due to the 
pronounced effects on performance measures that these 5 outliers had, each of their 
values was mean replaced with the average performance of other members of the same 
sex and treatment group. 
 
3. Results 
3.1. Reproductive and Developmental Endpoints 
     No overt clinical signs of toxicosis were noted in the dams. There were no significant 
differences between treatment groups for the following dam-related measures: live birth 
rate, litter size, percent live pups, percent male pups, percent gestational weight gain, 
and dam’s liver weight:body weight ratio (p=0.095 for the last measure). The main effect 
of treatment for percent lactational weight gain was significant [F(4,61)=3.0, p=0.026]. 
However post-hoc comparisons between groups did not detect any significant 
differences between treatment groups. Upon visual inspection of the data, percent 
lactational weight gain appeared to be less for the 3 mg/kg PCB and 11.4 mg/kg PBDE 
dams as compared to the control and 6 mg/kg PCB dams. Values for each treatment 
group are reported in Table 3.1. 
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     No overt clinical signs of toxicosis were noted in the pups. Treatment group 
significantly affected pup weights at all days measured: birth [F(4,140)=8.8, p<0.001], 
PND 7 [F(4, 126)=4.7, p=0.002], PND 14 [F(4,126)=7.2, p<0.001], and PND 21 
[F(4,126)=19.9, p<0.001] (see Table 3.2). Post-hoc analysis revealed that at birth, the 
weights of the 22.8 mg/kg PBDE group were greater than the weights of control and 
both PCB groups (all p<0.05). On PND 7, the 22.8 mg/kg PBDE group no longer 
weighed more than the control group, but did still weigh more than the 6 mg/kg PCB 
group (p<0.001). Although they were not significantly different from controls at birth or 
PND 7, by PND 14 and 21, the body weights in both PCB groups were significantly less 
than the control and both PBDE groups (all p<0.05 at PND 14, all p≤0.005 at PND 21). 
At weaning, the 3 mg/kg PCB group weighed 91% of control and the 6 mg/kg group 
weighed 85% of control. 
     The most notable organ weight finding for the pups was the ratio of liver:body weight, 
which was significantly affected by treatment [F(4,103)=124.3, p<0.001]. Post-hoc 
analysis revealed that all PCB and PBDE groups had greater liver:body weight ratios 
than control (all p<0.001), and also that both PCB and the 22.8 mg/kg PBDE group had 
greater liver weight ratios than the 11.4 mg/kg PBDE group (all p<0.005).  
     Thymus:body weight ratio was also significantly affected by treatment 
[F(4,103)=22.3, p<0.001]. Post-hoc analysis revealed that both PCB groups had smaller 
thymus:body weight ratios than the control group and both PBDE groups (all p≤0.01). 
None of the treatment groups differed from control with respect to brain:body weight 
ratio. 
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     The average day of eye opening was significantly affected by treatment 
[F(4,125)=3.6, p=0.008], with post-hoc analysis revealing that the 6 mg/kg PCB group 
opened their eyes 1.3 and 1.2 days earlier than the control and 22.8 mg/kg PBDE 
groups, respectively (all p<0.05).                                                                                                                                                
 
3.2. Training 
Day 1 of DRL 5, DRL 10, DRL 15 
     Contaminant treatment group was not a significant factor for any of the days 
examined, nor were there any significant interactions with treatment. Males lever 
pressed significantly more [F(1,56)=23.6, p<0.001] (see Figure 3.2), resulting in a 
significantly smaller ratio of reinforced:non-reinforced lever presses [F(1,56)=13.9, 
p<0.001] (not shown) than females on the first session of DRL 5. However sex was not 
a significant factor for either measure on day 1 of DRL 10 or DRL 15. 
 
Training During DRL 15 Phase 
     Analysis of the data from the DRL 15 training phase did not find a main effect of 
treatment, but a main effect of blocks resulted from significant decreases in total lever 
presses [F(2,108)=88.3, p<0.001] (see Figure 3.3) and increases in reinforced:non-
reinforced presses in all groups [F(3,195)=103.5, p<0.001] (see Figure 3.3). Neither the 
main effect of sex nor any of the interactions were significant. 
     Evaluation of all 5 dependent measures (total lever presses, ratio of reinforced:non-
reinforced presses, reinforcers earned, post-reinforcement pause, and latency to collect 
reinforcement) during block 5 did not reveal significant effects of treatment group or sex 
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for any of the measures. Analyses were done in order to examine baseline performance 
after it had stabilized and just before drug trials began. In block 5, there were an 
average of 299.6 ± 6.6 total lever presses and 121.2 ± 2.6 reinforcers earned per 
session. The average ratio of reinforced:non-reinforced lever presses was 0.843 ± 
0.036. The average post-reinforcement pause was 17.3 ± 0.6 sec while the average 
latency to collect reinforcement was 0.42 ± 0.01 sec. 
 
3.3. Drug Trials 
Total Lever Presses During Drug Trials 
     While lever pressing during FLU trials was not significantly affected by contaminant 
treatment group, lever pressing decreased with increasing doses of FLU 
[F(2,119)=43.9, p<0.001] (see Figure 3.4.A). Post-hoc analysis revealed that the 
administration of 0.25 mg/kg FLU resulted in significantly less lever pressing than when 
vehicle or the 2 lower dosages were administered (all p<0.001). Administration of 0.125 
mg/kg also resulted in less lever pressing than the vehicle control (p=0.029). Lever 
pressing decreased to 89% and 64% of control at 0.125 and 0.25 mg/kg, respectively.  
Neither the main effect of sex nor any of the interactions were significant. 
     Although treatment group did not have an effect, lever pressing increased with 
increasing doses of AMPH [F(2,98)=74.5, p<0.001] (see Figure 3.4.B), in contrast to the 
drug dose effect of FLU. Post-hoc analysis revealed that the administration of 1.0 mg/kg 
resulted in significantly more lever pressing than when the vehicle control or the 2 lower 
dosages were administered (all p<0.001). Administration of 0.5 mg/kg also resulted in 
more lever pressing than the vehicle control (p=0.009). Lever pressing increased to 
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122% and 185% of control at 0.5 and 1.0 mg/kg, respectively. Neither the main effect of 
sex nor any of the interactions were significant. 
     For the drug combinations, treatment group was not significant, but drug dose 
[F(3,155)=25.3, p<0.001] and sex [F(1,55)=4.8, p=0.033] were significant factors. 
However, none of the interactions, including the dose x sex interaction, were significant. 
Post-hoc analysis of drug dose revealed that the 0.125/1.0 mg/kg COMBO resulted in 
significantly more lever pressing than other dosages (all p<0.001) (see Figure 3.4.C). 
However post-hoc comparison of sex at each dose determined that there were no 
significant sex differences at any of the individual combination doses. 
 
 Reinforcers Earned During Drug Trials 
     The number of reinforcers earned was not affected by contaminant treatment, but it 
did decrease with increasing doses of FLU [F(2,100)=74.5, p<0.001] (see Figure 3.5.A). 
Neither the main effect of sex nor any of the interactions were significant. Post-hoc 
analysis revealed that significantly fewer reinforcers were earned after 0.25 mg/kg FLU 
than with the other 3 doses (all p<0.001). Additionally, significantly fewer reinforcers 
were earned with 0.125 mg/kg than with the vehicle control or the 0.05 mg/kg FLU dose 
(all p<0.05). The 0.125 and 0.25 mg/kg FLU doses resulted in only 90% or 63%, 
respectively, of reinforcers earned relative to the vehicle control. 
     Reinforcers earned were not affected by treatment, but they decreased with 
increasing doses of AMPH [F(3,151)=80.4, p<0.001] (see Figure 3.5.B), similar to the 
effect of dose for FLU. Additionally, the main effect of sex was significant [F(1,55)=6.8, 
p=0.011], but the interaction between sex and dose was not. Females earned less 
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reinforcers than males. The effect of sex was not seen with FLU or during initial pre-
drug testing. Other interactions were not significant. Post-hoc analysis revealed that 
significantly fewer reinforcers were earned after 1.0 mg/kg AMPH than with the other 3 
doses (all p<0.001). Additionally, significantly fewer reinforcers were earned with 0.5 
mg/kg than with control or 0.25 mg/kg AMPH (p<0.001). The 0.5 and 1.0 mg/kg AMPH 
doses resulted in only 87% or 60%, respectively, of reinforcers earned relative to the 
vehicle control. 
     For drug combinations, treatment group was not significant, but drug dose 
[F(3,150)=78.9, p<0.001] and sex [F(1,55)=4.9, p=0.031] were significant factors, with 
the dose x sex interaction also being significant [F(3,160)=4.5, p=0.005]. Other 
interactions were not significant. Post-hoc analysis revealed that at 0.125/1.0 mg/kg 
COMBO males earned significantly more reinforcers than females exposed to the same 
combined FLU/AMPH doses (p=0.018), but there were no significant sex differences at 
any of the other dose combinations (see Figure 3.5.C). Regarding responses to doses 
within each sex, all 3 COMBO doses resulted in females earning significantly less 
reinforcers when compared to the vehicle control (all p≤0.001) (see Figure 3.5.D). Also 
females earned significantly less reinforcers at 0.125/1.0 mg/kg than at 0.125/0.5 mg/kg 
(p=0.001). Males receiving the 0.125/1.0 and 0.25/1.0 mg/kg COMBO drug doses 
earned significantly fewer reinforcers than at 0/0 and 0.125/0.5 mg/kg (all p<0.001 
except p=0.015 for the comparison of 0.125/0.5 to 0.125/1.0) (see Figure 3.5.D). 
 
Ratio of Reinforced:Non-Reinforced Lever Presses During Drug Trials 
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     For the FLU trials, contaminant treatment, drug dose, and sex did not significantly 
affect the ratio of reinforced:non-reinforced presses. There were no significant 
interactions.  
     While treatment did not have a significant effect during the AMPH trials, increasing 
doses of AMPH decreased the ratio of reinforced:non-reinforced presses 
[F(3,155)=50.3, p<0.001] (see Figure 3.6.A). Neither the main effect of sex nor any of 
the interactions were significant. Post-hoc analysis revealed that the ratios of 
reinforced:non-reinforced presses at 0.5 and 1.0 mg/kg were each significantly different 
from the ratios at all other doses, with the ratios at 0.5 and 1.0 mg/kg being 61% and 
32% of the vehicle control, (all p<0.005, all p<0.001 respectively). 
     For combined FLU/AMPH, treatment was not significant, but drug dose was a 
significant factor [F(3,142)=53.0, p<0.001] (see Figure 3.6.B). Neither the main effect of 
sex nor any of the interactions were significant. Post-hoc analysis revealed that all 
combination dosages resulted in decreases in the ratio of reinforced:non-reinforced 
presses compared to vehicle control (all p<0.001). Furthermore the ratios seen with 
0.125/1.0 and 0.25/1.0 mg/kg COMBO did not differ from each other but were 
significantly less than the ratio with 0.125/0.5 mg/kg (all p<0.05).  
 
Post-Reinforcement Pause During Drug Trials 
     While contaminant treatment did not affect post-reinforcement pause, increasing 
FLU doses increased the pause time [F(2,120)=28.8, p<0.001] (see Figure 3.7). Neither 
sex nor any interactions were significant. Post-hoc analysis revealed that the post-
reinforcement pause at a dose of 0.25 mg/kg was significantly greater than the pause 
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after the vehicle control and 0.05 mg/kg dose (all p≤0.001), with the pause time 
increasing 145% from 17.1 sec after vehicle control to 24.8 sec after the 0.25 mg/kg 
dose. 
     Treatment had no effect on post-reinforcement pause during the AMPH and COMBO 
trials. While AMPH dose had no effect on post-reinforcement pause, the main effect of 
dose for the COMBO trials was significant [F(2,99)=4.5, p=0.016]. However, none of the 
post-hoc comparisons between the individual doses were significant, although visual 
inspection of the graph (not shown) suggests that there was a trend for post-
reinforcement pause to be longer at the 0.25/1.0 mg/kg COMBO. Neither sex nor any 
interactions were significant for the AMPH or COMBO trials. 
 
Average Latency to Collect Reinforcement During Drug Trials 
     Contaminant treatment did not have a significant effect on latency to collect 
reinforcement during any of the drug trials. Increasing FLU doses increased the latency 
to collect reinforcement [F(2,101)=12.2, p<0.001] (see Figure 3.8). Specifically, the 
latency was longer at the 0.25 mg/kg dose than at the vehicle control or 0.05 mg/kg FLU 
doses (all p≤0.001), increasing 130% from 0.40 sec at control to 0.52 sec at 0.25 mg/kg. 
AMPH dose alone did not affect the latency, but when both FLU and AMPH were 
administered together, dose had a significant effect on latency [F(2,106)=3.9, p=0.025] 
(not shown). Post-hoc analysis revealed that increasing the dose of FLU to 0.25 mg/kg 
significantly prolonged the latency as compared to 0.125/0.5 mg/kg (p=0.047) and 
0.125/1.0 mg/kg (p=0.018) COMBO. Yet none of the combination dosages resulted in a 
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latency that was significantly different than the control. Sex did not have an effect on the 
latency during any of the drug trials, nor were any interactions significant.  
      
Stability of Performance During Drug Trials 
     Total lever presses, reinforcers earned, and the ratio of reinforced:non-reinforced 
lever presses were compared across the 4 saline days that were included before each 
block of drug injections and at the end of the experiment. Although saline injection day 
was significant for total lever presses, reinforcers earned, and the ratio of 
reinforced:non-reinforced lever presses in the repeated-measures analyses (all F≤4.5, 
all p<0.05), performance between individual saline injection days did not significantly 
differ on any of the post-hoc comparisons. Visual inspection of the data (not shown) 
supports that performance did not change over the course of the drug trials. 
 
4. Discussion 
     The doses of PCBs and PBDEs used in this study were sufficient to cause systemic 
changes including increased liver weights and decreased thymus weights, as well as 
reductions in pup body weights, at weaning; yet the exposures did not have long term 
effects on inhibitory control as assessed in the DRL task and did not alter the pattern of 
response to pharmacologic challenges with the dopaminergic drugs AMPH and FLU on 
the DRL task. PCB and PBDE treatment did not affect total lever presses, reinforcers 
earned, the ratio of reinforced:non-reinforced presses, post-reinforcement pause, or the 
latency to collect reinforcement. The absence of contaminant effects is contrary to the 
experimental hypotheses. The absence of effects is also contrary to the majority of prior 
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findings including those of Holene et al. (1999) and Sable et al. (2009) in rats, Rice 
(1998) in monkeys, and Stewart et al. (2006) in humans, but is consistent with a Sable 
et al. (2006) study in rats.  
      
Lack of Contaminant Effects on Behavior at Baseline (Block 5) 
     The main goals of this study were to determine whether PCBs or PBDEs cause 
impulsive performance on DRL or cause differences in dopaminergic-signaling that 
result in changes in DRL performance that could be detected by drug challenge. 
However, there were no differences in DRL performance between PCB- or PBDE-
exposed groups and controls either before or during challenges. 
     Because prior studies have shown that PCB exposure impairs DRL task 
performance (Holene et al. 1999; Sable et al. 2009), it is important to consider the 
differences between the current study and the prior ones to attempt to understand the 
results. The study design by Holene et al. (1999) differs the most from the current study. 
Dams were dosed with 5 mg/kg of one congener, PCB 153, every other day from PND 3 
to 13 (6 doses total). Then multiple female pups from each litter underwent behavioral 
testing, first on a FI-extinction task, then on a conjunctive variable interval 120 sec.-DRL 
14 sec. schedule. The latter schedule results in a very low rate of responding because 
not only must a subject wait at least 14 sec. to lever press to satisfy the DRL 
component, but reinforcers are only available to be delivered every 120 sec., on 
average, as dictated by the variable interval component. It was found that the PCB 153-
exposed females pressed more frequently during the initial sessions of the task, but that 
there was no difference with controls by the later sessions of the task.  
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     The current study differs from the PCB 153 study in that a mixture of PCB congeners 
was evaluated and the subjects were tested solely on a DRL task, with no prior testing 
experience. The Fox River Mix is comprised of numerous congeners, including PCB 
153. Prior studies have demonstrated that individual PCB and PBDE congeners can 
differ greatly in their effects on intracellular endpoints, especially on calcium 
sequestration and release, and protein kinase C translocation (Kodavanti & Ward 2005; 
Fonnum et al. 2006). So the neurobehavioral effects of a PCB mixture would not 
necessarily be expected to be similar to that of an isolated congener. Another 
consideration is that the contingencies of the variable interval-DRL schedule likely tax 
subjects’ response inhibition greater than DRL alone because appropriately timed lever 
presses that meet the DRL contingency often go unrewarded because of the variable 
interval contingency. Similar to this, Mele et al. (1986), in a study evaluating perinatal 
exposure to Aroclor 1248 in monkeys performing a FI task, only elicited increased 
responding in the PCB-exposed subjects when 25% of the earned reinforcers were 
randomly omitted. Thus it is possible that the contingencies of the DRL 15 schedule in 
the current study do not sufficiently tax response inhibition mechanisms to the extent 
that differences caused by contaminant exposure can be detected.  
     The findings of Sable et al. (2006) more closely match the current findings. Similar 
experimental methods were followed in that study, namely a perinatal exposure 
paradigm in Long Evans rats including daily Fox River Mix dosages of 0, 3, and 6 
mg/kg. No significant differences between PCB-exposed subjects and controls were 
found in the DRL component of the study. Increased lever pressing in PCB-exposed 
subjects was seen in the extinction component of the study. The current study did not 
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include an extinction component after the initial training period because drug challenges 
were administered. A notable difference between studies is that in the 2006 study the 
subjects did not begin DRL until approximately PND 240, after completing testing on 
spatial reversal learning and delayed spatial alternation, whereas subjects began testing 
at PND 90 with no prior testing experience in the current study. 
     A second study that closely matches the current one in methodology is that by Sable 
et al. (2009). In that study, there were 1 and 3 mg/kg PCB treatment groups, as 
compared to 3 and 6 mg/kg groups in the current study. A clear dose response of 
decreasing ratio of reinforced:non-reinforced presses with increasing PCB dose was 
seen. Additionally, both groups of PCB-exposed males, but not females, were less 
sensitive to the disruptive effect of 1 mg/kg AMPH on reinforced:non-reinforced 
responses. Similar to the 2006 study, the subjects in the 2009 study did not begin DRL 
until approximately PND 180, after completing testing on spatial reversal learning, 
delayed spatial alternation, and differential reinforcement of high rates of responding, 
compared to the current study in which testing began at PND 90 with no prior testing 
experience. 
     One possible explanation for the difference in findings is that a DRL 15 sec schedule 
is not as sensitive to contaminated-related changes as would be ideal. While the ratio of 
reinforced:non-reinforced responses was significant in the 2009 study, total lever 
presses and reinforcers delivered, which are the two values used to determine the ratio, 
did not differ between PCB groups and controls. If this is true, then it is possible that 
unrecognized factors, such as a greater degree of individual variation between subjects 
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or the extent of prior testing experience, influenced performance to a great enough 
extent that any effects due to contaminant exposure were obscured.  
     Another possibility related to the issue of task sensitivity is whether there are strain 
differences in DRL performance that may make some strains less suited for detecting 
differences in performance. If a strain is already relatively impulsive, then it may be 
harder to detect whether a treatment, be it a contaminant or a drug, makes subjects 
from that strain more impulsive. The question of whether Long Evans rats may be too 
impulsive to reliably detect changes that have small to moderate effect sizes is 
interesting, but it awaits further research before it can be answered. 
     Another factor that differed between this and the two prior studies was a dietary 
change made in the current study to reduce exposure to phytoestrogens. In the 2006 
and 2009 studies, the subjects were housed with corn cob bedding and fed 8604 diet 
(Teklad Global Extruded Rodent Diet, Harlan Laboratories). In the current study, the 
subjects were housed on pine bedding and fed 2020X diet, which is described by the 
manufacturer as a “minimal” phytoestrogen diet (Harlan Laboratories 2013). Although it 
seems unlikely, it can not be ruled out that there was a dietary interaction between the 
8604 diet (which varies greatly from lot to lot in phytoestrogen content) and the PCBs in 
the 2009 study which was altered by reducing phytoestrogen exposure in the current 
study. PCBs (Dickerson & Gore 2007) and PBDEs (Ceccatelli et al. 2006; Hamers et al. 
2006) potentially interact with both endogenous estrogen and testosterone. By reducing 
phytoestrogen exposure in the current study, the balance of endogenous hormones, 
hormonal xenobiotics, or both in the subjects could have been altered through 
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mechanisms such as increased biotransformation and clearance (Kirk et al. 2001), 
resulting in an attenuation of behavioral effects that are mediated hormonally. 
     The factors which may have reduced the sensitivity of the DRL to detect differences 
between treated and control subjects may also explain why the findings of the current 
study were not concordant with previous studies in monkeys (Rice 1998) or humans 
(Stewart et al. 2006). However, until questions about possible intra-species influences 
on DRL performance, such as strain differences, are more closely explored, it will 
remain difficult to make inferences from the findings of the current study to other 
species. 
 
Non-Contaminant Effects During Training      
     With toxicant-naïve subjects, lever pressing increases on days in which a transition 
to a longer delay occurs during the DRL task (Pizzo et al. 2009). A prior study of 
adolescent exposure to Aroclor 1248 revealed that PCB-treated subjects lever pressed 
on the FI task more frequently than controls on the first day of transitioning to schedules 
in which a longer period of time elapsed before reinforcement became available (Berger 
et al. 2001). However, in the current study, PCB or PBDE exposure did not result in a 
change in frequency of lever pressing relative to controls on these transitional days. Of 
interest, males lever pressed more frequently than females on the first day of DRL 5, 
while there were no differences in lever pressing between sexes in the subsequent 
phases of the experiment. Increased lever pressing by males has been noted in at least 
one prior study of DRL 15 performance in rats (van Hest et al. 1987). However the 
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finding of no sex difference in subsequent phases of the task parallels results of DRL 
studies performed in our lab (Sable et al. 2009) and others (van Haaren et al. 1986). 
     The finding that total lever presses decreased while the ratio of reinforced:non-
reinforced presses increased over the 30 days of DRL 15 training indicates that the 
subjects learned the experimental contingencies, with their performance becoming 
increasingly more efficient over the training period. PCB or PBDE exposure did not 
result in differences in these learning curves, or differences at the end of the training 
period, that differed from controls. 
 
Non-Contaminant Effects During Drug Trials 
     AMPH increased lever pressing while FLU decreased lever pressing in DRL 15 in a 
dose-dependent manner. Additionally, both AMPH and FLU decreased reinforcers 
earned in a dose-dependent manner. Also, FLU significantly increased the post-
reinforcement pause and the latency to collect reinforcement at the highest dosage, 
0.25 mg/kg. These findings confirm that dopaminergic signaling influences DRL 
performance in the absence of contaminant treatment effects. 
     The finding that AMPH increases DRL lever pressing is consistent with prior studies 
(Robbins & Iversen 1973; Sanger et al. 1974; van Haaren et al. 1986; Wiley et al. 2000; 
Cheng & Liao 2007; Ferguson et al. 2007). Several studies have shown that AMPH 
administration results in a shift to shorter IRTs (Sanger et al. 1974; Wiley et al. 2000; 
Cheng & Liao 2007). The end result of the IRT shift is that premature responding 
increases, thus the trial timer is reset more frequently and less reinforcers are earned. 
The increase in lever pressing was marked enough to greatly reduce the ratio of 
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reinforced:non-reinforced lever presses. Importantly, AMPH did not alter post-
reinforcement pause or the latency to collect reinforcement at the doses used, so the 
changes can not be attributed to changes in motoric ability or motivation of the subjects.  
     The effects of FLU on DRL performance have not been reported before, with the 
exception of a study in which rats were initially trained on DRL, then given 36 weekly 
injections of a long-lasting depot formulation of FLU, and finally retested on DRL 7 
weeks after the last FLU injection (Nielsen 1977). Due to dramatically different study 
designs, the findings of the 2 studies are difficult to compare, although both found that 
FLU resulted in decreased lever pressing on a DRL schedule. In the current study, less 
reinforcers were earned at the higher dosages, although the extent to which lever 
pressing decreased was not enough to significantly alter the ratios of reinforced:non-
reinforced presses. The latency to collect reinforcers was significantly increased at 0.25 
mg/kg. This may suggest that the highest dose of FLU affected the subjects’ motivation, 
but an increase in latency of 0.12 sec above control by itself does not suggest a large 
motivational deficit. However, a 7.7 sec increase in post-reinforcement pause time 
above control at 0.25 mg/kg makes it more difficult to discount the argument that 
motivational and motoric effects are contributing to the impaired performance at the 
highest FLU dose. 
     An interesting finding of the COMBO trials is that when AMPH and FLU were 
administered in a 4:1 dosage ratio, the effects of increased dopamine release by AMPH 
and D1/D2 receptor antagonism by FLU on lever pressing were balanced so that total 
lever presses did not differ from control. Increasing the AMPH:FLU ratio to 8:1 resulted 
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in increased lever pressing, suggesting that FLU is a competitive inhibitor of the effects 
of dopamine on DRL performance.  
     Sex effects were seen under 3 conditions in the drug study: females lever pressed 
more than males during COMBO trials, females earned less reinforcers than males 
during AMPH trials, and females earned less reinforcers than males at 0.125/1.0 mg/kg 
COMBO. So in all 3 instances, the performance of females was worse than that of 
males in drug trials involving AMPH administration. Sable et al. (2009) did not find sex 
differences in response to AMPH in control subjects, but instead found sex differences 
in response to AMPH with PCB-exposed subjects, which is different than the current 
findings. However, it is interesting that in Sable et al.’s study that PCB-exposed females 
were more sensitive to the effects of AMPH than males. In a separate study that 
examined sex differences in DRL performance, doses of 0.2, 0.4, and 0.8 mg/kg AMPH 
all increased lever pressing and decreased reinforcers earned and response efficiency 
to a greater extent in females than males (van Haaren et al. 1986). Because there were 
no sex differences during FLU trials, it is more likely that the sex effects during the 
COMBO trials are due solely to the effect of AMPH. This is particularly evident in the 
finding that females earned less reinforcers than males at 0.125/1.0 mg/kg COMBO, 
which is the combination dose at which the FLU dose is smallest relative to the AMPH 
dose. 
 
Reproductive and Developmental Findings 
     The absence of treatment-related effects in dams parallels the findings of other 
studies using similar exposure paradigms and dosages of the Fox River Mix (Kostyniak 
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et al. 2005; Sable et al. 2009; Poon et al. 2011) and DE-71 (Zhou et al. 2002; Poon et 
al. 2011). The most pronounced differences in developmental endpoints of the offspring 
were decreased weight gain in PCB groups, increased liver:body weight ratio in PCB 
and PBDE groups, decreased thymus:body weight ratio in PCB groups, and earlier eye 
opening in PCB groups. Reductions in weight gain have also been reported in prior PCB 
studies in our laboratory (Kostyniak et al. 2005; Sable et al. 2009; Poon et al. 2011), in 
other laboratory species (Safe 1994), and in humans (Schantz et al. 2003), whereas the 
lack of a difference in weight gain in PBDE subjects replicates what has been seen in 
prior studies of developmental exposure to DE-71 (Zhou et al. 2002; Poon et al. 2011). 
Increased liver:body weight ratio in the pups from PCB and PBDE treatment groups 
match the findings from prior studies of developmental PCB and PBDE exposure in 
rodent models (Zhou et al. 2002; Kostyniak et al. 2005; Sable et al. 2009; Bondy et al. 
2013; Poon et al. 2011) and other laboratory species (Safe 1994). Decreased 
thymus:body weight ratio in PCB but not PBDE subjects also parallels findings from 
prior studies in our laboratory (Kostyniak et al. 2005; Sable et al. 2009; Poon et al. 
2011) and in other laboratory species (Safe 1994).  
     Earlier eye opening in the 6 mg/kg PCB group is an interesting finding. PCBs did not 
affect day of eye opening in previous studies using the Fox River Mix (Sable et al. 2009; 
Poon et al. 2011) or in some studies of Aroclor 1254 (Overmann et al. 1987; Crofton et 
al. 2000). However, early eye opening was reported in studies employing higher 
dosages of Aroclor 1254 (Goldey et al. 1995; Goldey & Crofton 1998). Eye opening is a 
commonly used physical developmental landmark that is included in developmental 
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neurotoxicology screening batteries (Henck 2002), with a finding of early eye opening 
suggesting that a chemical has the ability to affect neurodevelopment.  
      
5. Conclusions      
     The current study did not detect alterations in DRL performance in subjects 
developmentally exposed to PCBs or PBDEs, raising the question of whether PCBs and 
PBDEs truly affect impulsive action. However, as discussed, there are studies across 
multiple species utilizing DRL tasks that have shown that PCBs result in changes such 
as increased lever pressing and decreased performance efficiency, which are 
interpreted as impulsive responding (Rice 1998; Holene et al. 1999; Stewart et al. 2006; 
Sable et al. 2009). 
     The question that remains is why did the current study not detect PCB effects? The 
study by Sable et al. (2009) was almost identical to the current study in methodology 
and resulted in there being a significant decrease in the ratio of reinforced:non-
reinforced presses in PCB groups. However there were not differences in total lever 
presses or reinforcers earned in that study. This suggests that the DRL task can detect 
toxicant-induced changes under some circumstances, but that it is possible that subtle 
factors such as inter-individual variation, strain or dosage differences, and dietary 
manipulations may hinder the ability for differences to be detected.  
     Significant inter-individual variation exists in performance of tasks that assess 
impulsive action (Dellu-Hagedorn et al. 2004) and impulsive choice (Galtress et al. 
2012). Methodologies exist for predicting impulsivity in individual subjects, such as 
locomotor response to cocaine (Stanis et al. 2008) or performance on a screening 
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behavioral test (Anker et al. 2009). This enables segregating subjects based on 
impulsive tendency before experimental manipulations are introduced, which allows 
inter-individual variation to be accounted for in the statistical analysis. However studies 
which involve perinatal manipulations, such as the current study, do not allow for 
determination of whether subjects are impulsive prior to the exposure period and, thus, 
preclude accounting for inter-individual variation in the statistical analysis. Historically, 
behavioral tests such as DRL have been shown to be useful for assessing the effects of 
chemical exposures on response inhibition. However, until better methods of accounting 
for inter-individual variation are devised, the ability of such studies to reliably detect 
significant effects across studies may be compromised.  
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6. Tables and Figures 
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Figure 3.1. The 3 successive blocks of drug injections including the drug dosages given 
to each subject within each block. SAL = the relative positions of saline days from which 
data was used to examine whether baseline performance remained stable across the 
blocks of drug trials. 
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Figure 3.2. Comparison of total number of lever presses between sexes on the first 
session of DRL 5, DRL 10, and DRL 15. Males (M) pressed significantly more frequently 
than females (F) on day 1 of DRL 5 but not DRL 10 or DRL 15. ***p<0.001. 
 
 
 
Figure 3.3. Changes in total lever presses and ratio of reinforced:non-reinforced 
presses across five 6-day blocks during DRL 15 training phase. As training progressed, 
total lever presses per session decreased (closed circles) while reinforced:non-
reinforced presses increased (open circles). 
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Figure 3.4. Changes in lever pressing with drug treatment. A. FLU decreased pressing. 
There was less pressing 0.25 mg/kg than with the other 3 doses. There was also less 
pressing with 0.125 mg/kg than with control. B. AMPH increased pressing. There was 
more pressing with 1.0 mg/kg than with the other 3 doses. There was also more 
pressing with 0.5 mg/kg than with control. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.4 (cont). Changes in lever pressing with drug treatment. C. FLU and AMPH 
together counteracted each other. When the AMPH dose increased to 1.0 mg/kg, there 
was significantly more pressing, but this difference was not present when FLU was then 
increased to 0.25 mg/kg. Sex had a significant effect on lever pressing for COMBO 
trials, but the interaction between sex x dose was not significant. Females lever pressed 
more than males when administered FLU/AMPH together. ***p<0.001. 
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Figure 3.5. Changes in reinforcers earned with drug treatment. A. and B. FLU and 
AMPH both decreased reinforcers earned. Significantly less reinforcers were earned at 
the highest 2 doses of each drug as compared to control and the lowest dose, while the 
highest dose also resulted in significantly less reinforcers than the next highest dose. 
Sex had a significant effect on reinforcers earned for AMPH, but the interaction between 
sex x dose was not significant. Females earned less reinforcers than males when 
administered AMPH. *p<0.05, ***p≤0.001. 
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Figure 3.5 (cont.). Changes in reinforcers earned with drug treatment. C. Males (M) and 
females (F) did not differ except at 0.125/1.0 mg/kg COMBO. D. Drug combinations also 
resulted in significantly less reinforcers at all higher dosages in females and the 2 higher 
dosages in males. *p<0.05, ***p≤0.001.  
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Figure 3.6. Changes in ratio of reinforced:non-reinforced lever presses. A. AMPH 
caused a decrease in the ratio at 0.5 and 1.0 mg/kg, with both of those doses 
significantly differing from all other doses. B. All 3 COMBO doses resulted in ratios 
smaller than control. Also the ratios at the 2 highest COMBO doses were smaller than 
the ratio at 0.125/0.5 mg/kg COMBO. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.7. FLU increases post-reinforcement pause, but only at the highest dose. 
***p≤0.001. 
 
 
Figure 3.8. FLU increases the latency to collect reinforcement, but only at the highest 
dose. ***p≤0.001. 
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Chapter 4: Effects of PCBs and PBDEs on the Delay Discounting Task1 
 
1. Introduction 
     Examining the effects of developmental exposure to polychlorinated biphenyls 
(PCBs) and polybrominated diphenyl ethers (PBDEs) on different aspects of response 
inhibition is one of the primary goals of the current research. In the previous chapter, the 
effects of these contaminants on impulsive action were examined. In this chapter the 
effects of PCBs and PBDEs on impulsive choice will be scrutinized.  
     Impulsive choice, as assessed through delay discounting (DD) tasks, is one of the 
better-studied types of impulsivity in laboratory animal and human studies (Winstanley 
2011). In DD paradigms, subjects must choose between a smaller reinforcer that is 
delivered immediately and a larger reinforcer that is delivered after a delay. Subjects 
typically choose the larger-delayed reward when the delay is short, but then begin to 
choose the smaller-immediate reward as the delay length increases (Tesch & Sanfey 
2008). Hence they discount the value of the larger reward in order to avoid longer 
delays. In this context, a greater choice of the smaller-immediate reward as compared 
to controls is considered impulsive. These findings can be graphed as a hyperbolic 
curve referred to as a discounting curve. 
     A strength of the DD paradigm is that the relationship between delay and the 
subjective value of the reward is best described by a hyperbolic function in both humans 
and animals (Paule et al. 2012), even though the rewards are typically hypothetical in 
1Some text in this chapter is modified from the manuscript “Sex differences in adult 
Long Evans rats performing a delay discounting task” authored by Eubig and submitted 
for publication. The data is original. 
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human studies and real (i.e., food) in animal studies. Despite this difference in DD 
methodology between humans and laboratory species, it has been argued that DD 
studies in the latter have been very beneficial in exploring the underlying mechanisms of 
impulsive choice (Winstanley et al. 2006a).  
     Rodent DD models have been important in understanding the neural pathways and 
neurochemical signaling underlying impulsive choice (Dalley et al. 2008; Pattij & 
Vanderschuren 2008; Winstanley 2011). Dopaminergic systems, in particular, have 
been found to be important mediators of DD performance (van Gaalen et al. 2006; 
Winstanley 2011). 
     Anatomic regions important for DD performance, including the frontal cortex and 
nucleus accumbens (NAC), have been investigated by a variety of techniques. One 
study of the medial prefrontal cortex (mPFC) found that lesioning resulted in flattened 
discounting curves (Cardinal et al. 2001). This was interpreted to mean that the mPFC 
has an important role in regulating how the passage of time impacts DD behavior. Other 
studies have examined the role of the orbitofrontal cortex (OFC) in DD performance. 
Lesioning the OFC in rats resulted in increased choice of smaller-more immediate 
rewards (Kheramin et al. 2002; Mobini et al. 2002). In a recent study, electrodes were 
implanted in the OFC of rats in order to measure firing of individual neurons during DD 
performance (Roesch et al. 2012). Firing rates were associated with the length of delay 
to the reward but not the size of the reward, which highlights the importance of the OFC 
in encoding information about the delay during DD performance.  
     The role the NAC plays in DD has also been investigated. Lesioning the NAC core 
resulted in increased choice for the smaller-more immediate reward when the delay to 
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the reward changed within each experimental session (Cardinal et al. 2001; Bezzina et 
al. 2007), and resulted in a flattening of the discounting curve when the delay changed 
between sessions (Acheson et al. 2006). Furthermore, the connectivity between the 
OFC and the NAC has also been shown to be important in DD performance, with 
leucotomy of the corpus callosum combined with one-sided lesions of the OFC and 
NAC resulting in even greater choice for the smaller-more immediate reward than in 
subjects that were either only lesioned or only callosotomized (Bezzina et al. 2008). 
     The contributions of striatal regions (i.e., dorsal, ventral) to DD performance have not 
been scrutinized in animal models. However, several human imaging studies have 
shown that the ventral striatum is activated during DD performance (McClure et al. 
2004; Hariri et al. 2006; Wittman et al. 2010; Sripada et al. 2011; Cho et al. 2012), in 
addition to the mPFC (McClure et al. 2004; Ballard & Knutson 2009; Sripada et al. 2011; 
Cho et al. 2012), medial OFC (McClure et al. 2004), and the nucleus accumbens 
(Ballard & Knutson 2009). 
     Pharmacologic studies have demonstrated the importance of dopaminergic signaling 
in DD performance. In general, administration of amphetamine (AMPH), which 
increases synaptic concentrations of dopamine, increases choice for the larger-delayed 
reward (Cardinal et al. 2000; van den Bergh et al. 2006; van Gaalen et al. 2006; 
Floresco et al. 2008). However, the effect is biphasic. AMPH dosages of approximately 
1.0 mg/kg or higher increase choice for the smaller-immediate reward (Evenden & Ryan 
1996; Cardinal et al. 2000; Slezak & Anderson 2009; Koffarnus et al. 2011). 
Administration of the D1 receptor antagonist SCH 23390 increased choice of the small-
immediate reward (van Gaalen et al. 2006; Koffarnus et al. 2011), while the D2 receptor 
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antagonist eticlopride did not affect choice (van Gaalen et al. 2006). However when 
either dopamine receptor antagonist was administered together with 0.5 mg/kg AMPH, 
both SCH 23390 and eticlopride attenuated the effect of AMPH on choice of the large-
delayed reinforcer (van Gaalen et al. 2006). Along these lines, flupenthixol (FLU), a 
D1/D2 receptor antagonist, consistently increased choice for the small-immediate 
reinforcer (Cardinal et al. 2000; Floresco et al. 2008). In addition, a study in which 
dopaminergic input to the OFC was selectively lesioned resulted in increased choice of 
smaller-more immediate rewards (Kheramin et al. 2004). However, lesioning the 
dopaminergic input to NAC did not alter DD choice (Winstanley et al. 2005), suggesting 
that dopaminergic innervation has a differential effect in different regions important for 
DD performance. 
     At the same time, other neurotransmitter systems, particularly the serotonergic 
system, have roles in DD performance. Administration of either the 5-HT1A/1B agonist 
eltoprazine (van den Bergh 2006) or the 5-HT1A agonist 8-OH-DPAT (Winstanley et al. 
2005) increased choice of the larger-delayed reward. Other studies have focused on the 
relationship between the dopaminergic and serotonergic systems in DD performance. 
Winstanley et al. (2003) injected a serotonergic neurotoxin intracerebroventricularly to 
deplete forebrain serotonin levels by over 85%. While this manipulation did not directly 
affect DD choice, it attenuated the ability of AMPH to increase choice. In the study by 
Winstanley et al. (2005) in which dopaminergic input to the NAC was lesioned, 8-OH-
DPAT was unable to increase choice for the larger-delayed reward post-lesioning. This 
suggests that an interaction between the serotonergic and dopaminergic systems 
occurs in the NAC, and that the NAC is unable to function normally in DD task 
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performance if serotonergic input increases concurrently with impaired dopaminergic 
functioning. Winstanley et al. (2006b) also used microdialysis techniques to quantitate 
dopamine and serotonin turnover in the mPFC and OFC during DD performance. It was 
found that dopamine turnover increased in both regions while serotonin efflux increased 
only in the mPFC. Thus performance on DD is not only influenced by dopaminergic 
signaling, but also by other neurotransmitter systems. 
     Despite the large body of knowledge that exists about the DD task, it has received 
little use as a means to explore the effects of toxicant exposure on response inhibition. 
A literature search did not locate any studies involving PCB or PBDE exposure and DD. 
Because it is known that PCBs affect response inhibition, as discussed in Chapter 1, the 
current experiment used the DD task to assess whether PCBs and PBDEs affect an 
important aspect of response inhibition: impulsive choice. It was hypothesized that 
developmental PCB or PBDE exposure would result in more impulsive DD 
performance as compared to controls. This would manifest as a shift of the 
discounting curve towards greater choice of smaller-immediate rewards as compared to 
controls as the delays to the larger reward increased.  
     Because DD is sensitive to dopaminergic manipulation and because PCBs and 
PBDEs perturb dopaminergic signaling, as discussed before, it was hypothesized that 
developmental PCB or PBDE exposure would result in a shift in the dose 
response curve to dopaminergic agents. More specifically, based on in vivo evidence 
that PCBs result in lower synaptic concentrations of dopamine (Seegal et al. 2002), 
AMPH administration to PCB- or PBDE-exposed rats was hypothesized to improve DD 
performance at lower AMPH doses and impair performance to a lesser extent at higher 
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AMPH doses than in controls. Also, FLU was predicted to impair DD performance to a 
greater extent in contaminant-exposed subjects than in controls. 
 
2. Methods 
2.1. Animals and Exposure 
     Details of the perinatal exposure paradigm of experimental subjects to PCBs and 
PBDEs are discussed in Chapter 3. In brief, Long Evans rat dams were allocated 
between 5 treatment groups: control, 3 mg/kg PCBs, 6 mg/kg PCBs, 11.4 mg/kg 
PBDEs, and 22.8 mg/kg PBDEs. Dams were exposed daily beginning 4 weeks prior to 
breeding and continuing through post-natal day 20 (PND 20). Pups were weaned from 
the dams on PND 21 and male-female pairs of pups from each litter were allocated to 
begin behavioral testing on PND 90. Two litters were not assigned to the DD study: 1 
litter had all female pups and 1 litter had only 1 male-female pair that was assigned to 
the DRL study (Chapter 3). Starting at PND 70, food restriction commenced so that food 
pellets could be used as reinforcement for the behavioral task, as detailed in Chapter 3. 
Sixty-four male-female pairs completed behavioral testing. Their allocation to treatment 
groups was as follows: 12 pairs of control, 14 pairs of 3 mg/kg PCB, 13 pairs of 6 mg/kg 
PCB, 11 pairs of 11.4 mg/kg PBDE, and 14 pairs of 22.8 mg/kg PBDE.  
 
2.2. Behavioral Testing Procedures 
Apparatus 
     Behavioral testing was conducted in 8 automated operant chambers (Med 
Associates; St. Albans, VT) housed in sound attenuated cubicles, each ventilated by a 
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fan. All operant chambers contained 3 stimulus cue lights, positioned above the 2 
retractable response levers and the centrally located pellet trough. The levers, which 
were 6 cm above the floor, were located symmetrically on both sides of the pellet 
trough. An external pellet dispenser delivered 45 mg AIN-76A purified rodent food 
pellets (TestDiet; Richmond, IN). An 80 decibel white-noise generator masked 
extraneous sounds. A house light positioned at the rear of the chamber provided 
general illumination. The experimental contingencies were programmed using Medstate 
Notation behavioral programming language (Med Associates; St. Albans, VT). 
 
Autoshaping (Training Phase 1) 
     Daily sessions of operant testing were conducted 6 days per week, excluding 
Sundays. Beginning at PND 90, an autoshaping program (training phase 1) was used to 
train the subjects to press the response levers. The contingencies of the program and 
the criterion for advancement to the next phase were the same as in DRL training phase 
1 (see Chapter 3 for details). Autoshaping was completed in 3.1 sessions on average 
(range 2 to 8). 
 
Fixed Ratio Training (Training Phase 2)  
     The next training phase elicited lever pressing in response to cue light illumination. 
The contingencies of the program and the criterion for advancement to the next phase 
were the same as in DRL training phase 2 (see Chapter 3 for details). This phase was 
completed in 3 sessions on average (all subjects completed in 3 days, except for 2 that 
were mistakenly tested for 2 days and 2 that took 4 and 5 days to meet criterion). 
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DD Training (Training Phases 3-5) 
     Training on the DD task took place over 3 more phases. The purpose of the third 
phase was to introduce alternating levers and time-controlled trials. This phase 
consisted of 60 trials/session with each trial lasting 40 seconds. Animals were required 
to initiate each trial with a nosepoke into the food trough, when the center cue light was 
illuminated. Also, a 10-second limited hold on lever presses was introduced, wherein a 
subject had 10 seconds to nosepoke or the trial was counted as an omission.  If the 
subject initiated a trial with a nosepoke, the center cue light was extinguished and a 
single response lever was extended at random. If the subject pressed the lever, a food 
pellet was immediately delivered, and the lever retracted. After the next nose poke, the 
opposite lever was extended. An extended lever was always accompanied by an 
illuminated cue light. For this and all subsequent phases of DD training and testing, the 
house light was on during the times the subject could nosepoke or lever press, but off 
for the remainder of the time. Progression to the next phase of testing required ≥40 
successful responses, with at least 20 responses on the left lever and 20 responses on 
the right lever. This phase was completed in 2.1 sessions on average (range 1 to 6). 
     The fourth training phase consisted of two sessions where rats were introduced to 
large and small reinforcers. Half of the subjects were assigned to the left lever as the 
large reinforcer lever, and the other half to the right lever. This phase also consisted of 
60 trials/session (5 blocks of 12 trials), but the length of each trial was increased to 80 
seconds. The first 2 trials of each block were forced choice trials in which the large 
reinforcer lever (resulting in 4 pellets if pressed) and the small reinforcer lever (resulting 
 113 
 
in 1 pellet if pressed) were alternately introduced.  Both levers were presented in the 
remaining 10 trials of each block, termed choice trials. There was no delay in delivery of 
either the small or large reinforcers in this phase. All subjects were tested for 2 sessions 
on this phase. 
     Delays to the large reinforcer were introduced in the fifth testing phase. Parameters 
of this phase remained the same as in the fourth phase, but delays to the larger 
reinforcer increased across the 5 trial blocks, progressing from 0 seconds in the first 
block of 12 trials to 5, 10, 20, and then 40 seconds over the course of the 5 blocks of 
trials in each session (see Figure 4.1). Importantly, if the subject chose the delayed 
reinforcer, the cue light above that lever remained illuminated until the delay was 
complete and delivery of the food pellets began. Performance was evaluated for the 
development of a sensitivity to delay, according to the criteria discussed below. All 
subjects were tested for a minimum of 30 sessions on this phase (average 33.5, range 
26 to 35) except for 2 who were tested for 26 and 29 sessions.  
 
Drug Challenges (Phase 6) 
     The experimental parameters for the drug trials were identical to those in phase 5. 
Drug doses were selected based on their previous use in similar behavioral experiments 
(Cardinal et al. 2000; Floresco et al. 2008; Sable et al. 2009). Drugs and dosages were 
the same as those used in the DRL drug trials (see Chapter 3). In short, FLU dosages 
were 0, 0.05, 0.125, and 0.25 mg/kg. AMPH dosages were 0, 0.25, 0.5, and 1.0 mg/kg. 
Intraperitoneal injections of FLU and AMPH were administered 30 and 10 minutes, 
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respectively, before testing, based on their pharmacokinetic properties (Jorgensen et al. 
1969; Kunh and Schanberg 1978).  
     Injections were administered in 3 successive blocks: FLU, then AMPH, then 
FLU/AMPH combined (COMBO). Each dose within a block was administered once to 
each subject, with the dosing order individually randomized using a balanced Latin 
Square design. Drugs were administered on Tuesdays and Fridays, with 7 calendar 
days between each block of injections. Additional saline injections were given for the 
two days before the FLU block, one day before the AMPH block, one day before the 
COMBO block, and one day after the COMBO block. The first additional saline injection 
was performed to acclimate the subjects to the injection procedure. Results from the 
subsequent additional saline days were examined to assess whether baseline 
performance remained stable across the drug trials. 
 
2.3. Data Analysis 
     All statistical analyses were conducted using SPSS for Windows (version 20.0, 
SPSS Inc.; Chicago, IL) with statistical significance set at p<0.05. For some repeated-
measures factors, a sphericity violation was noted. In these instances a Greenhouse-
Geisser correction was used to reduce the risk of a Type I error if ε was <0.75 and a 
Huynh-Feldt correction was used if ε was ≥0.75 (Rogan et al. 1979). Analyses requiring 
these corrections are reported using the adjusted degrees of freedom rounded to the 
nearest integer. When significant main effects or interactions were obtained, post hoc 
one-way ANOVA followed by Tukey’s least significant difference (LSD) analyses were 
performed. Data are reported as mean ± SEM. 
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     Four dependent measures were evaluated. Choice ratio was defined as the number 
of lever presses for the larger, delayed reinforcer divided by the total number of lever 
presses for both delayed and immediate reinforcers (i.e., the percent choice of the 
delayed reinforcer). Omissions occurred when a subject either did not make a nose 
poke to initiate a trial or did not make a choice when the levers were extended. Total 
omissions included both omission types across all trials (choice and forced choice). Trial 
initiation latency was defined as the time at the beginning of a trial from when the cue 
light above the pellet trough was illuminated to when the subject poked its nose into the 
food trough to initiate the trial. Choice latency was defined as the time from when the 
levers extend to when the subject pressed one of the levers. 
 
Analyses of Training 
     Choice ratios for each delay during the Training Phase 5 were averaged across 6 
consecutive daily sessions for each subject to form five 6-session-blocks of training (30 
days). Choice ratios were then analyzed via a 5 (block) x 5 (delay) x 2 (sex) x 5 
(treatment group) repeated-measures ANOVA, with block, delay, and sex (nested within 
litter; Hughes 1979) as within-subjects factors. Criteria that a sensitivity to delay had 
developed were met when there was either a significant main effect of delay or a 
significant block x delay interaction, and when post-hoc analysis confirmed significantly 
smaller choice ratios for one or more of the longer delays.  
     Examination of the final session-block of training (Block 5) was undertaken to 
document baseline performance just prior to commencing the drug challenges. Choice 
ratios were analyzed with a 5 (delay) x 2 (sex) x 5 (treatment group) repeated-measures 
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ANOVA, with delay and sex (nested within litter) as within-subjects factors. Total 
omissions, trial initiation latency, and choice latency were each analyzed with a 2 (sex) 
x 5 (treatment group) mixed ANOVA, with sex (nested within litter) as a within-subjects 
factor. 
 
Analyses of Drug Trials 
     Choice ratios from drug challenges were analyzed with 4 (drug dose) x 5 (delay) x 2 
(sex) x 5 (treatment group) repeated-measures ANOVAs, with treatment group as a 
between-subjects factor. Total omissions, trial initiation latency, and choice latency were 
each analyzed with 4 (drug dose) x 2 (sex) x 5 (treatment group) repeated-measures 
ANOVAs, with treatment group as a between-subjects factor.  
     It was noted that especially 0.125 and 0.25 mg/kg FLU caused more omissions in 
some subjects than 0 or 0.05 mg/kg FLU, with choice for an entire block of trials for a 
delay sometimes being omitted. When a subject omits an entire block of trials, the 
choice ratio is reported by the software as 0%, which incorrectly implies that the subject 
chose only the immediate reinforcer for that delay, when in fact no choices were made. 
The percent of individual blocks in which all 10 trials were omitted was examined for 
each drug dose and delay. Doses and delays in which all trials were omitted by > 10% 
of subjects were as follows: 0.25 mg/kg FLU at 40 sec (42% of subjects omitted all 
trials), at 20 sec (28%), at 10 sec (22%); 0.125 mg/kg FLU at 40 sec (13%); and 
0.25/1.0 mg/kg FLU/AMPH (13%). To address this concern, the 40 sec delay for FLU 
was removed from the statistical analysis of choice latency due to excessive omissions. 
Also, whenever a subject omitted all 10 trials at a given delay and drug dose, mean 
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replacement was performed for the subject’s choice ratio by averaging choice ratio for 
all other subjects of the same sex at the same dose and delay. 
     Choice ratios from the saline administration days one day before the FLU block, one 
day before the AMPH block, one day before the COMBO block, and one day after the 
COMBO block were analyzed via a 4 (saline day) x 5 (delay) x 2 (sex) x 5 (treatment 
group) repeated-measures ANOVA, with treatment group as a between-subjects factor.  
 
3. Results 
3.1. DD Training 
     Analysis of choice ratio during the 5 6-session-blocks of DD training did not show a 
significant treatment effect but did reveal significant main effects of block 
[F(2,143)=12.1, p<0.001] and delay [F(2,89)=695.7, p<0.001] and a significant block x 
delay interaction [F(4,265)=51.9, p<0.001]. Neither the main effect of sex nor other 
interactions were significant. Post-hoc analysis confirmed that during the first session-
block (Block 1, testing days 1-6) a sensitivity to delay developed as evidenced by a 
decrease in choice ratio as delay to reinforcement increased (see Figure 4.2, Block 1). 
Once the sensitivity to delay developed, it was maintained throughout the experiment, 
as all subsequent repeated-measures ANOVAs on choice ratio were significant for the 
main effect of delay [all F≥374.5, all p<0.001]. 
     Analysis of choice ratio during Block 5 did not show a significant treatment effect but 
did reveal a main effect of delay [F(2,100)=433.3, p<0.001] (see Figure 4.2, Block 5). 
Neither sex (see Figure 4.3) nor any of the interactions were significant. Choice ratio 
decreased from 88.2 ± 1.4% at 0 sec delay to 18.1 ± 2.4% at 40 sec delay. Total 
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omissions were minimal during Block 5 (< 1 omission per session). Neither treatment 
group nor sex had significant effects on omissions. Trial initiation latency was not 
significantly affected by treatment group or sex (see Figure 4.4). Average initiation 
latency was 1.15 ± 0.03 seconds. Treatment group did not significantly affect choice 
latency, but sex did have a significant effect [F(1,59)=4.5, p=0.039], with females 
choosing faster than males (0.97 ± 0.03 sec versus 1.07 ± 0.04 sec; see Figure 4.4). 
Because sex differences in choice ratios and trial initiation latencies were seen during 
the drug trials, performance for both sexes on these measures are shown to allow for 
comparisons between pre-drug and drug performance. 
 
3.2. Drug Trials 
Choice Ratio 
     With FLU administration, the main effect of PCB/PBDE treatment group and 
interactions with treatment were not significant, but significant effects of drug dose 
[F(3,167)=24.1, p<0.001] and delay [F(2,111)=444.8, p<0.001] on choice ratio were 
seen, as well as a significant drug dose x delay interaction [F(6,353)=3.0, p=0.008]. Sex 
did not significantly affect choice ratio, nor were other interactions with sex significant. 
Post-hoc analysis comparing choice ratio at the different drug doses within each delay 
revealed significant differences at 5 and 10 sec delays (see Figure 4.5). Choice ratio at 
the highest FLU dose (0.25 mg/kg) was smaller than at the control dose at 5 and 10 sec 
delays (p=0.001 at 5 sec, p=0.024 at 10 sec) and also smaller than the 0.05 mg/kg dose 
at the 5 sec delay (p=0.007). 
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     With AMPH administration, treatment group effects and interactions with treatment 
group were not significant, but significant effects of drug dose [F(2,131)=4.7, p=0.009] 
and delay [F(2,138)=419.5, p<0.001] on choice ratio were seen, as well as a significant 
drug dose x delay interaction [F(7,433)=8.3, p<0.001]. There was a significant effect of 
sex [F(1,59)=4.4, p=0.039], but sex did not significantly interact with other factors. Post-
hoc analysis comparing choice ratio at the different drug doses within each delay 
revealed significant differences at 0, 10, and 20 sec delays (see Figure 4.6). At the 0 
sec delay, 1 mg/kg AMPH resulted in a smaller choice ratio than the control (p=0.003) 
and 0.05 mg/kg (p=0.026) doses, whereas at the longer delays 1 mg/kg AMPH 
increased choice ratio above that of control (p=0.016 at 10 sec, p=0.001 at 20 sec). 
Because there were not significant interactions of sex with other factors, further post-
hoc analysis was not performed. Inspection of the graphs (see Figure 4.7) reveals that 
although AMPH increased choice ratio in both sexes as the delays lengthened, choice 
ratio was always smaller for females than males at each AMPH dose. 
     The statistical findings from the COMBO trials were similar to those from AMPH 
trials. While the main effect of treatment group and the interactions involving treatment 
group were not significant, drug dose [F(3,161)=3.9, p=0.013] and delay 
[F(2,139)=460.4, p<0.001] significantly affected choice ratio, and the interaction for dose 
x delay was significant [F(8,449)=2.1, p=0.042]. Sex [F(1,59)=7.1, p=0.01] and an 
interaction between dose x sex [F(3,152)=2.8, p=0.048] were also significant, but no 
other significant interactions were observed. Post-hoc analysis of choice ratio of the 
different drug doses within each delay did not find any significant differences between 
COMBO doses (all p>0.17; see Figure 4.8). Inspection of the graphs (see Figure 4.9) 
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reveals that overall choice ratio was always smaller for females than males across 
COMBO doses. 
 
Total Omissions 
     For FLU, PCB/PBDE treatment group did not have a significant effect on omissions 
(p=0.105), but a significant effect of drug dose [F(1,86)=103.6, p<0.001] was seen along 
with a significant drug dose x treatment group interaction [F(6,86)=2.3, p=0.047]. Sex 
did not have a significant effect, nor were other interactions of treatment or sex with 
other factors significant. Post-hoc analyses of differences in omissions between 
treatment groups within each FLU dose did not find any significant differences (all 
p≥0.065). When differences in omissions between drug doses alone were analyzed, it 
was determined that increasing the FLU dose caused increases in omissions (see 
Figure 4.10). There were significantly more omissions with 0.125 and 0.25 mg/kg FLU 
than with control or 0.05 mg/kg FLU (all p<0.01), and 0.25 mg/kg FLU also caused more 
omissions than 0.125 mg/kg.  
     For AMPH, treatment group was not significant, but significant effects of drug dose 
[F(2,103)=19.7, p<0.001] and sex [F(1,59)=6.5, p=0.014] on omissions were seen, as 
well as a significant drug dose x sex interaction [F(2,119)=9.0, p<0.001]. Post-hoc 
analysis determined that in females only 1.0 mg/kg AMPH caused a significant increase 
in omissions over the smaller doses (all p<0.001; see Figure 4.11). Because AMPH did 
not have this effect in males, the number of omissions seen at 1.0 mg/kg in females was 
also significantly greater than at the same dosage in males (p<0.001). 
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     With COMBO injections, although treatment group was not significant, a significant 
effect of drug dose [F(2,122)=26.0, p<0.001] on omissions was seen. Sex did not have 
a significant effect, nor were any interactions of treatment or sex with other factors 
significant. COMBO 0.25/1.0 mg/kg FLU/AMPH was found on post-hoc analysis to 
result in significantly more omissions than with other dosages, while 0.125/1.0 mg/kg 
also resulted in more omissions than control (all p≤0.001; see Figure 4.12). 
 
Trial Initiation and Choice Latencies 
     With FLU, PCB/PBDE treatment group was not significant, but drug dose 
significantly affected trial initiation latency [F(3,148)=88.6, p<0.001]. Sex did not affect 
initiation latency, nor were any interactions of treatment group or sex with other factors 
significant. Post-hoc analysis revealed that both 0.125 and 0.25 mg/kg significantly 
increased initiation latency, with latency at each of those doses differing from latencies 
at all other doses (all p<0.001; see Figure 4.13). While treatment group was not 
significant for choice latency, FLU dose significantly affected choice latency 
[F(2,119)=43.2, p<0.001]. Sex did not have a significant effect, nor were any 
interactions of treatment group or sex with other factors significant for choice latency. 
Post-hoc analysis revealed that both 0.125 and 0.25 mg/kg FLU significantly increased 
choice latency, with latency at each of those drug doses differing from latencies at all 
other doses (all p<0.01; see Figure 4.14). 
     Although treatment group was not significant for AMPH trials, the dose of AMPH 
significantly affected trial initiation latency [F(2,110)=21.3, p<0.001]. Also, sex 
[F(1,59)=12.5, p<0.001] and the drug dose x sex interaction [F(2,126)=11.9, p<0.001] 
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were significant. No other interactions of treatment or sex with other factors were 
significant. Post-hoc analysis revealed that initiation latency after 1.0 mg/kg AMPH was 
significantly longer than with all smaller doses in females as well as longer than the 
latency seen with the same dose in males (all p≤0.001; see Figure 4.15). AMPH 0.5 
mg/kg in females also resulted in a longer initiation latency than control and the same 
dose in males (both p<0.05). While treatment group was not significant, AMPH dose 
also significantly affected choice latency [F(2,125)=32.5, p<0.001]. Sex did not affect 
choice latency (p=0.073), nor were any interactions of treatment group or sex with other 
factors significant for choice latency. Post-hoc analysis determined that only 1.0 mg/kg 
resulted in significantly longer choice latency than all other AMPH doses (all p<0.001; 
see Figure 4.16). 
     With COMBO administration, the main effects of treatment group [F(4,59)=2.9, 
p=0.029], drug dose [F(3,167)=42.7, p<0.001], and sex [F(1,59)=4.7, p=0.035] on trial 
initiation latency were all significant. Post-hoc analysis of differences due to treatment 
group determined that the initiation latency in the 22.8 mg/kg PBDE group was 
significantly shorter than that of controls (p=0.034), while the 6 mg/kg PCB group had a 
longer latency than that of both PBDE groups (both p<0.05) but did not differ from that 
of controls (see Figure 4.17). The drug dose x sex interaction approached significance 
[F(3,156)=2.7, p=0.055], and thus was examined post-hoc to better understand the 
effects of drug dose and sex on trial initiation latency. It was determined that in females 
0.125/1.0 and 0.25/1.0 mg/kg significantly increased initiation latency compared to the 
lower COMBO doses, while this effect was only seen with 0.25/1.0 mg/kg in males (all 
p<0.05; see Figure 4.18). The latencies of females did not differ from males when 
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compared at the same dosages. Although treatment group did not affect choice latency, 
COMBO drug dose significantly affected choice latency [F(3,165)=42.7, p<0.001], and 
an interaction between drug dose x treatment group was also significant [F(11,165)=1.9, 
p=0.04]. Sex did not have a significant effect, nor were other interactions significant. 
Post-hoc analyses of choice latencies between treatment groups at each COMBO dose 
were not significant. Post-hoc analysis of drug doses alone revealed that choice 
latencies at 0.125/1.0 and 0.25/1.0 mg/kg were significantly longer than at smaller 
dosages, while the 2 higher COMBO dosages also differed from each other (all p<0.05; 
see Figure 4.19).  
 
Stability of Performance During Drug Trials      
     Treatment group was not significant for choice ratio across the 4 saline 
administration days, but saline day [F(3,177)=4.8, p=0.003] and delay [F(2,129)=374.5, 
p<0.001] were significant, as was a day x delay interaction [F(8,485)=3.4, p=0.001]. Sex 
was not significant, nor were other interactions. To examine the day x delay interaction, 
choice ratios for each of the 4 days were compared at each delay. None of the post-hoc 
analyses were significant. Visual inspection of the data supports these findings. 
 
4. Discussion 
     This is the first study to examine the effects of PCBs and PBDEs on impulsive 
choice. It was found that developmental exposure to PCBs or PBDEs did not result in 
impulsive choice on the DD task. Nor did contaminant-exposed subjects differ in their 
response to the dopaminergic drugs AMPH or FLU, with the exception that subjects in 
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the 22.8 mg/kg PBDE group were significantly faster to initiate trials than controls and 
subjects in the 6 mg/kg PCB group after combined exposure to FLU and AMPH. These 
findings are contrary to the experimental hypotheses.  
 
Lack of PCB/PBDE Treatment Effect on DD 
     While it is possible that PCBs and PBDEs do not affect impulsive choice, it is also 
possible that the experimental methodology used to test impulsive choice in this study 
impaired the ability for differences to be detected between treated and control subjects. 
Whether or not the delay to the larger reward is cued has been shown to impact the 
experimental findings on DD tasks. In the current experiment the delay was cued. That 
is, if the subject chose the larger-delayed reward lever then the cue light above the lever 
remained on until the reward was delivered. Cueing the delay has been suggested to 
serve as a conditioned reinforcer that bridges the interval between choosing the delayed 
reward lever and the delivery of the reward (Cardinal et al. 2000).  
     A study of ADHD children performing DD illustrates how cueing the delay can greatly 
influence the experimental findings. Antrop et al. (2006) tested ADHD and non-ADHD 
children on both cued and uncued conditions of a DD task. It was found that under the 
uncued condition ADHD children chose the smaller-immediate reward much more often 
than non-ADHD children. However, under the cued condition, the choice for the larger-
delayed reward increased in both groups so that the performance of the two groups was 
indistinguishable. Thus, a concern with the current study is that the cued DD task used 
in the study may actually have served to mask differences in performance between the 
treatment groups and the control group. 
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     Unfortunately, the above explanation may not always hold true. In a study by Zeeb et 
al. (2010), male Long Evans rats were trained with either cued rewards or uncued 
rewards, and then subjects in each group were either classified as low impulsive (LI) or 
high impulsive (HI). As compared to the uncued condition, the cued condition resulted in 
a substantial increase in choice for the larger-delayed reward, but only in the LI 
subjects. Cueing the delay did not significantly improve the performance of the HI 
subjects. So it is possible that cueing the delay in rodents may improve choice ratio in 
only a subset of subjects. When subjects in the Zeeb et al. study were collapsed 
together to compare cued versus uncued conditions, there was a small increase in 
preference for the larger-delayed reward in the cued group as compared to the uncued 
group (Stan Floresco, personal communication, May 2013). Other studies in “normal” 
unexposed rats have found a minimal effect of cueing the delay on choice ratio when 
subjects were trained on either cued or uncued delays and the subjects were not 
subdivided by impulsivity (Cardinal et al. 2000; Slezak & Anderson 2009), and it was 
found that choice ratio did not differ between the cued and uncued groups. Thus, the 
effect of cueing the delay may vary based on the characteristics of the populations 
being examined in each study. 
     Another complicating factor, as suggested by the Zeeb et al. experiment, is the large 
degree of variation in performance between “normal” unexposed subjects on DD. 
Galtress et al. (2012) found that 55% of the variance in DD performance was due to 
individual differences, which was a greater effect than the delay to reward. In addition, 
differences in DD performance can also vary by strain of rat (Huskinson et al. 2012; 
Garcia & Kirkpatrick 2013), although individual differences also accounted for a greater 
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degree of variation than strain (Garcia & Kirkpatrick 2013). A large degree of variance 
within groups makes it more difficult to statistically detect differences between groups. 
So although the goal of this study was to have approximately 12 male-female pairs per 
treatment group, it is possible that this sample size was insufficient to detect effects 
caused by PCBs or PBDEs because of the large individual variability in DD 
performance. Because it is possible that factors such as cueing the delay, individual 
variation in performance, and strain of rat can either act alone or together to influence 
DD performance and the ability to detect differences between groups, it would be ideal if 
the study were repeated with a larger sample size using an uncued DD task. 
 
Drug Effects on DD 
     Although contaminant exposure did not have an effect on choice ratio during the 
drug trials, the influence of sex and the effects of the drug doses on choice ratio were 
interesting. The effect of sex on choice ratio following AMPH treatment was unexpected, 
especially in that sex did not interact with other factors; rather, females chose the 
smaller-immediate reward more frequently across AMPH doses and delays, whereas 
there was no difference in choice ratio between sexes prior to the drug challenges. This 
suggests that females were more sensitive than males to the effects of AMPH on choice 
between immediate and delayed rewards. While other DD studies have not compared 
the effects of AMPH on performance between sexes, greater behavioral response to 
AMPH in female rodents has been demonstrated using locomotor activity assessment 
(Milesi-Halle et al. 2007; Simpson et al. 2012). In addition, estrogen, but not 
testosterone, increases dopamine release in the striatum and nucleus accumbens and 
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alters performance on dopamine-mediated tasks in female rats relative to males 
(Becker 1999). AMPH also differentially affected females in some of the other 
measures. AMPH increased total omissions at the highest dose and increased trial 
initiation latency at the 2 highest doses only in females. Interestingly, the sex difference 
in choice latency seen during Block 5, with females being significantly faster to choose a 
lever, was not seen during any of the drug trials. This suggests that both drugs 
obscured the baseline tendency of females to choose faster. Overall, these findings 
suggest that while AMPH may have affected impulsive choice, other factors such as 
diminished motivation to perform may have also come into play with AMPH, resulting in 
increased choice for the smaller-immediate reinforcers in females as compared to 
males.  
     Regarding the significant effect of AMPH dose on choice ratio, interactions with 
delay were only seen at the highest dose (1.0 mg/kg): AMPH decreased choice ratio at 
0 sec delay but increased choice ratio at 10 and 20 sec delays. The decrease at 0 sec 
is concerning because a shift towards the smaller reward when there is no delay for the 
larger reward suggests that the drug may have affected the ability to distinguish 
between the experimental contingencies (Koffarnus et al. 2011). This makes 
interpretation of the findings difficult. However, such a scenario usually involves a shift 
of the entire discounting curve or a flattening of the curve at shorter delays (Madden & 
Johnson 2010; e.g., AMPH and apomorphine curves in Koffarnus et al. 2011). In the 
current study, there was a modest but significant decrement from 91% choice of the 
larger reward in the control group to 81% choice in the 1.0 mg/kg AMPH group. While 
this suggests that other factors, such as diminished motivation to perform or difficulty in 
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distinguishing experimental contingencies, may have come into play, a decrease in 
choice for the larger reward should have carried over to longer delays if these factors 
were the only explanation.  
     The increases in choice ratio at 10 and 20 sec delays with 1.0 mg/kg AMPH more 
likely represent a decrease in impulsive choice for the reasons discussed above. An 
increase in choice ratio at this dosage corresponds with findings in at least one other 
DD study (Huskinson et al. 2012), but is contrary to the findings of studies which found 
a decrease in choice ratio at 1.0 mg/kg (Evenden & Ryan 1996; Cardinal et al. 2000; 
van Gaalen et al. 2006; Slezak & Anderson 2009; Koffarnus et al. 2011). However, 
Cardinal et al. (2000) qualified the effects of 1.0 mg/kg AMPH in decreasing choice ratio 
as only being present when the delay was uncued. There was no effect of AMPH when 
the delay was cued. Also, although van Gaalen et al. (2006) reported that 1.0 mg/kg 
AMPH decreased choice ratio when the delay was cued, that dose actually did not 
increase choice ratio any more than 0.5 mg/kg AMPH. So 1.0 mg/kg may be a threshold 
dose at which the effect of AMPH on choice ratio may vary with experimental 
methodology or due to other factors, such as the rat strain. Huskinson et al. (2012) 
compared the baseline DD performance and response to AMPH in Lewis and Fischer 
344 rats. It was concluded that the Lewis rats were more impulsive at baseline and, 
subsequently, demonstrated an increase in choice ratio at 1.0 mg/kg, as compared to 
the less impulsive Fischer 344 rats in which the same dosage decreased choice ratio. It 
is possible that Long Evans rats are more impulsive on the DD task than strains in the 
studies in which 1.0 mg/kg AMPH reduced choice ratio [Sprague Dawley (Evenden & 
Ryan 1996; Slezak & Anderson 2009; Koffarnus et al. 2011), Lister Hooded (Cardinal et 
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al. 2000), and Wistar (van Gaalen et al. 2006)], which could account for an increase in 
choice ratio at longer delays. However, no studies have compared the performance of 
Long Evans rats on DD with that of other strains. Nor have the effects of 1.0 mg/kg 
AMPH on the DD performance of Long Evans rats been reported before. Floresco et al. 
(2008) used Long Evans rats in their study, but the highest AMPH dose in that study 
was 0.5 mg/kg, which did not alter choice ratio. 
     An effect of sex on choice ratio was not seen with FLU, but an effect of dose was 
seen, with 0.25 mg/kg decreasing choice ratio in both sexes. The findings for FLU are 
similar to those seen in other DD studies (Cardinal et al. 2000; Wade et al. 2000; 
Floresco et al. 2008), but these other studies only tested male subjects. In the current 
study, dopaminergic blockade appeared to affect choice in a similar manner in both 
sexes. However, it is important to ask whether FLU actually increased impulsive choice 
at that dose or affected other components of task performance such as locomotion 
(Pitts & Horvitz 2000). FLU 0.25 mg/kg significantly increased trial omissions, to the 
extent that the data from the 40 sec delay was removed from the statistical analysis, 
and significantly increased latency to initiate trials by 0.7 sec and choice latency by 0.4 
sec in both sexes. So it is likely that, to some extent, the changes seen with FLU 
involved alterations in locomotor activity or motivation. In support of this, it has been 
suggested that D1/D2 receptor antagonism produced by FLU diminishes the value of 
conditioned food reinforcers (Beninger & Ranaldi 1993; Wade et al. 2000). At the same 
time, 0.25 mg/kg FLU did not significantly decrease choice ratio at 0 sec delay, which 
suggests that the subjects still were willing to follow the experimental contingencies to 
maximize reward at the 0 sec delay.  
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     In the COMBO drug trials, the effect of contaminant treatment on trial initiation 
latency was unanticipated since it was not seen prior to drug challenges or with AMPH 
or FLU alone. It is possible that both PBDE treatment groups were faster to initiate trials 
than the 6 mg/kg PCB group due to enhancement either of the ability to detect a signal 
(i.e., the light above the food tray illuminating) or of some other component of the 
response assessed by trial initiation latency. Whether PBDEs affect attentional 
processes in rodents has not been examined, while one study of developmental 
exposure to the commercial PCB mixture, Aroclor 1254 found no effect on signal 
detection (Bushnell et al. 2002). Because this treatment effect was only seen during the 
COMBO trials, it is not clear to what extent D1 and D2 receptors were stimulated by 
increased synaptic dopamine due to AMPH versus antagonized by FLU binding in order 
to produce the changes seen.  
     The effect of sex on choice ratio during COMBO trials mirrors that seen during the 
AMPH trials. Yet the effect also appeared to be tempered by FLU. Although drug dose 
of FLU/AMPH was not significant, visual inspection of the data showed a tendency for 
choice ratios at delays above 0 sec to increase as AMPH dose increased from 0.5 to 
1.0 mg/kg, but then choice ratios decreased back to the levels seen with control 
injections as FLU dose increased from 0.125 to 0.25. The sex effect on trial initiation 
latency also mirrored that seen with AMPH, although it is not surprising that trial 
initiation latency and choice latency both increased as the doses of AMPH and then 
FLU increased, since both drugs independently increased latencies. There was not a 
sex effect on trial omissions, unlike the findings seen with AMPH alone. It is clear from 
the trials of FLU and AMPH alone that FLU is more potent than AMPH in causing 
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omissions. So in the COMBO trials the omissions were more likely due to the effect of 
FLU, which did not cause a sex difference in omissions, being tempered by the effect of 
AMPH.  
  
5. Conclusions 
     Other than a finding of treatment group affecting trial initiation latency during trials in 
which AMPH and FLU were administered together, PCB or PBDE exposure did not 
affect performance on the DD task. The original hypothesis was that developmental 
exposures to PCBs or PBDEs would affect impulsive choice by decreasing choice ratio. 
There is concern that the version of the DD task used in this study, in which delays to 
delivery of the large rewards were cued, may have masked changes in choice ratio. A 
version of the task in which delays to reinforcement are not cued may be more sensitive 
to detecting changes in choice ratio when the effects of developmental exposure to 
contaminants are assessed.  
     Similarly, if the cued version of the task was inadequate to detect changes in choice 
ratio, then any differences between contaminant-exposed subjects and controls during 
the drug trials may have also been masked. Despite a lack of contaminant effects on 
choice ratio, interesting sex effects of AMPH on choice ratio were found which have not 
been previously reported. If preclinical studies are to be successfully extrapolated to 
human populations, then investigating sex differences in the DD paradigm is important.  
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6. Figures 
 
 
Figure 4.1. Delay discounting task. Each daily session had 5 blocks of trials, with the 
delay to the larger reinforcer increasing between blocks. The rat chose between two 
levers, one associated with a smaller, immediate reward and the other associated with a 
larger, delayed reward. Delays were signaled by an illuminated cue light above the 
lever. Each trial lasted 80 seconds, regardless of choice. Modified from Winstanley et al. 
(2004). 
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Figure 4.2. Choice ratios from Blocks 1 and 5 during the fifth training phase. In both 
Block 1 and Block 5, choice ratios at 5, 10, 20, and 40 sec delays were significantly 
different than the choice ratio at 0 sec delay (all p≤0.001).  
 
 
Figure 4.3. Choice ratios of female and male subjects from Block 5. There are no 
significant differences between the sexes. This figure is provided to allow comparison to 
differences in choice ratios between sexes that occurred during drug trials. 
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Figure 4.4. Trial initiation and choice latencies for both sexes during Block 5. Females 
chose which lever to press significantly faster than males. *p≤0.05. 
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Figure 4.5. Choice ratio following administration of 0, 0.05, 0.125, and 0.25 mg/kg FLU. 
Choice ratio was significantly smaller than control with 0.25 mg/kg FLU at 5 and 10 sec 
delays. Also 0.25 mg/kg resulted in a smaller choice ratio than 0.05 mg/kg at 5 sec 
delay. Sex differences were not seen during the FLU trials. Data from the 40 sec delay 
was removed from the analysis due to excessive trial omissions caused by 0.25 mg/kg 
FLU. *p<0.05, ***p<0.001 as compared to control. 
 
 
Figure 4.6. Choice ratio following administration of 0, 0.25, 0.5, and 1.0 mg/kg AMPH. 
At 0 sec delay, choice ratio was significantly smaller with 1.0 mg/kg AMPH than control 
or 0.05 mg/kg FLU. However, as the delay to reinforcement lengthened, choice ratio 
became significantly greater with 1.0 mg/kg AMPH than control. *p<0.05, **p<0.01, 
***p≤0.001 as compared to control. 
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Figure 4.8. Choice ratio following administration of 0/0, 0.125/0.5, 0.125/1.0, and 
0.25/1.0 mg/kg FLU/AMPH. There were no significant differences between doses at 
each delay. 
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Figure 4.10. Increasing FLU dosages increased omissions. Both 0.125 and 0.25 mg/kg 
caused significantly more omissions than 0 and 0.05 mg/kg. More omissions were also 
seen at 0.25 mg/kg than at 0.125 mg/kg. **p<0.01, ***p<0.001 as compared to control. 
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Figure 4.11. AMPH increased the number of omissions in females only. 1.0 mg/kg 
AMPH resulted in significantly more omissions than with smaller dosages in females 
and when compared to the same dosage in males. ***p<0.001 as compared to control. 
+++p<0.001 as compared to same dosage in males. 
 
 
Figure 4.12. FLU/AMPH together increased the number of omissions. Significantly more 
omissions occurred in combinations involving 1.0 mg/kg AMPH. ***p≤0.001 as 
compared to control. 
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Figure 4.13. FLU increased trial initiation latency. Both 0.125 and 0.25 mg/kg increased 
initiation latency as compared to 0 and 0.05 mg/kg. A higher latency was also seen at 
0.25 mg/kg as compared to 0.125 mg/kg.***p<0.001 as compared to control. 
 
Figure 4.14. FLU increased choice latency. Both 0.125 and 0.25 mg/kg increased 
choice latency as compared to 0 and 0.05 mg/kg. A higher latency was also seen at 
0.25 mg/kg as compared to 0.125 mg/kg.**p<0.01, ***p<0.001 as compared to control. 
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Figure 4.15. AMPH increased trial initiation latency in females but not males. Latency 
was longer at 1.0 mg/kg than at all other dosages in females, and also at 0.5 mg/kg as 
compared to control in females. Initiation latency was also longer at the 2 higher 
dosages in females as compared to the respective dosages in males. *p<0.05, 
***p≤0.001 as compared to control. +p<0.05, +++p<0.001 as compared to same dosage 
in males. 
 
Figure 4.16. AMPH increased choice latency at the highest dose. Latency at 1.0 mg/kg 
was longer than at the other doses. ***p<0.001 as compared to control. 
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Figure 4.17. Trial initiation latencies varied with treatment group during COMBO trials. 
Initiation latency in the 22.8 mg/kg PBDE group was significantly shorter than that of 
controls, while the 6 mg/kg PCB group had a longer initiation latency than that of both 
PBDE groups. Low PCB=3 mg/kg; High PCB=6 mg/kg; Low PBDE=11.4 mg/kg; High 
PBDE=22.8 mg/kg. *p<0.05. 
 
Figure 4.18. Trial initiation latency increased with COMBO dosages. In females 
0.125/1.0 and 0.25/1.0 mg/kg FLU/AMPH significantly increased initiation latency 
compared to smaller dosages, while in males only 0.25/1.0 mg/kg significantly 
increased initiation latency. Latencies of females did not differ from that of males when 
compared at the same dosages. **p<0.01, ***p<0.001 as compared to control. 
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Figure 4.19. Higher FLU/AMPH COMBO dosages lengthened choice latency. The 2 
higher combination dosages significantly differed from smaller dosages and from each 
other. ***p<0.001 as compared to control. 
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Chapter 5. Effects of PCBs and PBDEs on Dopamine Transporter Expression in 
the Brain 
 
1. Introduction 
     One mechanism by which polychlorinated biphenyls (PCBs) and polybrominated 
diphenyl ethers (PBDEs) have been proposed to exert their effects on 
neurodevelopment is by influencing the levels of synaptic dopamine. The role of 
dopamine in response inhibition, and the general effects of PCBs and PBDEs were 
discussed in Chapter 1. This chapter will more closely focus on the effect of these 
contaminants on dopamine transporter (DAT), a neuroprotein that regulates synaptic 
dopamine.  
     DAT is a 12-transmembrane domain transporter protein that imports synaptic 
dopamine along its concentration gradient into the cytosol of the presynaptic terminal 
(Torres et al. 2003). DAT levels are much higher in the striatum as compared to other 
brain regions (Moll et al. 2000) due to the greater density of dopaminergic neurons in 
the striatum. Functionally, striatal DAT recycles synaptic dopamine, whereas in the 
prefrontal cortex norepinephrine transporter has a greater role than DAT in clearing 
synaptic dopamine (Yamamoto & Novotney 1998; Devoto et al. 2004). Vesicular 
monoamine transporter 2 (VMAT2), in turn, is a 12-transmembrane domain protein that 
imports cytosolic dopamine into the vesicles against its concentration gradient as part of 
the repackaging process (Wimalasena 2011). It is vital that both transporters function in 
concert to terminate synaptic signaling and to minimize cytosolic dopamine 
concentrations. Because dopamine serves as a neuromodulator, DAT dysfunction can 
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result in either excess or reduced levels of dopamine binding to D1 receptor, which has 
detrimental effects on many different cognitive functions (Seamans & Yang 2004). 
VMAT2 dysfunction can also alter the amount of dopamine released into the synapse, 
but it can additionally result in oxidative damage to dopaminergic neurons if excess 
dopamine, which is readily oxidized, accumulates in the cytosol (Guillot & Miller 2009).  
     There is evidence that PCBs reduce expression as well as impair the function of 
DAT and VMAT2. Two commercial PCB mixtures, Aroclors 1016 and 1260 decreased 
striatal DAT expression in adult male mice, but only Aroclor 1260 decreased VMAT2 
expression in the same subjects (Richardson & Miller 2004). In a follow-up study, it was 
shown that exposure to a 1:1 mixture of Aroclor 1254 and 1260 decreased DAT and 
VMAT2 expression in the striatum. However the change in DAT expression was not due 
to altered DAT mRNA levels in the dopaminergic cell bodies in the ventral 
mesencephalon (Caudle et al. 2006). In the same study, DAT expression was unaltered 
in the PFC of mice. Recently, it was shown that DE-71 also decreased DAT and VMAT2 
expression in the striatum of adult mice (Bradner et al. 2013). Of interest, these rodent 
study findings parallel those in a study of adult humans who were occupationally 
exposed to PCBs. In that study, higher serum PCB levels were associated with lower 
striatal DAT densities in women, but not men, as assessed by an advanced imaging 
technique (Seegal et al. 2010). 
     Complementing the studies of transporter expression, studies utilizing in vitro 
preparations of synaptosomes, to assess DAT function, and neurotransmitter vesicles, 
to assess VMAT2 function, have led to a better understanding of the effects of PCBs 
and PBDEs on functioning of these transporters. Aroclors1242 and Aroclor 1254 were 
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shown to inhibit dopamine uptake into synaptosomes from rat brains (Mariussen & 
Fonnum 2001). Similar findings were seen in a study using synaptosomes of mice 
postnatally exposed to Aroclor 1254 (Tian et al. 2011). Furthermore, individual ortho-
chlorinated (non-coplanar) PCB congeners, but not coplanar congeners, were shown to 
inhibit dopamine uptake into rat brain synaptosomes (Mariussen & Fonnum 2001) and 
vesicles (Mariussen et al. 2001). The same researchers then demonstrated that DE-71, 
but not more highly brominated PBDE mixtures, also inhibited synaptosomal and 
vesicular dopamine uptake (Mariussen & Fonnum 2003). Relevant to the current study, 
Fox River PCB Mix was shown to be 2-3 times more potent than DE-71 at inhibiting 
synaptosomal dopamine uptake in immature rats (Dreiem et al. 2010).  
     Building upon the current body of evidence, this study sought to determine whether 
the Fox River Mix and DE-71 alter DAT expression in 4 brain regions that are important 
for the performance of 2 behavioral tasks which are mediated through dopaminergic 
signaling. It was hypothesized that developmental PCB or PBDE exposure would 
decrease DAT expression at postnatal day (PND) 90 in 4 regions of the brain. 
Specific regions postulated to be affected were medial prefrontal cortex (mPFC), 
orbitofrontal cortex (OFC), nucleus accumbens (NAC), and dorsal striatum (dSTR). 
These regions play important roles in the differential reinforcement of low rates of 
responding (DRL)  and delay discounting (DD) behavioral tasks used in this research 
(see Chapters 3 and 4). 
 
2. Methods and Materials 
2.1. Animals and Exposure 
 153 
 
     Details of the perinatal exposure of experimental subjects to PCBs and PBDEs were 
discussed in Chapter 3. In brief, Long Evans rat dams were allocated between 5 
treatment groups: control, 3 mg/kg PCBs, 6 mg/kg PCBs, 11.4 mg/kg PBDEs, and 22.8 
mg/kg PBDEs. Dams were exposed daily beginning 4 weeks prior to breeding through 
postnatal day (PND 20). Pups were weaned from the dams on PND 21 and male-
female pairs of pups from each litter were allocated to behavioral testing or to western 
blot analysis of brains on PND 90. Pups allocated for western blot analysis were double- 
or triple-housed together with others of the same sex and same contaminant exposure 
group until PND 90. On PND 90, these subjects were euthanized by overexposure to 
CO2 followed by decapitation. The brains were quickly removed, weighed, and then 
snap frozen in liquid nitrogen. The brains were stored at -80° C until western blot 
analysis was performed.  
 
2.2. Brain Dissection 
     Each PND 90 brain was positioned on the frozen stage (-20° C) of a microtome so 
that successive coronal slices could be taken in an anterior to posterior direction. 
Landmarks from the Paxinos and Watson (1998) brain atlas were used to guide cutting, 
but it should be noted that the anterior-posterior distances noted in the atlas did not 
perfectly correspond with the distances in the specimens. Thus when distances from 
Bregma are noted, they are only intended to allow orientation to the appropriate 
diagrams in the brain atlas that show relevant landmarks.  
     Slices were removed until Bregma 5.20 mm was reached, at which point the sizes of 
the frontal cortices and the olfactory bulbs were approximately equal. Then a 1.75 mm 
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(females) or 1.85 mm (males) thick coronal slice was cut. The slice was placed on a 
glass slide with the anterior side facing down. Using a 2.0 mm circular tissue punch 
(Harris Uni-Core; Ted Pella, Inc.) a single punch of the mPFC was taken (see Figure 
5.1) with the punch directed perpendicular to the plane of the slide. The punch was 
primarily centered on the prelimbic portion of the mPFC. From this same slice, two 2.0 
mm circular punches of the OFC were taken (see Figure 5.1). The punches were 
centered over the ventral orbital portion of the OFC and directed in a ventro-medial and 
anterior direction to follow the contour of the ventral orbital OFC. All tissue punch 
specimens were immediately placed in closed vials and snap frozen with subsequent 
storage at -80° C until the time of western blot analysis.  
     Next, thin slices were taken and discarded until Bregma 1.70 mm was reached, at 
which point the two sides of the corpus callosum were < 1 mm apart. From this point, a 
1.75 mm (females) or 2.0 mm slice (males) thick coronal slice was cut and placed on a 
glass slide with the posterior side facing down. Two 2.0 mm circular punches were 
taken with the punch directed perpendicular to the plane of the slide. The punch was 
centered over the NAC core, but also included NAC shell and some of the ventro-medial 
striatum (see Figure 5.2). From this same slice, two 2.0 mm punches of the dSTR were 
also taken (see Figure 5.2). Each punch was centered just ventral to the corpus 
callosum and then directed in a dorso-posterior direction so that the punch remained 
centered under the corpus callosum throughout.  
 
2.3. Chemicals 
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     Complete Mini Protease Inhibitor (PI) Cocktail Tablets were obtained from Roche. 
Pierce T-PER Tissue Protein Extraction Reagent, Pierce BCA Protein Assay Kit, 
Restore Plus Western Blot Stripping Buffer, and CL-XPosure X-ray film were obtained 
from Thermo Scientific. Corning Costar 96-Well Cell Culture Plates, Amersham Full-
Range Rainbow Molecular Weight Markers, and Tris Buffered Saline 10x were obtained 
from Fisher Scientific. NuPAGE Novex 4-12% Bis-Tris Gels, NuPAGE LDS Sample 
Buffer 4x, NuPAGE Sample Reducing Agent 10x, NuPAGE MES SDS Running Buffer 
20x, NuPAGE Antioxidant, NuPAGE Transfer Buffer 20x, and Invitrolon PVDF/Filter 
Paper Sandwiches (0.45 μM pore size) were obtained from Life Technologies. TWEEN 
20 was obtained from Sigma-Aldrich. Blotting Grade Blocker nonfat dry milk was 
obtained from Bio-Rad Laboratories. Anti-Dopamine Transporter rabbit polyclonal 
antibody (#AB2231) and Goat Anti-Rabbit IgG, HRP-conjugate, polyclonal antibody 
(#12-348) were obtained from Millipore. These were used as the primary and secondary 
antibodies for dopamine transporter. Anti-Alpha Tubulin rabbit polyclonal antibody 
(#ab4074) and Goat Secondary Antibody to Rabbit IgG polyclonal antibody (#ab6721) 
were obtained from Abcam. There were used as the primary and secondary antibodies 
for alpha tubulin. 20x LumiGLO Reagent and 20x Peroxide were obtained from Cell 
Signaling Technology.  
 
2.4. Western Blot Analysis 
     Only PND 90 brains were analyzed for this project. There were 5 male-female pairs 
of brains analyzed from each treatment group, except for the 3 mg/kg PCB group which 
had 6 pairs analyzed. 
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Protein Extraction and Quantitation      
     One PI tablet was dissolved in 10 mL T-PER. The samples from each brain region 
were suspended and homogenized in the following amounts of T-PER/PI: 190 μL for 
each mPFC sample; 375 μL for each pooled pair of OFC, NAC, and dSTR samples; 500 
μL for each liver sample (see methods for negative control for more details on liver 
samples). The homogenized sample was then centrifuged at 10,000 x g for 5 minutes, 
at 4° C. The supernatant was used in the BCA protein assay. Also at this time, an 
aliquot of the supernatant from each sample was diluted 1:20 in T-PER/PI. The 1:20 
dilution of protein sample would later be loaded into each lane of the gels. 
     The protein assay was performed using the directions for the microplate procedure 
provided in the instructions of the Pierce BCA Protein Assay Kit. In brief, for each 
sample, 10μL of protein supernatant was diluted in 15 μL of TPER-PI so that the 
measured protein amounts were within the range of the standard curve. The samples 
and standards were added to wells of a microplate and incubated at 37˚ C for 30 
minutes. The absorbance of the samples at 562 nm was then measured using a 
Multiskan Ascent microplate reader (Type 354; Thermo Scientific). Protein 
concentrations were calculated using Ascent Software (v. 2.6, Revision 3.1, Dec. 2003; 
Thermo Scientific).  
     In order to be able to compare protein expression between different gels, a protein 
standard that was put in one lane of every gel was created. This was done by preparing 
mPFC, OFC, and NAC samples from one subject using the methods described above. 
Then the supernatants from the 3 samples were combined and the concentration in the 
 157 
 
resulting solution was analyzed. As with the other samples, a 1:20 dilution of the protein 
standard was used during the western blot procedure.   
 
Electrophoresis and Membrane Transfer 
     A stepwise description of the methods used for western blotting is in the Appendix. In 
brief, for each sample, a volume equal to a target amount of 0.25 μg protein was added 
to reducing agent, sample buffer, and a sufficient quantity of T-PER/PI to attain 15 μL 
sample volume. For the molecular weight ladder, 5 μL of marker was used in place of 
0.25 μg protein. Samples were denatured while heating at 70˚ C for 10 minutes. Then 
the protein ladder, protein standard, and protein samples were loaded into the lanes of 
the gel. Each gel contained samples from one brain region and at least one male-
female pair of samples from each treatment group. The pairs of samples were 
randomized across gels. Once running buffer was added, gels were electrophoresed at 
150 volts for 1 hour.  
     In preparation for membrane transfer, the PVDF membrane was soaked in methanol, 
water, and then transfer buffer. Filter paper, fiber pads, and each gel were soaked in 
transfer buffer. A “sandwich” was made with the gel and membrane apposed in the 
middle surrounded by filter paper and then fiber pads on the outside. Transfer buffer 
was added and the transfer module was electrophoresed in a cold room at 30 volts for 
1.5 hours.  
 
Blocking and Probing 
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     The membrane was rinsed in Tris Buffered Saline and TWEEN 20 (T-TBS). T-TBS 
was used for all subsequent rinses. The membrane was blocked in 5% milk solution for 
1 hour and then incubated with anti-DAT primary antibody at 1:2000 w/v in 5% milk 
overnight.  
     The next day an incubation of goat anti-rabbit secondary antibody (Millipore) at 
1:2000 w/v in 1% milk was performed for 1 hour. The membrane was then treated with 
LumiGLO and chemiluminescence was captured on X-ray film. The membrane was 
subsequently stripped and then blocked again in 5% milk solution for 1 hour. It was then 
incubated with anti-alpha tubulin primary antibody at 1:10,000 w/v in 5% milk overnight. 
     On the third day the membrane was incubated with goat anti-rabbit secondary 
antibody (Abcam) at 1:2500 w/v in 2% milk for 1 hour. Then the membrane was treated 
with LumiGLO and chemiluminescence was captured on X-ray film. 
 
2.5. Negative Experimental Control 
     The aim of the negative control was to demonstrate that the bands suggested to be 
DAT protein were not present in tissue that does not have a significant amount of DAT. 
Liver is poorly innervated by dopaminergic neurons (Eldrup et al. 1989). Because liver 
does not have appreciable levels of DAT protein, it has been used as a negative control 
for DAT by others (Maggos et al. 1997). The hypothesis for the negative control was 
that there would not be a band present in liver tissue at the molecular weight of DAT 
protein.  
     Liver from PND 21 had been stored at -80° C from when it was collected. The liver 
was allowed to thaw enough to allow 2.0 mm tissue punches to be taken from the 
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parenchyma. Western blotting was performed. It was determined that undiluted 
supernatant from protein extraction had to be used to detect alpha tubulin in liver 
samples.  
 
2.6. Data Analysis 
     Following probing for DAT, bands were detected between the 76K and 102K 
molecular weight markers, which was the anticipated location for DAT (see Figure 5.3 
for example). Following probing for alpha tubulin, bands were detected above the 52K 
molecular weight marker, which was the anticipated location for alpha tubulin (see 
Figure 5.4 for example). Densitometry of the bands was performed using ImageJ 
(version 1.46r, http://imagej.nih.gov/ij). Briefly, developed X-ray films were scanned (HP 
Scanjet 4850, Hewlett-Packard) and saved as 600 ppi in TIFF format. The densities of 
samples for DAT and alpha tubulin were determined and then standardized to the 
protein standard densities on each image to obtain relative densities for DAT and alpha 
tubulin. Then adjusted densities for the samples were determined by dividing the 
relative density of each sample by the relative density of the standard. Adjusted 
densities were used in the statistical analyses, which were conducted using SPSS for 
Windows (version 20.0, SPSS Inc.). Statistical significance was set at p<0.05. Adjusted 
densities for treatment groups were compared for each of the 4 brain regions using 
mixed ANOVAs with sex (nested within litter) as the within-subjects factor and treatment 
group as the between-subjects factor. Negative control data were not subjected to 
statistical analysis. Data are reported as mean ± SEM. 
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3. Results 
     DAT protein expression in mPFC, OFC, NAC, or dSTR was not significantly altered 
by PCB or PBDE exposure (see Figure 5.5). However, upon visual inspection, it 
appears that there was a tendency for DAT density to be increased for the 6 mg/kg PCB 
group in the striatum. Sex had a significant effect on DAT expression in the NAC, but 
not in the other 3 regions [F(1,21)=4.564, p=0.045] (see Figure 5.6). The adjusted 
density for DAT expression in NAC was decreased for females (1.250±0.108) versus 
males (0.986±0.096). 
     For the negative control experiment, there was not a detectable band in the location 
where a DAT band was expected for the liver sample (see Figure 5.7). However, there 
was an alpha tubulin band detected for the liver sample. 
 
4. Discussion 
     Perinatal contaminant exposure did not alter DAT expression at PND 90 in the 4 
brain regions examined: mPFC, OFC, NAC, dSTR. This is in contrast to the findings of 
earlier studies. Visual inspection of the results suggests a trend for DAT expression in 
dSTR to be greater in the 6 mg/kg PCB group. While the direction of the difference is in 
the opposite direction than was hypothesized, the striatum is the region where changes 
in DAT expression in PCB and PBDE exposure have consistently been reported 
(Richardson & Miller 2004; Caudle et al. 2006; Bradner et al. 2013). It should be noted 
that these findings are based upon 5-6 subjects from each sex per treatment group. 
Brains from additional PND 90 subjects have been archived, so analyzing additional 
samples is planned. If a significant increase in DAT expression in the striatum is 
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detected after increasing the sample size, it may suggest that there are differences in 
response of the dopaminergic system following perinatal PCB exposure, given that all of 
the studies cited above involved contaminant exposure in subjects that were young 
adults or older. 
     When considering why there was a lack of findings in the current study versus 
previous studies, closer examination of the methodologies of the prior studies reveals 
differences that may account for the negative findings in the current study. Richardson 
and Miller (2004) administered a single, very high dosage (500 mg/kg) of Aroclor 1016 
or Aroclor 1260 to 8-10 month-old male mice and examined striatal DAT expression 1, 
7, and 14 days later. Decreases in DAT expression were seen at all time points. Caudle 
et al. (2006) administered 7.5 or 15 mg/kg of Aroclor 1254:Aroclor 1260 to 8 week-old 
male mice for 3, 7, 14, or 30 days and then examined DAT expression in the striatum 
and prefrontal cortex the day after dosing was finished. No changes were seen after 3 
or 7 days of exposure, and there were no changes in prefrontal DAT expression at 
either dose for up to 30 days of exposure. However, decreased striatal DAT expression 
was seen after 14 and 30 days of exposure at either dose. In the DE-71 study, 4 month-
old mice administered 30 mg/kg for 30 days were shown to have decreased striatal DAT 
expression 1 day post-dosing (Bradner et al. 2013).  
     As already mentioned, one of the main ways the prior studies differ from the current 
one is that exposure occurred perinatally in the current study, while older subjects were 
exposed in the previous studies. In addition, the interval between when dosing was 
completed and when DAT expression was evaluated was from 1 day up to 2 weeks. In 
the current study, the last day of exposure was on PND 20 while the brains were 
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collected on PND 90. It is possible that there were changes in DAT expression present 
earlier that were resolved by the time of assessment. Another way that prior studies 
differ is that they were performed in mice while the current study utilized rats. Although 
similar findings were seen in rats and mice in studies of the effects of PCBs on DAT 
functioning (Mariussen & Fonnum 2001; Tian et al. 2011), species-differences in the 
effect of PCBs on DAT expression can not be completely discounted.  
     One more consideration raised by the prior studies is whether the doses of PCBs 
and PBDEs were sufficient to induce changes in DAT expression. It is clear that higher 
doses of PCBs cause changes more quickly: 500 mg/kg PCBs produced a decrease in 
DAT expression within 24 hours (Richardson & Miller 2004), while it took more than 7 
days for 7.5-15 mg/kg PCBs administered daily for decreased DAT expression to 
develop (Caudle et al. 2006). It could be possible, given that it was the dams that were 
dosed with 3 or 6 mg/kg PCBs or 11.4 or 22.8 mg/kg PBDEs that the amount of either 
contaminant to cross the placenta to the pups was insufficient to cause changes in DAT 
expression.  
     The best way to try to answer questions about whether the exposure period, the 
interval after dosing, and dose itself contributed to the negative findings is to examine 
brains from PCB- and PBDE-exposed subjects earlier in development. This is possible 
because PND 21 brains from pups from all treatment groups were collected and 
archived. The next step should be to examine DAT expression on the PND 21 brains. 
The findings may address the concerns raised by examining PND 90 brains. 
     The finding of females having greater DAT density than males in the NAC, but not in 
the other 3 regions, is interesting. While there is sufficient evidence available that there 
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are sex differences in dopaminergic and, specifically, DAT functioning (Becker 1999; 
Dluzen & McDermott 2008), surprisingly limited information is available on sex 
differences in DAT expression in laboratory species. Significantly higher levels of DAT 
binding in the whole striatum and higher levels of DAT mRNA in the substantia nigra 
have been reported in females versus males (Morissette & Di Paolo 1993; Rivest et al. 
1995). The evidence is even stronger for higher striatal DAT density in human females, 
as discussed by Wong et al. (2012). It should be acknowledged that the difference in 
DAT expression in the NAC in the current study was subtle. However, given that it was 
based on findings from 26 subjects of each sex it is unlikely to be a spurious finding. It is 
also not clear why a similar sex difference was not found in the dSTR, which is very 
richly innervated with dopaminergic neurons. It will be of interest to determine if there 
are any sex differences in the brains of PND 21 subjects. 
 
5. Conclusions 
     While the other studies have reported decreased DAT density in rodent brains 
following PCB exposure, the current study did not find such differences subsequent to 
developmental exposure to PCBs or PBDEs. The brain regions in which DAT 
expression was examined are important for performance of the DRL and delay 
discounting tasks, which are modulated by dopaminergic signaling (see Chapters 3 and 
4). Thus, the lack of PCB/PBDE-related findings in the western blot study is consistent 
with the negative results of the behavioral studies. Sex differences in DAT expression in 
NAC or prefrontal regions have not been examined before, so the finding of increased 
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DAT density in the striatum of females is new. However a sex difference in dSTR was 
not found, which differs from findings in the limited number of prior studies.  
     Several reasons exist for why DAT density may not have been affected in the current 
study, all of which reflect differences in experimental design from prior studies. At this 
point, an important next step will be to examine PND 21 brains for treatment- and sex-
related differences in DAT expression. The brains from that time point will more closely 
match the time frame after the exposure period when DAT expression was examined in 
prior studies.  
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6. Figures 
 
 
 
Figure 5.1. Locations of tissue punches of frontal cortices. One 2.0 mm punch was 
centered over the prelimbic (PrL) portion of the medial prefrontal cortex. Two 2.0 mm 
punches were centered over the ventral orbital (VO) portion of the orbitofrontal cortices. 
Figures modified from Paxinos and Watson (1998). 
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Figure 5.2. Locations of tissue punches of striatal regions. Two 2.0 mm punches were 
bilaterally centered over the nucleus accumbens core (AcbC). Two separate 2.0 mm 
punches were bilaterally centered over the dorsal striatum (CPu). Figures modified from 
Paxinos and Watson (1998). 
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Figure 5.3. Example of DAT bands in all 4 brain regions. These bands were consistently 
visible between molecular weights of 76K and 102K. The double bands were common 
in NAC and dSTR samples. The bands are those of the same female (F) subject on the 
left and the same male (M) subject on the right for each of the 4 brain regions. dSTR = 
dorsal striatum; mPFC = medial prefrontal cortex; NAC = nucleus accumbens; OFC = 
orbitofrontal cortex; std = protein standard. 
 
 
 
 
Figure 5.4. Example of alpha tubulin bands in all 4 brain regions. These bands were 
consistently visible above the 52K marker. The bands are from the same subjects and 
the abbreviations are the same as in Figure 5.3. 
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Figure 5.5. Examining for differences in DAT expression in 4 brain regions. Neither PCB 
nor PBDE exposure significantly affected DAT density. Abbreviations are the same as in 
Figure 5.3. Low PCB = 3 mg/kg exposure group; High PCB = 6 mg/kg; Low PBDE = 
11.4 mg/kg; High PBDE = 22.8 mg/kg.  
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Figure 5.6. Examining for differences in DAT expression in 4 brain regions. Sex had a 
significant effect on DAT expression in NAC only. Abbreviations are the same as in 
Figure 5.3. *p<0.05.  
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Figure 5.7. In the negative control experiment, DAT was not detected in liver samples 
but alpha tubulin was. Both proteins were detected in brain samples. Lane 1: undiluted 
supernatant from liver extraction. Lane 2: supernatant from liver extraction diluted 1:10. 
Lanes 3-5: pooled protein standards from brain; lane 4 is the protein standard used 
throughout the experiment. A. There is no detectable DAT band at the appropriate 
position in lane 1 or lane 2 (liver). There is binding of DAT antibody to protein of a 
molecular weight much less than that of DAT in lane 1. The protein standards (brain) all 
have a DAT band in the appropriate position. B. Alpha tubulin was detected in the liver 
sample in lane 1 and the brain samples in lanes 3-5. The molecular weight marker is not 
included in B. for reasons similar to that stated in Figure 5.5. The asterisk (*) indicates 
the position of the alpha tubulin bands. The left-pointing arrowhead (<) points to the 
residual DAT bands after membrane stripping; the right-pointing arrowhead (>) points to 
the bound protein in lane 1 in A. Both arrowheads permit visualization of the position of 
the alpha tubulin bands relative to the DAT bands. Abbreviations are the same as in 
Figure 5.3. 
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Chapter 6: Conclusions 
 
1. Discussion 
     The first specific aim of this research was to use a rodent model to assess the 
effects of developmental exposure to polychlorinated biphenyls (PCBs) and 
polybrominated diphenyl ethers (PBDEs) on two distinct aspects of response inhibition: 
impulsive action and impulsive choice. The differential reinforcement of low rates of 
responding (DRL) task was used to assess impulsive action while the delay discounting 
(DD) task was used to assess impulsive choice. It was hypothesized that contaminant-
exposed subjects would exhibit deficits on DRL and DD tasks as compared to controls.  
     It was found that PCB or PBDE exposure did not affect DRL performance. This is in 
contrast to a study by Sable et al. (2009) which found that developmental PCB 
exposure decreased the ratio of reinforced:non-reinforced lever presses. It is possible 
that differences in diet, contaminant dose, or prior experience account for the absence 
of significant findings in the current study. PCBs and PBDEs also did not affect choice 
ratio on the DD task. However, an important experimental manipulation, cueing the 
delay to delivery of the large reinforcer, may have affected subjects’ choice to the extent 
that the task was unable to elicit differences in performance. Providing a visual cue 
while the subject is waiting for the larger-delayed reward can make it easier for both 
high and low impulsive subjects to wait. The result is that choice ratio may increase in 
cued versus uncued tasks, especially with impulsive subjects, at longer delays. Another 
important factor which may have confounded the ability to detect treatment differences 
in either task is inter-individual variation in impulsivity. Much variation has been shown 
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to exist between subjects in performance of tasks that assess impulsive action (Dellu-
Hagedorn et al. 2004) and impulsive choice (Galtress et al. 2012). As a result, the 
variance due to inter-individual differences in impulsivity reduces the ability of statistical 
analyses to detect a difference. Although efforts were made to have 12 pairs of male-
female subjects per treatment group in this study, it is possible that a larger sample size 
may be needed to enable the detection of treatment-related effects when employing 
behavioral tasks in which there is sizeable inter-individual variation in impulsive 
performance. 
     The second specific aim was to use drug challenges to assess the role of 
perturbations in dopaminergic neurotransmission in mediating the effects of 
developmental exposure to PCBs and PBDEs on response inhibition. Amphetamine 
(AMPH) and the D1/D2 receptor antagonist flupenthixol (FLU) were parenterally 
administered to test the hypothesis that there would be shifts in the dose-response 
curves such that performance of contaminant-exposed subjects on DRL and DD tasks 
would be more improved by drugs that enhance dopaminergic neurotransmission 
(AMPH) and more disrupted by drugs that reduce dopaminergic neurotransmission 
(FLU). 
     Neither drug produced treatment-related differences on the primary measures used 
to assess impulsive performance on either DRL or DD task. It is possible that if the 
current experimental methods were not sensitive enough to detect a difference between 
treated subjects and controls, then differences in dopaminergic signaling between 
groups were not great enough to result in a greater or lesser degree of perturbation 
between treated subjects and controls. However, due to the number of trial omissions 
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produced by the highest FLU and AMPH dosages, further increases in dosage of either 
drug would not be beneficial in trying to elicit differences between groups. A treatment 
effect on trial initiation latency was detected in the FLU and AMPH combination drug 
trials: the 22.8 mg/kg PBDE group was significantly faster than controls to initiate trials, 
while the 6 mg/kg PCB group was significantly slower than both PBDE groups, but not 
controls. This effect was not seen in testing that occurred prior to the drug challenges or 
with FLU or AMPH alone, so it is not clear to what extent binding of dopamine to D1 and 
D2 receptors under the combination drug condition differed from dopamine binding 
during the single drug trials to produce the changes seen.  
     The third specific aim was to use western blot analysis to quantify expression of the 
dopamine transporter (DAT) in specific regions of the prefrontal cortex and striatum 
following developmental exposure to PCBs and PBDEs. Tissue punches of medial 
prefrontal cortex, orbitofrontal cortex, nucleus accumbens, and dorsal striatum were 
taken on postnatal day (PND) 90 from subjects perinatally exposed to PCBs or PBDEs 
and controls. These regions were chosen because they are important for performance 
of either DRL or DD tasks. It was hypothesized that DAT expression would be reduced 
in the prefrontal cortex and striatum of subjects developmentally exposed to PCBs and 
PBDEs.  
     Contaminant exposure did not alter DAT expression in any of the brain regions 
examined. It is possible that the doses of PCBs and PBDEs used in the current study 
were not sufficient to induce changes in DAT expression. It is also possible that 
changes in DAT expression occurred, but that differences then normalized during the 
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interval between when contaminant exposure ceased (PND 20) and when the brains 
were evaluated (PND 90).  
     In conclusion, developmental PCB and PBDE exposure did not result in any 
significant changes in impulsive action or impulsive choice as assessed by the DRL and 
DD tasks; nor did FLU or AMPH differentially alter performance of PCB- or PBDE-
treated groups on either task. Additionally, DAT expression did not differ between 
contaminant-exposed groups and controls in any of 4 different brain regions when 
assessed at PND 90. While it is tempting to conclude that the influence of PCBs and 
PBDEs on impulsive action and choice and DAT expression is minimal, a large body of 
experimental and epidemiologic evidence argues otherwise, as discussed in Chapter 1. 
It is more accurate to state that PCB and PBDE exposure did not result in impulsive 
behavior or altered DAT expression under the current experimental methodologies. 
Reasons were outlined above as to why certain experimental factors and the 
experimental methods used in these studies may have prevented differences from 
being discerned between treatment groups. Thus, it is difficult to draw conclusions 
about the effects of the PCB and PBDE mixtures used in this study on impulsive 
behavior and DAT expression. Because of these concerns, it is also difficult to 
extrapolate the current findings to whether PCBs and PBDEs influence the clinical 
manifestation of attention deficit hyperactivity disorder (ADHD).  
 
2. Future Studies 
     It has been shown that cueing the delay during the DD task may enable more 
impulsive subjects to better tolerate delays to the larger reinforcer, resulting in greater 
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choice ratios at longer delays than if delays are uncued (Antrop et al. 2006). Because 
the current study used cued delays, an important consideration would be to assess 
whether differences become evident between contaminant-exposed groups and 
controls if a version of the DD task that does not cue delays is used. Another 
improvement on the current methodology would be to investigate whether differences in 
DAT expression between PCB- and PBDE-exposed groups and controls are evident in 
PND 21 brains. If differences were found, it would raise questions about whether 
changes in dopaminergic signaling are present earlier in the developmental period and 
then resolve as treated subjects mature. Regardless of differences in DAT expression, it 
would also be interesting to investigate whether PCB and PBDE exposure results in 
impulsive behavior at a younger age than that evaluated in the current studies. If there 
were positive findings, it would have interesting implications for the role of 
developmental contaminant exposure in ADHD, for which the prevalence decreases as 
subjects age and enter adulthood (Faraone et al. 2006). 
     Another interesting route of investigation would be to explore the potential for 
brominated flame retardants other than PBDEs to affect response inhibition and 
dopaminergic signaling. Hexabromocyclododecane (HBCD) and tetrabromobisphenol-A 
(TBBPA) are 2 high production level brominated flame retardants that are among those 
that have replaced PBDEs in industrial products (Kemmlein et al. 2009). Both HBCD 
and TBBPA have been shown to be more potent than PBDEs in impairing DAT and 
vesicular monoamine transporter 2 reuptake (Mariussen & Fonnum 2003). Both 
contaminants have also been shown to increase intracellular concentrations of free 
calcium, similar to PCBs and PBDEs (Dingemans et al. 2009; Hendriks et al. 2012). 
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HBCD has also been shown to alter latency to movement time in a haloperidol 
catalepsy test in rats, which is an experimental measure that is strongly influenced by 
dopaminergic signaling (Lilienthal et al. 2009). Using some of the methods developed in 
the current study to further assess the effects of HBCD and TBBPA on different aspects 
of dopaminergic neurotransmission will potentially further what is known about these 
two newer contaminants which are widely used but relatively unstudied. 
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Appendix: Western Blot Procedure 
 
Running the Gel 
For 15 well gels with 15 μL sample volume per well. 
1) Prepare 1.5 μL reducing agent and 3.75 μL sample buffer per well so have total 
of 27 μL reducing agent + 67.5 μL sample buffer. 
2) In 1.5 mL tubes, add T-PER/PI, then calculated amount of protein, then 5.25 μL 
of sample buffer + reducing agent combination. For ladder, add 5 μL of ladder 
instead of protein. 
3)  Mix and centrifuge briefly. 
4) Heat at 70° C for 10 min. Mix and centrifuge briefly. 
5) Make Running Buffer in 1000 mL container:  
a. 1 gel: 825 mL nanopure water + 43.4 mL NuPAGE MES SDS Running 
Buffer. 
b. 2 gels: 875 mL nanopure water + 46.1 mL NuPAGE MES SDS Running 
Buffer. 
6) Make buffer for inside of gel compartment: 
a. 1 gel: pour 250 mL in conical container and add 625 μL antioxidant. 
b. 2 gels: pour 300 mL in conical container and add 750 μL antioxidant. 
7) Remove gel from packaging and rinse with regular water. 
8) Remove comb and white strip. 
9) Use solution from step 6 and transfer pipette to flush wells in gel 3x. 
10) Put gels in tank and seal. Make sure the open side of the gels face the inner 
compartment. Then add running buffer from step 6 to fill inner compartment. 
11) Load lanes using long 200 μL pipette tip and pipetter set to 16.5 μL. Avoid 
bubbles. Suggested order for lanes is ladder, blank, universal standard, then 10-
12 samples. 
12) Pour rest of running buffer from step 5 into outer compartment to bring it to a 
level even with buffer in inner compartment. 
13) Put lid on and run at 150 V for 1 hour. 
 
Transfer 
1) When gel is halfway through, prepare transfer buffer and other things needed for 
transfer. 
2) Prepare transfer buffer in 500-1000 mL container 
a. 1 gel: 255 mL nanopure water, 15 mL NuPAGE Transfer Buffer (20X), 30 
mL methanol, 300 μL antioxidant. 
b. 2 gels: 510 mL nanopure water, 30 mL NuPAGE Transfer Buffer (20X), 60 
mL methanol, 600 μL antioxidant. 
3) Fill a tray with methanol, one with water, and one with transfer buffer – just 
enough to soak membranes. Fill 2 more trays with buffer. 
4) Remove PVDF membrane from between filter papers and write date and other 
info on it in pencil.  
5) Soak membrane in methanol for 30 sec, then briefly agitate in the water, then 
soak in transfer buffer. Filter papers also soak in transfer buffer. 
6) Soak sponges in transfer buffer. 
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7) Use gel knife to carefully crack open gel cassette. Pull the cassette off to expose 
the gel. Rinse gel with transfer buffer using a transfer pipette. Cut off the wells 
and the bottom of the gel below the blue streak.  
8) Soak gel in transfer buffer for a few minutes. 
9) Put gel on one filter paper and then make a sandwich in the transfer module: 3 
sponges – filter paper – gel – PVDF membrane – filter paper – 3 sponges. Roll 
over topmost filter paper with pipette to remove air bubbles before putting the last 
3 sponges in place. 
10) Lock transfer module into gel tank and fill inner compartment with transfer buffer. 
11) Fill outer chamber with ice cold water. 
12) Put lid on and transfer in cold room at 30 V for 1.5 hours. 
 
Blocking and Incubation for DAT then Developing 
1) Prepare T-TBS (TBS with Tween 20) as needed: 1 L of 1X TBS and 1 mL of 
Tween 20. Stir for 1 hour. 
2) Prepare 5% blocking milk: 2.5 g nonfat powdered milk per 50 mL T-TBS 
3) Remove membrane from transfer module. Briefly rinse in T-TBS. 
4) Block in 15 mL of 5% milk for 1 hour on orbital shaker. 
5) Primary antibody: Add 7.5 μL of rabbit anti-DAT (Millipore) to 15 mL of 5% milk. 
Incubate overnight on orbital shaker in cold room. Wrap tray in saran wrap. 
6) Rinse 3X in T-TBS for 10 min each time on orbital shaker. 
7) Secondary antibody: Make 1 % milk (3 mL of 5% milk + 12 mL T-TBS) and add 
7.5 μL of goat anti-rabbit (Millipore). Incubate 1 hr on orbital shaker. 
8) Rinse 3X in T-TBS for 10 min each time on orbital shaker. Turn on film developer 
30 min ahead of time. 
9) Supplies for dark room: 
a. 13.5 mL nanopure water in 15 mL tube 
b. Membrane in T-TBS 
c. Spare tray for treating membrane 
d. LumiGLO Reagents A and B 
e. 1000 mL capacity pipette and tips 
f. Tweezers 
g. Film and cassette 
h. Kim wipes 
i. Timer 
j. Keys 
k. Sharpie 
10) LumiGLO is light sensitive so only do this under red light. Add 0.75 mL from clear 
bottle (Reagent B) then 0.75 mL from dark bottle (Reagent A).  
11) Remove membrane from T-TBS and put in spare tray. Pour LumiGLO over 
membrane and rotate tray for 1 min. 
12) Drain excess LumiGLO from membrane and put membrane between protector 
sheets in cassette. Wipe with Kim wipe to remove any air bubbles. 
13) 30 sec exposure of film. 
14) Crimp corner of film that is in corner of cassette so can go back and mark the 
ladder on the film after developing.  
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15) Run film through developer.  
16) Decrease or increase exposure time of subsequent films as needed to attain 
bands that are visible but not too dark. 
 
Blocking and Incubation for Alpha Tubulin then Developing 
1) Strip antibodies from membrane by rinsing briefly in T-TBS then put membrane in 
15 mL of Restore Plus Western Stripping Buffer for 15 min on orbital shaker. 
2) Rinse 3X in T-TBS for 5 min each time on orbital shaker. 
3) Block in 15 mL of 5% milk for 1 hour on orbital shaker. 
4) Primary antibody: Add 10 μL of rabbit anti-alpha tubulin (Abcam ab4074) to 15 
mL of 5% milk. Incubate overnight on orbital shaker in cold room. Wrap tray in 
saran wrap. 
5) Rinse 3X in T-TBS for 10 min each time on orbital shaker. 
6) Secondary antibody: Make 2% milk (6 mL of 5% milk + 9 mL T-TBS) and add 6 
μL of goat anti-rabbit (Ab6721). Incubate 1 hr on orbital shaker. 
7) Rinse 3X in T-TBS for 10 min each time on orbital shaker. Turn on film developer 
30 min ahead of time. 
8) Supplies for dark room: 
a. 13.5 mL nanopure water in 15 mL tube 
b. Membrane in T-TBS 
c. Spare tray for treating membrane 
d. LumiGLO Reagents A and B 
e. 1000 mL capacity pipette and tips 
f. Tweezers 
g. Film and cassette 
h. Kim wipes 
i. Timer 
j. Keys 
k. Sharpie 
9) LumiGLO is light sensitive so only do this under red light. Add 0.75 mL from clear 
bottle (Reagent B) then 0.75 mL from dark bottle (Reagent A).  
10) Remove membrane from T-TBS and put in spare tray. Pour LumiGLO over 
membrane and rotate tray for 1 min. 
11) Drain excess LumiGLO from membrane and put membrane between protector 
sheets in cassette. Wipe with Kim wipe to remove any air bubbles. 
12) 30 sec exposure of film. 
13) Crimp corner of film that is in corner of cassette so can go back and mark the 
ladder on the film after developing.  
14) Run film through developer.  
15) Decrease or increase exposure time of subsequent films as needed to attain 
bands that are visible but not too dark. 
 
Preparing membrane for storage 
1) Assuming the bands for DAT and alpha tubulin turned out well, strip antibodies 
from membrane by rinsing briefly in T-TBS then put membrane in 15 mL of 
Restore Plus Western Stripping Buffer for 15 min on orbital shaker. 
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2) Rinse 3X in T-TBS for 5 min each time on orbital shaker. 
3) Store in 4˚ C walk-in freezer in generous level of T-TBS with container sealed 
with saran wrap. 
 
 
